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Abstract 
Monogenic autoimmune diseases are highly variable syndromes that usually 
have onset in the first year of life and are often fatal in early childhood. Identifying 
monogenic autoimmune diabetes is important as it can have implications for 
medical management of patients, informs families and clinicians of prognosis and 
recurrence risk, and gives insights into beta-cell autoimmunity and immune 
tolerance. 
The first section of this thesis introduces monogenic autoimmune disease, with 
focus on the conditions that have autoimmune endocrine disorders as part of their 
clinical phenotype. The following section details the methodologies used 
throughout this thesis. 
In chapter 1, we used a type 1 diabetes genetic risk score (T1D-GRS) based on 
the top 10 risk alleles for T1D to identify patients with monogenic autoimmunity 
from patients with early-onset polygenic diabetes and additional autoimmunity. 
We showed that the T1D-GRS was highly discriminatory of monogenic 
autoimmunity, especially when combined with age of onset (ROC-AUC 0.88). We 
also identified 16 families for gene discovery studies. Furthermore, this work 
shows that polygenic risk for the development of T1D does not affect the 
development of diabetes in monogenic autoimmunity. 
Chapter 2 describes the genetic and phenotypic information for the largest cohort 
of patients with IPEX syndrome, caused by hemizygous mutations in FOXP3, 
reported to date (n=48). We analysed this data to determine if there were any 
genotypic or clinical characteristics of IPEX syndrome that could predict 
prognosis. We did not find evidence of phenotype-genotype relationships and 
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showed that presenting feature did not predict prognosis. Medical management 
of IPEX syndrome cannot, therefore, be based on genotype or presentation. 
In chapter 3 we employed whole exome sequencing to look for causal variant(s) 
in a patient with diabetes (diagnosed aged 7 weeks) and autoimmune 
lymphoproliferative disease. This identified recessively inherited causative 
variants in LRBA. We then used targeted next generation sequencing (NGS) to 
screen a large cohort of patients (n=169) and identified an additional 8 probands 
and an affected family member. This confirms the role of LRBA as a neonatal 
diabetes gene, bringing the total number of genes to 25. 
In chapter 4, we assessed if immunoglobulin E (IgE) could be useful to identify 
patients with early-onset multisystem autoimmune disease caused by gain of 
function (GOF) STAT3 mutations. We showed that serum IgE was below the 
lower limit of the normal reference range (2KU/L) in all patients with STAT3 GOF 
(n=6), giving this threshold a sensitivity of 100% (95% CI: 54.1 – 100) and 
specificity 97.2% (95% CI: 96.2-97.9). We also found that IgE in patients with 
IPEX (n=16) was significantly higher than those with STAT3 GOF (p=0.002) 
suggesting it could be useful to identify IPEX from STAT3 GOF in non-
consanguineous males with early-onset autoimmunity. 
The final concluding section summarises the key findings of each chapter, the 
impact of these findings and suggests future avenues for research.  
Identifying monogenic autoimmunity has enabled prenatal diagnoses, given 
families and clinicians knowledge on recurrence risk, and could enable targeted 
therapies to be employed. This body of work will enable better discrimination of 
monogenic autoimmunity from polygenic clustering of early-onset autoimmunity, 
and gives insights into the factors that determine disease phenotype and clinical 
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course in monogenic autoimmunity. Gene discovery on the remaining patients 
will give new insights into the mechanisms of beta-cell autoimmunity and the 
regulation of the adaptive immune system and maintenance of immune tolerance.  
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Organisation of thesis 
 
As each data chapter within this thesis is presented as a publication, each 
begins with acknowledgments to co-authors and personal contributions of the 
first author.  
Introduction 
The introduction is split into two parts. The first, part 1, is a review article 
published in the Lancet Diabetes and Endocrinology detailing monogenic 
disorders that include diabetes and autoimmune thyroid disease as part of the 
disease spectrum. This is followed by a post-script discussing heterozygous 
TNFAIP3 mutations and new insights into the phenotype associated with AIRE 
and STAT1 mutations which were published after the publication of the review. 
Part 2 of the introduction details other monogenic autoimmune disorders that do 
not include diabetes as a feature, neonatal diabetes, maturity-onset diabetes of 
the young (MODY), type 1 diabetes, the use of biomarkers in monogenic disease 
and contains information to introduce genetic risk scores to the reader. 
Methods 
This section details the methods used in this thesis, ranging from immunoglobulin 
testing to next generation sequencing. It references the chapters in which each 
method was used and contains information on bioinformatic and statistical 
methods employed, as well as wet-lab techniques. 
Chapter 1 
Chapter 1 is an article currently under review in Diabetologia titled ‘A Type 1 
diabetes genetic risk score can discriminate monogenic autoimmunity with 
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diabetes from early onset clustering of polygenic autoimmunity with diabetes’. In 
this we used a genetic risk score based on risk alleles for type 1 diabetes to 
identify patients with monogenic autoimmunity and showed that it performed 
better than clinical features. 
Chapter 2 
Chapter 2 is a manuscript prepared for submission to the Journal of Clinical 
Immunology titled ‘Genotype and clinical phenotype do not predict prognosis in 
IPEX syndrome’. In this chapter, we studied a large cohort of patients with 
hemizygous FOXP3 mutations (n=48) to identify genotype-phenotype 
relationships in IPEX disorder and determine if clinical features could predict 
prognosis. We also discuss in detail atypical cases that are worthy of note. 
Chapter 3 
This chapter is a manuscript published in Diabetes entitled ‘Recessively inherited 
LRBA mutations cause autoimmunity presenting as neonatal diabetes’. In this 
chapter, we identified LRBA as a novel cause of neonatal diabetes in 9 probands 
and one affected family member, and go on to show that it has a minimum 
prevalence of 0.6% of patients diagnosed with diabetes under 12 months.  
Chapter 4 
This chapter is split into two sections. The first, part a, gives background on 
immunoglobulin E (IgE) in health and disease and provides data on serum 
immunoglobulin in patients with gain-of-function STAT3 mutations and 
hemizygous FOXP3 mutations. It also discusses a recent publication which is 
related to Chapter 4b. Part b is a letter published in Clinical Chemistry which 
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describes the use of low IgE to identify patients with STAT3 gain-of-function 
mutations and its specificity and sensitivity.  
 
 
Conclusions 
This chapter summarises the 4 data chapters, discusses the impact of the key 
findings in each chapter and discusses future directions for research. At the end 
of the thesis, the final remarks section places the research into context (including 
the broader contribution to knowledge and how this may translate to type 1 
diabetes research), highlights the issues faced during this the research that is 
contained with this thesis and how these were overcome, and suggests the future 
avenues of research for the cohorts studied. 
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Introduction Part 1 
 
Monogenic Autoimmune Diseases of the 
Endocrine System 
M. B. Johnson, A. T. Hattersley, S. E. Flanagan  
 
 
Lancet Diabetes & Endocrinology 2016 4(10):862-872  
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Search strategy and selection criteria: 
We searched PubMed and Google scholar for articles published in English 
between January 1970 and July 2015 and examined original articles, case 
reports, large series write-ups and review articles. The following terms were used 
in various combinations; “monogenic”, “autoimmune”, “endocrinopathy”, “single 
gene”, “mutation”, “mendelian”, “inherited”, “congenital”, “neonatal diabetes”, 
“type-1 diabetes”, “autoimmune thyroid disease”, “hypothyroidism”, 
“hyperthyroidism”, “Graves’ disease”, “Hashimoto’s”, “AIRE”, “APS1”, 
“Autoimmune Polyendocrinopathy Syndrome Type 1”, “FOXP3”, “IPEX”, 
“Immunodysregulation, Polyendocrinopathy, Enteropathy, X-Linked”, “IL2RA”, 
“CD25”, “Immunodeficiency 41 with lymphoproliferation and autoimmunity”, 
“ITCH”, “Ubiquitin ligase E3”, “Autoimmune disease, multisystem, with facial 
dysmorphism”, “LRBA”, “Common Variable Immunodeficiency -8”, “CVID-8”, 
“STAT1”, “Gain of function”, “Immunodeficiency 31C”, “STAT3”, “Infantile-onset 
multisystem autoimmune disease”. Where less than 50 individuals are reported 
with a specific disorder we used all cases to inform our article, otherwise large 
series were used. We used our judgement to select articles in order to provide a 
summary of the monogenic causes of autoimmune endocrine disease rather than 
aiming to provide an exhaustive list of all research into any particular subtype. 
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Summary 
The most common endocrine diseases, type-1 diabetes and hyper/hypo thyroid 
disease, are the result of autoimmunity. Clustering of autoimmune 
endocrinopathies can result from polygenic predisposition or more rarely may 
present as part of wider syndrome due to a mutation within one of 7 genes. These 
monogenic autoimmune diseases show highly variable phenotypes both within 
and between families with the same mutations. The average age of onset of the 
monogenic forms of autoimmune endocrine disease is younger than that of the 
common polygenic forms and this, combined with the manifestation of other 
autoimmune disease and/or specific hallmark features can inform clinicians as to 
the relevance of genetic testing. A genetic diagnosis can guide medical 
management, give an insight into prognosis, inform families of recurrence risk 
and can facilitate prenatal diagnoses.  
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The major disorders of the endocrine system result from autoimmune destruction 
of cells within the endocrine glands. The autoimmune thyroid diseases, hypo- or 
hyperthyroidism, are the most commonly diagnosed endocrinopathy with a 
European prevalence of 3% and 0.75% respectively.2 Type 1 diabetes which 
results from autoimmune infiltration and destruction of the insulin-producing 
pancreatic beta cells is the second most commonly diagnosed endocrine disorder 
with a UK prevalence of 0.34%.3  
Clustering of Autoimmune Endocrine Disease 
Due to the high prevalence of autoimmune endocrinopathies some individuals 
will develop more than one disease over a lifetime. The number of patients with 
multiple autoimmune endocrine disease is however higher than expected by 
chance (table 1).2, 3 Clustering of autoimmune endocrinopathies that is not the 
result of an underlying monogenic aetiology is due to a polygenic predisposition.4-
6 Common variants identified by genome-wide association studies account for 
approximately 9.3% of the heritability of autoimmune thyroid disease.7 For type 1 
diabetes over 50% of the λs (sibling relative-risk) is explained by common genetic 
variants,8 with the greatest contributor being variation in the human leukocyte 
antigen (HLA) genes (see box 1). This compares to estimates of up to 88% (type 
1 diabetes) and 39-75% (autoimmune thyroid disease) heritability calculated from 
disease concordance studies in twins. 5, 9 Whilst there are known flaws in twin 
studies (i.e. the effects of shared environment and possible epistasis) this missing 
heritability suggests that there are additional rare variants to be discovered. 
Perhaps the most striking example of polygenic clustering of autoimmune 
endocrinopathies is observed in polyendocrine syndrome type II (APS2, or 
Schmidt’s syndrome). APS2 has a prevalence of 1.4-4.5 cases per 100,000 and 
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most commonly affects females during middle age. The syndrome is 
characterised by autoimmune adrenal insufficiency and either autoimmune 
thyroid disease (69%) type 1 diabetes (52%), or both. The DR3 and DR4 HLA 
haplotypes are strongly associated with autoimmune adrenal insufficiency, 
autoimmune thyroid disease (DR3) and type 1 diabetes (DR3, DR4 and 
DR3/DR4). 10-12  This shared polygenic predisposition may offer some 
explanation for the clustering of autoimmune features reported in this syndrome. 
 
When to Suspect a Monogenic Aetiology 
Highly penetrant mutations in a single gene can give rise to multiple autoimmune 
endocrine diseases. To date pathogenic mutations in seven genes have been 
reported to cause multi-organ autoimmunity which includes type 1 diabetes and 
autoimmune thyroid disease (table 2). In these individuals monogenic 
autoimmunity is often suspected when multiple autoimmune conditions present 
in early childhood or when specific features are present (table 2). There may also 
be a family history suggesting Mendelian inheritance.  
Diagnosing Monogenic Autoimmune Endocrinopathy 
Box 1: Genome-wide Association studies 
Genome-wide association studies (GWAS) have investigated polygenic susceptibility to the major 
autoimmune diseases. Large meta-analyses have identified 53 different loci for type 1 diabetes and 22 loci 
for autoimmune hyperthyroidism (supplementary table 1).1 43% of the genes identified are involved in 
immune function (23/53 diabetes loci, 9/22 hyperthyroidism loci).  Furthermore, 18 associations have been 
identified in three of the genes described within this article (1 within AIRE, 11 in IL2RA and 6 in STAT3) as 
contributing to the development of diverse immunological diseases and traits, ranging from type 1 diabetes 
to anti-retroviral drug response (supplementary table 2).1 In at least two cases the same association 
increases risk to two different autoimmune diseases suggesting a shared mechanism is driving 
pathogenesis. Whilst these findings highlight the importance of these genes in normal immune function, 
many GWAS ‘hits’ are in genes or non-coding regions of unknown function and such studies have so far 
yielded limited new information on the underlying mechanisms of disease.  
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Genetic testing must be performed to accurately diagnose monogenic 
autoimmune endocrine disease. Specific patterns of disease both in terms of the 
organs affected and the age at diagnosis are observed in some monogenic 
subtypes (table 2). Whilst this clinical phenotype may provide a guide as to the 
most likely underlying genetic aetiology, the variability in penetrance associated 
with each condition means they are not pathognomonic.  
The Importance of a Diagnosis 
The underlying pathophysiological mechanism of autoimmune disease is likely to 
differ in monogenic disorders compared to the polygenic counterpart. This has 
implications for medical management as personalised therapy may be possible 
for individuals with autoimmunity resulting from a single gene defect. Identifying 
these individuals also provides a unique opportunity to investigate the role of the 
gene in health, development and disease in vivo.   
Of the seven known causes of monogenic autoimmune polyendocrinopathy, four 
have been discovered since 2010 reflecting advances in genetic technology and 
recognition of the importance of a genetic diagnosis for these individuals. 
Identifying novel genes has improved understanding of the disease mechanism 
which has led to some progress in the development of targeted therapies for 
these disorders.13, 14 This review will describe the established and newly identified 
genes in which mutations are known to cause multiple autoimmune disease 
including type 1 diabetes and autoimmune thyroid disease. For the purpose of 
this review these syndromes will be referred to as monogenic autoimmune 
polyendocrinopathies. We will explore the specific clinical manifestations, 
underlying mechanisms of disease and treatment options associated with each 
genetic subtype and provide a comparison to common polygenic autoimmunity.  
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Autoimmune Polyendocrinopathy Syndrome type 1 - AIRE 
Disease Phenotype 
Autoimmune Polyendocrinopathy syndrome type 1 (APS1, also known as 
APECED - Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy) 
is the most commonly reported monogenic autoimmune syndrome with 107 
disease causing mutations listed in the Human Gene Mutation Database 
(accessed 04/02/2016).15 The majority of knowledge on the disease course of 
APS1 has come from Finnish and Sardinian longitudinal studies where there is 
increased research activity on this disorder as a result of founder mutations within 
these populations. 16-18 APS1 presents early in childhood (median age: 3.3 years) 
and is characterised by three major components; chronic mucocutaneous 
candidiasis is usually the presenting feature which is followed by the development 
of hypoparathyroidism and later autoimmune adrenal insufficiency (see table 
2).16, 17 Rarer disease components often dominate the clinical picture. These 
include type 1 diabetes which is present in 13% of individuals at 30 years, and 
autoimmune hepatitis which affects 20% of individuals at 18 years16, 17. Gonadal 
insufficiency occurs in approximately 50% of individuals with APS1 and is usually 
primary. Alopecia is present in 39% of adults and ectodermal dystrophies are 
common with dental enamel hypoplasia identified in 77% of individuals in one 
large series.19 
Genetics 
APS1 is most commonly caused by recessively inherited loss-of-function 
mutations in the autoimmune regulator gene, AIRE.20, 21 Increased rates of APS1 
are observed in the Finnish (1:25,000) and Sardinian (1:14,000) populations as 
a result of founder mutations and also in the Jewish Iranians (1:9000) which is 
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likely to reflect the high rate on consanguineous unions within this population. 17, 
22-24 Dominant negative missense mutations have also been reported in six 
families with APS1. These mutations are located within specific domains of the 
protein and act to reduce the function of the AIRE tetramer.25-27 Patients with 
dominantly acting mutations often show a less severe phenotype compared to 
those with recessive mutations. 26, 27  
Disease mechanism 
AIRE encodes a protein by the same name which forms a homotetramer that 
activates the ectopic transcription of tissue-specific self-antigens within the 
thymus (box 2).28 The self-antigens under the control of AIRE are subsequently 
presented to naïve T cells via the major histocompatibility complex resulting in 
the negative selection of self-reactive T-cells. Individuals with loss-of-function 
AIRE mutations are unable to express these specific ectopic transcripts within the 
thymus and consequently there is no negative selection of self-reactive T-cells. 
Failure of the immune system to recognise specific tissues as ‘self’ ultimately 
results in the cells of the immune system attacking the target organs. AIRE also 
has a role in the development of regulatory T-cells which are important for 
maintaining peripheral tolerance (box 2).29 Dominant mutations reported in AIRE 
exert their effects via a dominant negative mechanism resulting in reduced 
function of the multimeric protein. Residual protein function may explain the 
reduced phenotypic severity associated with these mutations when compared to 
recessively inherited mutations.27 
Medical management 
Treatment for APS1 focusses on the management of the individual components 
of the syndrome. The prognosis depends predominantly on the effective 
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treatment of endocrine deficiencies, the management of which is particularly 
challenging in some individuals due to the co-existence of type 1 diabetes, 
adrenal insufficiency and/or autoimmune thyroid disease. Dietetic management 
to maintain electrolyte balance is often necessary and parenteral feeding may be 
required for patients with severe malabsorption due to enteropathy. Combined 
systemic and topical treatments are used to combat chronic mucocutaneous 
candidiasis. For some patients with severe enteropathy or autoimmune hepatitis 
immune suppressive therapy is required.16, 17 Early detection of autoimmune 
disease can assist in treatment optimisation, therefore educating patients on the 
chronic features of APS-1 is important.16 
When should genetic testing be considered? 
Genetic testing of AIRE should be considered in patients with any two of the most 
common features of APS1 (autoimmune adrenal insufficiency, 
hypoparathyroidism and/or chronic mucocutaneous candidiasis), or one feature 
in those with a family history of APS1. 
Immunodysregulation, Polyendocrinopathy, Enteropathy, X-linked (IPEX) 
Syndrome - FOXP3 
Disease Phenotype 
IPEX syndrome is an X-linked disorder affecting males. There are currently 77 
mutations recorded in the HGMD database (accessed 31/05/2016) and a recent 
international study confirmed a genetic diagnosis of IPEX syndrome in 0.7% of 
individuals diagnosed with diabetes before the age of six months (14/1020).30 
This however is likely to be underestimation of the true prevalence of the disease 
as the high mortality rate will mean that some patients will not receive a genetic 
diagnosis.  
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The most common feature of IPEX syndrome is enteropathy which presents as 
severe protein losing diarrhoea and can be life threatening. Type 1 diabetes 
usually follows and is often diagnosed in the first six months of life, additional 
features include dermatitis.31 Whilst individuals have a demonstrable ability to 
mount an effective immune response, a break down in the skin and gut barrier 
function due to the severe eczema, autoimmune enteropathy and intensive 
immunosuppressive therapy increases the risk and severity of infections. 32, 33 
The majority of individuals present extremely early with aggressive autoimmunity 
however a less severe phenotype has been reported in some families (table 2).34 
Recent studies suggest that IPEX syndrome may begin to manifest before birth 
and that miscarriage of male foetuses can occur due to IPEX syndrome.35  
Genetics 
Recessively acting loss-of-function mutations in FOXP3 cause IPEX syndrome.  
As FOXP3 is located on the X chromosome a single copy of a mutation 
(hemizygosity) is sufficient to cause disease in males. The variability in phenotype 
observed with this syndrome can be explained by the effect of the specific 
mutation with some functionally milder (hypomorphic) mutations that result in 
residual protein function described in a few individuals with a milder phenotype.31-
34 Additional genetic modifiers and environmental factors may also influence the 
severity of the disease. There is often no family history of IPEX syndrome as the 
patient will have inherited their X chromosome, and hence FOXP3 mutation, from 
their unaffected mother who has both a normal and mutated copy of the gene.36, 
37 
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Disease mechanism  
FOXP3 encodes a master transcription factor which controls the differentiation of 
lymphocytes into regulatory T cells (box 2).38 The absolute deficiency of 
regulatory T cells, due to a FOXP3 mutation,  results in a loss of peripheral 
tolerance leading to unregulated responses by self-reactive T cells and 
consequently autoimmune destruction of endocrine and non-endocrine tissues.38 
There is growing evidence that functional FOXP3 is also required for the on-going 
suppressive function of regulatory T cells. 
Medical management 
Diabetes can be difficult to manage in patients with IPEX syndrome due to the 
co-existence of severe enteropathy. Whilst parenteral nutrition may combat the 
effects of severe protein-losing diarrhoea it generally has limited success.31 
Immunosuppressive therapy is often required to manage the enteropathy, with 
Sirolimus offering a targeted approach. Sirolimus blocks IL-2 dependent signal-
Box 2: Loss of tolerance  
 
The immune system strikes a careful balance between a continued ability to mount effective responses to 
pathogens whilst remaining inert to self-antigens. This is achieved by several mechanisms of tolerance 
including central tolerance, the deletion of self-reactive cells in the thymus before their release into the 
periphery, and on-going peripheral tolerance mediated by regulatory T cells.  
 
Central tolerance is achieved by exposing naïve lymphocytes to self-antigens. The autoimmune regulator 
(encoded by AIRE) promotes the ectopic expression of tissue specific proteins in medullary thymic epithelial 
cells (mTECs). The mTECs display these proteins to the developing T-cells and promote apoptosis in those that 
are self-reactive, preventing their release into the lymphatic system. A similar, less rigorous, process occurs 
in the bone marrow in order to negatively select self-reactive B cells.  
 
Peripheral tolerance is an on-going process mediated by regulatory T-cells. Developing both within the 
thymus and in the periphery, the regulatory T cells account for 1-10% of CD4+ cells in healthy individuals. 
These cells constitutively express the IL-2 receptor, which regulates immune activity, and high levels of CTLA-
4 - a potent inhibitor of effector T cells.  
 
Regulatory T cells are essential for immune homeostasis and the regulation of immune responses; they both 
stimulate reactions to pathogens and suppress inappropriate autoimmune responses. As such the balance 
between self-reactive effector cells and their suppression by regulatory T cells maintains tolerance and 
prevents autoimmune disease. Six of the genes in which defects cause autoimmune endocrinopathies have a 
role in the differentiation and/or function of regulatory T-cells (figure 1).  
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transduction via interaction with mTOR (mammalian target of rapamycin), thus 
preventing T and B cell activation.39 It preferentially targets effector T cells over 
regulatory T cells, which are inherently compromised in patients with FOXP3 
mutations, thus giving increased benefit over other immunosuppressive agents.40 
Haematopoietic stem cell transplant (HSCT) can be curative for IPEX; an large 
international study showed that for 56% of IPEX patients receieving HSCT (n=58) 
it was fully curative, with an estimated overall survival rate of 73% at 15 years 
post-transplant.41 In order to improve outcomes and prevent non-reversible 
damage to the endocrine system, particularly the pancreatic islets, early pre-
emptive HSCT is necessary.42 Dermatological manifestations are managed by 
topical treatment with steroids and pain management. 
When should genetic testing be considered? 
Genetic testing for IPEX syndrome should be considered in any male presenting 
with infancy-onset severe enteropathy (manifesting as protein losing diarrhoea) 
and any patient diagnosed with diabetes before the age of six months.30 
Immunodeficiency 41 with lymphoproliferation and autoimmunity - IL2RA  
Disease Phenotype 
Reports of females with features very similar to IPEX syndrome (an X-linked 
disorder affecting males) led to the search for a novel aetiological gene. 43, 44  The 
disease was termed Immunodeficiency 41 with lymphoproliferation and 
autoimmunity and is characterised by extremely early presentation (median age 
5 weeks, see table 2) with severe enteropathy leading to malabsorption and 
failure to thrive, and chronic and recurring cytomegalovirus (CMV) infection.43-47 
In the four reported cases additional early onset autoimmunity including type 1 
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diabetes, hypothyroid disease, dermatological manifestations and alopecia were 
reported .43, 47  
Disease mechanism and genetics 
Immunodeficiency 41 with lymphoproliferation and autoimmunity results from 
recessively inherited loss-of-function mutations in IL2RA which encodes the 
interleukin-2 receptor alpha chain (also known as CD25). The IL2RA subunit 
forms part of a receptor that is essential for maintaining immune homeostasis 
following the binding of its ligand interleukin-2 (IL-2). IL-2 signalling is involved in 
immunoregulatory pathways and also promotes the transcription of FOXP3,48 
stimulating the differentiation of regulatory T cells (box 2). IL2RA is constitutively 
and highly expressed in regulatory T cells allowing for both their rapid recruitment 
in immune responses to pathogens and suppressive function.44 Loss of IL2RA 
reduces the suppressive function of regulatory T cells leading to loss of peripheral 
tolerance, unregulated responses by self-reactive T cells and ultimately 
autoimmunity. 
Medical management 
Prophylactic treatment with a combination of antibiotics is prudent as these 
individuals have a reduced ability to fight infections and to mount an adaptive 
response to previously encountered pathogens.43-47 Immunosuppressive therapy 
is required to treat severe and chronic autoimmunity and may have some effect 
in improving symptoms particularly those resulting from enteropathy.43 Sirolimus 
is the immunosuppressive of choice as this drug preferentially targets effector T 
cells over regulatory T cells which have reduced suppressive function in these 
individuals.40 Haematopoietic stem cell transplantation has proved successful in 
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one case with a complete remission of autoimmune symptoms achieved following 
treatment.46 
When should genetic testing be considered? 
Screening of IL2RA should be performed in infants with immunodysregulatory 
features including recurring infections, particularly cytomegalovirus, and/or 
enteropathy. This is particularly true for individuals from populations with high 
rates of consanguineous unions where there is an increased likelihood of a 
recessive genetic aetiology.  
Multisystem Autoimmune Disease with Facial Dysmorphism - ITCH  
Disease Phenotype 
This complex and multifaceted disease has been described in a single large ‘Old-
Order Amish’ pedigree with 10 affected individuals.49 This disorder combines 
significant craniofacial abnormalities, macrocephaly, growth failure with 
decreased muscle development and autoimmunity. Autoimmune endocrine 
disease was present in 5 individuals with 4 having autoimmune thyroid disease 
and one patient having type 1 diabetes diagnosed before 23 years (table 2).49 
Autoimmune hepatitis was reported in one case. Nine individuals had chronic 
lung disease, three died of respiratory failure in early childhood with pathology 
studies revealing nonspecific interstitial pneumonitis.49 
Disease mechanism and genetics 
Multisystem autoimmune disease with facial dysmorphism results from recessive 
mutations in the ubiquitin ligase gene ITCH.49 ITCH is involved in the addition of 
ubiquitin to proteins, which often targets these molecules for degradation, a 
process that is essential for the maintenance of normal immune function.50 
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Deficiency of functional ITCH is proposed to lead to uncontrolled activation of 
effector T cells leading to autoimmune attack. The non-immune phenotype of 
patients may relate to the absence of ubiquitination in multiple protein networks. 
Itch knockout mice show fatal autoimmune disease with multiple organ infiltration 
by lymphocytes, the dysmorphic features that are observed in humans are not 
detected.50  
Medical management 
Sirolimus, an immunosuppressive, was reported to improve severe enteropathy 
in one individual and combined treatment with bronchodilators, antibiotics and 
corticosteroids has been used to treat lung disease with some response.49 
Although ITCH replacement drugs are not currently available new therapies 
targeting the ubiquitination pathway are under investigation which may be 
relevant for patients diagnosed with this condition.51 
When should genetic testing be considered? 
Although ITCH mutations are extremely rare screening of this gene should be 
considered in patients presenting with macrocephaly and craniofacial 
dysmorphisms with or without additional autoimmunity, especially when other 
forms of monogenic autoimmune polyendocrinopathy have been excluded. 
Common Variable Immunodeficiency-8 with Autoimmunity (CVID-8) - LRBA 
Disease Phenotype 
The major presenting feature of Common Variable Immunodeficiency-8 with 
Autoimmunity (CVID-8) is autoimmune haematological disease which is 
observed in 79% of reported cases (23 of 29 reported individuals, table 2).13, 52-58 
Inflammatory bowel disease was observed in 69% of cases with type 1 diabetes 
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and autoimmune hypothyroid disease present in 17% and 14% of cases 
respectively (table 2). Immunodeficiency is a common feature of this disorder with 
recurrent infections resulting from hypogammaglobulinaemia.13, 52-58 Clinically 
CVID-8 is a heterogeneous disease with the phenotype ranging from severe 
multiple early-onset autoimmunity through to isolated irritable bowel disease.54, 57  
Disease mechanism and genetics  
CVID-8 results from recessively inherited loss-of-function mutations in LRBA.53 
This gene encodes an intracellular protein which is highly expressed in T and B 
lymphocytes.53, 59 Recently LRBA has been shown to have an essential role in 
the post-translational regulation and trafficking of CTLA-4, a receptor expressed 
on T regulatory cells with potent inhibitory function (see Box 2). Deficiency of 
LRBA prevents the CTLA-4 receptor from reaching the cell surface of regulatory 
T cells in response to T cell receptor activation. This abolishes the inhibitory 
function of CTLA-4 which decreases the suppressive action of the regulatory T 
cells leading to an unregulated immune response and autoimmune attack (box 
2).13 
Medical management 
Blood transfusions can treat prolonged cytopenic episodes with intravenous 
immunoglobulin therapy administered to reduce infections associated with 
hypogammaglobulinaemia. Two patients have been treated with haematopoietic 
stem cell transplantation and showed an improved clinical picture.52 Personalised 
medicine is also available for these individuals in the form of Abatacept™, a 
CTLA4-immunoglobulin fusion drug which mimics suppressive CTLA-4 
signalling. Six patients with LRBA mutations have been effectively treated with 
Abatacept™, which resulted in a dramatic improvement in inflammatory and 
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autoimmune symptoms with long term treatment (5-8 years duration).13 
Abatacept prevents co-stimulation of T-cells by CD80 and CD86 and thus 
reduces the level of T-cell activation.60 
When should genetic testing be considered? 
Genetic testing of LRBA is warranted in patients presenting with autoimmune 
haematological disorders (e.g. haemolytic anaemia, thrombocytopenia) and 
inflammatory bowel disease in early childhood.  
Immunodeficiency 31C - STAT1  
Disease Phenotype 
Over 50 patients have been reported with Immunodeficiency 31C syndrome.61, 62 
The hallmark feature of this disorder is chronic mucocutaneous candidiasis, an 
intractable fungal infection of the mucous membranes, nails and groin. There is 
also an increased incidence of autoimmune hypothyroid disease having been 
reported in 19% of cases (table 2).61 Five individuals have developed severe 
multi-organ autoimmunity which included type 1 diabetes, enteropathy and 
dermatitis.62 Short stature, delayed puberty and overt cardiac or vascular defects 
of unknown aetiology were also observed.  
Disease mechanism and genetics 
Dominantly acting gain-of-function mutations in the Signal Transducer and 
Activator of Transcription 1 (STAT1) gene cause Immunodeficiency 31C. STAT 
proteins are phosphorylated by Janus Kinases (JAK), which leads to their 
activation as a transcription factor. Activated STAT1 protein is involved in 
converting extracellular signals, via cytokines such as interferon alpha (IFNα), 
into transcriptional responses which in turn activate multiple cellular processes.63  
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STAT1 mutations prevent de-phosphorylation of STAT1, leaving it in a state of 
constitutive activation. Recent studies suggest that increased IFNα signalling can 
cause autoimmunity as patients with various cancers who have been treated with 
IFNα therapy have an increased risk of developing hypothyroidism, autoimmune 
hepatitis and type 1 diabetes.64, 65 The chronic mucocutaneous candidiasis that 
dominates the clinical picture in this disorder results from impaired IL-17-driven 
immunity caused by increased STAT1-dependent cellular responses to IL-17 
inhibitors which include IFNα.66 
Medical management 
Systemic steroid treatment, intravenous immunoglobulin therapy and 
immunosuppressive agents can be used to treat acute autoimmune disease (e.g. 
cytopenic episodes). Combined therapy with systemic and topical antifungal 
agents is required to manage Candida infection, whilst treatment with antibiotics 
may worsen or initiate episodes of chronic mucocutaneous candidiasis.  
When should genetic testing be considered? 
STAT1 screening should be considered in patients with chronic mucocutaneous 
candidiasis in whom mutations in AIRE (causing APS1) have been excluded 
especially if additional autoimmune features are present. 
Infancy-Onset Multi-system Autoimmune Disease - STAT3 
Disease Phenotype 
Early-onset multiple autoimmune disease is the most recent of the monogenic 
autoimmune disorders to be described.67 In the first report 4 of 5 individuals were 
diagnosed with neonatal diabetes (median age:  2.5 weeks, range 0-43 weeks) 
with autoimmune hypothyroid disease observed in 2 of the 5 cases (table 2). All 
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4 individuals with neonatal diabetes had intrauterine growth retardation (median 
birth weight: -1.59 SDS) suggesting that insulin secretion was impaired during 
foetal development and that autoimmune destruction of pancreatic beta-cells was 
occurring in utero.67 Subsequent reports have identified a further 15 individuals 
with this disorder, and have noted a lower incidence of diabetes (2/15) although 
autoimmune lymphoproliferation has since emerged as a common feature  (14/20 
reported cases). Additional features include short stature (< 5th centile), 
enteropathy (in 50% of individuals) and recurring infections (60%).14, 68, 69  
Disease mechanism and genetics 
Dominantly acting germline gain-of-function mutations in STAT3 cause Infantile-
onset multisystem autoimmune disease.  The STAT3 protein couples intra- and 
extracellular signals to multiple cellular functions including cell growth, 
differentiation and proliferation. The underlying mechanism of disease is yet to 
be fully elucidated, however it was recently shown that Th17 cell numbers were 
increased in an individual harbouring a STAT3 gain-of-function mutation.69 Th17 
cells, which develop in a STAT3-dependent manner, contribute to pro-
inflammatory responses in autoimmune disease by releasing IL-17.70 A reduction 
in the number of regulatory T cells has been reported in these patients; therefore 
reduced peripheral tolerance may also have a role in the development of 
autoimmunity.14 Loss of-function STAT3 mutations cause the opposing 
phenotype of Hyper-IgE (Job) syndrome which is characterised by recurrent 
bacterial and fungal infections, increased serum IgE and facial dysmorphism. 
Autoimmune endocrinopathies have not been reported in patients with Hyper IgE 
syndrome.71 
Medical management 
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Immune suppression may be useful to treat the severe autoimmune disease.69 
Haematopoietic stem cell transplantation has been performed in two patients; 
one patient survived the procedure and had complete resolution of autoimmune 
enteropathy, autoimmune hypothyroidism and recurrent cytopenias.14  There has 
been some progress in the development of targeted therapies for these 
individuals specifically in the form of a monoclonal antibody against the cytokine, 
IL-6.14 IL-6 is a pleitropic inflammatory cytokine that exerts its effects via janus 
kinases.72 The antibody binds to the IL-6 receptor preventing IL-6 from exerting 
its pro-inflammatory effects. 72, 73  For one patient with severe polyarthritis and 
scleroderma, treatment with this antibody resulted in a marked improvement in 
acute arthritic and dermatological symptoms.14  
When should genetic testing be considered? 
Screening of STAT3 should be performed in individuals presenting with early-
onset autoimmune lymphoproliferation and recurrent infections. In older children, 
short stature combined with autoimmunity should direct the clinician to a genetic 
test.  
MAKING A DIAGNOSIS OF MONOGENIC POLYENDOCRINOPATHY 
Identifying individuals for testing 
Genetic testing is essential for the accurate diagnosis of monogenic 
autoimmunity. Whilst a specific combination of autoimmune features, together 
with laboratory biomarkers (table 3), can help guide the clinical diagnosis, the 
variability in disease progression and phenotype, together with the overlap in 
clinical features observed with each monogenic subtype can make a clinical 
diagnosis challenging. Although family history of multiple early-onset 
autoimmune disease suggests a monogenic aetiology the absence of 
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autoimmune disease in other family members should not preclude testing as 
dominant, recessive and X-linked conditions will often be sporadic.31, 53, 62, 67  
Genetic testing should be considered when autoimmune disease is diagnosed 
atypically early, for example when diabetes is diagnosed before the age of 6 
months,30 or when two or more autoimmune conditions present in early 
childhood. For example the median age at presentation of autoimmunity in 
individuals with monogenic disease ranges from 2 weeks to 3.3 years (table 2). 
In contrast the median age at diagnosis of polygenic type 1 diabetes is 10 years 
whilst autoimmune thyroid disease generally presents between the ages of 20 
and 50 years (table 1).  
Genetic technology and access to testing 
Until recently genetic testing has predominantly relied on Sanger sequencing. 
Although robust and accurate, this analysis is relatively slow and expensive as 
single genes are tested in sections (by exon) and sequentially. This approach is 
problematic for disorders such as those described in this article where extensive 
overlap in phenotype exists both within and between genetic aetiologies. The 
recent adoption of massively parallel next-generation sequencing (NGS) by 
diagnostic laboratories has revolutionised the way in which we can now screen 
for these disorders.74 NGS allows for the targeted analysis of a panel of genes 
within a single reaction. This means that for genetically and phenotypically 
heterogeneous disorders such as monogenic autoimmune disease, detailed prior 
knowledge of the patients phenotype is no longer required to guide the order of 
genetic testing as all genes will be analysed in each patient who meets the criteria 
for genetic testing.  
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NGS technologies have reduced the cost of genetic testing by a factor of between 
100 and 200 in the last 5 years; the cost of sequencing an entire human genome 
is now comparable to the cost of a single gene test.75 As genetic testing continues 
to decrease in price and analysis methods improve, genetic testing will become 
more accessible to larger numbers of individuals with suspected monogenic 
autoimmunity. Moreover, current research efforts are focussing on characterising 
the genetics and phenotypic features of individuals with mutations in the known 
genes as well as searching for novel aetiologies. Consequently opportunities 
exist for individuals with suspected monogenic autoimmunity to enrol in research 
funded studies (supplementary table 3). This is particularly important for 
individuals from developing countries where there is limited affordable access to 
genetic testing.   
Disparities in genetic testing worldwide will have resulted in a gross 
underestimation of the true incidence of monogenic autoimmune endocrine 
disease. For example many countries with reduced access to genetic testing 
have an increased incidence of recessively inherited disease due to the high 
prevalence of consanguineous unions. As 4 of the known monogenic multiple 
autoimmune diseases are recessively inherited it seems likely that these 
conditions will be genetically undiagnosed in many individuals from these regions 
of the world. Moreover, the severity and complexity of disease observed in many 
of these conditions means that in countries without an adequate healthcare 
system many individuals are likely to die before a diagnosis is made which will 
also result in an underreporting of these conditions.  
IMPLICATIONS OF A GENETIC DIAGNOSIS 
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A genetic diagnosis provides important knowledge of recurrence risk which will 
inform family planning decisions, facilitate pre-implantation genetic testing and 
allow accurate prenatal screening. Crucially, identifying the underlying genetic 
aetiology also allows for the monitoring of disease progression, the introduction 
of timely treatment regimens to minimise complications, and provides important 
knowledge of the underlying disease mechanism(s) which is key for the initiation 
of personalised and targeted therapies. 
FUTURE PROSPECTS  
For Patients 
Recognising individuals with monogenic autoimmunity has implications for many 
areas of genetic and health research. The development of novel therapies and 
optimisation of existing treatment for both ‘rare’ monogenic and ‘common’ 
polygenic autoimmune endocrine disease relies on understanding the underlying 
mechanism(s) of disease. The fledgling field of gene therapy, where the genome 
is edited in a targeted manner, has shown some successes in monogenic 
disease.76 Whilst there is much work to be done to prove efficacy and assess 
potential side effects, the replacement of faulty genes with wild-type versions 
could lead to a cure for monogenic autoimmune endocrinopathies. 
Knowledge of the molecular basis of disease in monogenic disorders often yields 
limited results for clinical care. For example, the role of mutant AIRE protein in 
the development of APS1 is relatively well understood but personalised treatment 
for this disorder remains elusive.  Understanding the polygenic factors 
contributing to both the variability of disease and treatment response observed in 
patients with monogenic autoimmune endocrinopathies will be a key factor in the 
introduction of personalised therapies.  
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For individuals with monogenic autoimmune endocrinopathies resulting from 
FOXP3, IL2RA, LRBA or STAT3 mutations haematopoietic stem cell 
transplantation has been undertaken successfully to treat the disease. Whilst it is 
acknowledged that earlier transplantation can result in improved outcomes, the 
risks associated with this procedure often means that the decision to transplant 
is made once the disease has become life-threatening. Genotype-phenotype 
studies are therefore extremely important as information on the likely prognosis 
may inform clinicians on the decision to transplant early before further symptoms 
develop.  
For Science 
Academic led research teams and population level initiatives such as the United 
Kingdom’s 100,000 genomes project are likely to identify new genetic aetiologies 
for multiple diseases including monogenic polyendocrinopathies.77 As further 
genes are identified novel pathways of autoimmunity may be revealed which will 
be important for furthering understanding into both polygenic and monogenic 
autoimmune disease.  
Individuals with monogenic autoimmunity provide a unique opportunity to 
investigate how the targeted knock out of a single gene leads to severe 
autoimmune disease, providing valuable insight into the complex world of the 
adaptive immune system. Furthermore, the accuracy of data generated by clinical 
trials and genome wide association studies depends on the correct phenotypic 
classification of the participants. Identifying those with monogenic disease will 
prevent these individuals from enrolling in studies designed for their polygenic 
counterparts where the mechanism of pathogenesis is distinct.  
CONCLUSIONS 
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Monogenic autoimmune endocrinopathies are a clinically and genetically 
heterogeneous group of disorders which rely on genetic testing for an accurate 
diagnosis. A monogenic aetiology should be considered in all individuals with two 
or more early onset autoimmune conditions diagnosed before the age of 5 years 
as a genetic diagnosis is crucial for informing treatment strategies as well as 
providing important information on prognosis and recurrence risk.  
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FIGURE LEGENDS 
Figure 1 
Stylised representation of the mechanisms that underlie monogenic 
autoimmune endocrine disease pathogenesis. Mutations in genes known to 
cause monogenic autoimmunity, which includes type 1 diabetes and/or 
autoimmune thyroid disease, exert their effects by 1) breaking down immune 
tolerance related to the development or on-going suppressive function of 
regulatory T cells or 2) promoting the activation and proliferation of self-reactive 
effector T cells. (–) Denotes a reduction in normal function, (+) denotes an 
increase in normal physiological function. Bracketed genes have a 
putative/hypothesised role without direct evidence. 
Figure 2 
Infogram showing the major manifestations of four monogenic causes of 
multiple autoimmune endocrine disease. Whilst there is considerable overlap 
in phenotype associated with each genetic subgroup the prevalence of each 
disease varies and hallmark features exist for each of the disorders. The size of 
organs/systems in this image reflects the prevalence of the feature in the specific 
disorder. ARefers to the phenotype at age 30 years.  
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Tables 
Autoimmune 
disorder 
General 
population 
Type 1 
diabetes 
Autoimmune 
Hyperthyroidis
m 
 
Autoimmune 
Hypothyroidism 
 
Median age of 
onset (Y) 
- 10 20 – 40 30-50 
F:M ratio - - 6:1 7:1 
Type 1 Diabetes 0.34% - 1.11% 1.01% 
Autoimmune 
Hypothyroidism 
3% 10.5% - - 
Autoimmune 
Hyperthyroidism 
0.75% 1% - - 
Autoimmune 
adrenal disease 
0.01% 0.5% 0.11% 1.41% 
Autoimmune 
Enteropathies 
0.31% 3.4% 1.2% 1.2% 
 
Table 1: A summary of coexisting conditions in patients with polygenic type 
1 diabetes and autoimmune thyroid diseases.  F:M – female:male. 
Enteropathies include inflammatory bowel disease and coeliac disease.2, 3 
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GENE AIRE FOXP3 IL2RA ITCH LRBA STAT1 STAT3 
Disorder 
(OMIM number) 
Autoimmune 
Polyendocrinopathy 
Syndrome type 1A 
(#240300) 
Immunodysregulati
on 
Polyendocrinopath
y, Enteropathy, X-
linked (#304790) 
Immunodeficiency 
41 with 
lymphoproliferatio
n and 
autoimmunity        
(#606367) 
Multisystem 
Autoimmune 
Disease with 
Facial 
Dysmorphism         
(#613385) 
Common variable 
immunodeficiency 
8 with 
autoimmunity 
(#614700) 
Immunodeficienc
y 31C (#614162) 
Infancy-Onset 
Multisystem 
Autoimmune 
Disease (#615952) 
At 5 years At 30 years 
Mode of Inheritance Recessive X-Linked Recessive Recessive Recessive Dominant Dominant 
Median age of onset 3.3 years 2 weeks 5 weeks 2 years 2 years 1 year 2 years 
Endocrine disorders 
Type 1 diabetes 2/91 (2%) 12/91 
(13%) 
39/55 (71%) 1/4 (25%) 1/10 (10%) 5/29 (17%) 3/52 (6%) 6/20 (30%) 
Autoimmune 
Hypothyroidism 
1/91 (1%) 13/91 
(14%) 
19/55 (35%) 1/4 (25%) 4/10 (40%) 4/29 (14%) 10/52 (19%) 4/20 (20%) 
Autoimmune 
Hyperthyroidism 
1/91 (1%) 1/91 (1%) _ _ _ _ _ _ 
Hypoparathyroidism 31/91 
(34%) 
77/91 
(85%) 
_ _ _ _ _ _ 
Pituitary 1-3% 1-3% _ _ _ 1/29 (3%) Short stature 
(4/52, 8%) 
Short stature 
(12/20, 65%) 
Adrenal 8/91 (9%) 71/91 
(78%) 
_ _ _ _ _ _ 
Non-endocrine disorders 
Enteropathies 7/91 (8%) 20/91 
(22%) 
54/55 (98%) 4/4 (100%) 2/10 (20%) 20/29 (69%) 4/52 (8%) 10/20 (50%) 
Haematological _ _ _ 2/4 (50%) _ 23/29 (79%) 2/52 (4%) 14/20 (70%) 
Dermatological 2/91 (2%) 83/91 
(27%) 
38/55 (69%) 4/4 (100%) _ 3/29 (10%) 5/52 (10%) 10/20 (50%) 
Chronic 
Mucocutaneous 
Candidiasis 
45/91 
(48%) 
89/91 
(98%) 
_ 1/4 (25%) _ _ 51/52 (99%) _ 
Recurrent Infections _ _ Secondary to 
treatment 
4/4 (100%) _ 12/29 (41%) 4/52 (8%) 12/20 (60%) 
Other notable 
features 
Primary gonadal 
insufficiency (~50%) 
Enamel hypoplasia 
(~75%) 
Autoimmune hepatitis, 
Nephritis, Splenic 
hypoplasia 
Only present in 
males 
 
Develop-mental 
delay and 
macrocephaly 
(10/10, 100%) 
 
Cardiovascular 
malformations 
(3/52, 6%) 
 
References 16-18 41 43-47 349 13, 52-58 61, 62 14, 67-69 
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 Table 2: Summary of the main features present in monogenic autoimmune syndromes where diabetes and autoimmune thyroid 
disease is reported. Where <50 patients are reported in the literature, all individuals’ data is included. Where >50 patients are reported, large 
series were used. A Data is split into patient phenotype at 5 years and 30 years to reflect prognosis. 
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Table 3: Specific diagnostic tests or clinical criteria associated with the genetic 
subtypes of autoimmune endocrinopathies. Significant overlap exits between 
subtypes (i.e. LRBA and STAT3, AIRE and STAT1) reducing the specificity. FACS – 
fluorescence-activated cell-sorting. CMC – chronic mucocutaneous candidiasis. 
 
 
 
Gene Syndrome 
name 
Specific diagnostic 
test/criteria 
Notes 
AIRE Autoimmune 
Polyendocrine 
Syndrome type 
1 
Two of the following: Addison's 
disease, hypoparathyroidism, 
CMC, urticarial eruption, 
intestinal dysfunction and 
enamel hypoplasia; 
anti-interferon-w antibody 
testing 
Only one required for 
diagnosis if positive family 
history;  
Anti-IFN-w antibodies highly 
specific for APS1; 
FOXP3 Immunodysregul
ation, 
Polyendocrinop
athy, 
Enteropathy, X-
linked 
FACS analysis of 
CD4+CD25+FOXP3+ 
lymphocytes; Measurement of 
IgE  and eosiniphils; Presence 
of autoimmune enteropathy with 
eczema 
Usually decreased, but may 
be normal;  
Raised IgE and/or 
eosinophilia common 
IL2RA Immunodeficien
cy 41 with 
lymphoproliferati
on and 
autoimmunity 
FACS analysis of 
CD4+CD25+FOXP3+ 
lymphocytes 
Decreased/absent 
expression of CD25 
ITCH Autoimmune 
Disease, 
Multisystem, 
with Facial 
Dysmorphism 
Dysmorphic features and 
developmental delay 
Relative macrocephaly and 
facial dysmorphism 
LRBA Common 
Variable 
Immunodeficien
cy-8 with 
autoimmunity 
Immunoglobulin profiling Hypogammaglobulinaemia 
common 
STAT1 Immunodeficien
cy 31A 
Mucosal and disseminated 
fungal infections 
_ 
STAT3 Infantile-Onset 
Multisystem 
Autoimmune 
Disease 
Immunoglobulin profiling; 
enumeration of  
CD4+CD25+FOXP3+ 
lymphocytes  
Low IgE;  
Often low 
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Figure 1: Stylised representation of the mechanisms that underlie monogenic 
autoimmune endocrine disease pathogenesis. Mutations in genes known to cause 
monogenic autoimmunity, which includes type 1 diabetes and/or autoimmune thyroid 
disease, exert their effects by 1) breaking down immune tolerance related to the 
development or on-going suppressive function of regulatory T cells or 2) promoting the 
activation and proliferation of self-reactive effector T cells. (–) Denotes a reduction in 
normal function, (+) denotes an increase in normal physiological function. Bracketed 
genes have a putative/hypothesised role without direct evidence. 
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Figure 2: Infogram showing the major manifestations of four monogenic causes 
of multiple autoimmune endocrine disease. Whilst there is considerable overlap in 
phenotype associated with each genetic subgroup the prevalence of each disease 
varies and hallmark features exist for each of the disorders. The size of 
organs/systems in this image reflects the prevalence of the feature in the specific 
disorder. ARefers to the phenotype at age 30 years.  
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Gene(s) dbSNP rsID  
(Strongest risk allele) 
Risk Allele 
Frequency 
p-Value Odds 
Ratio 
Type 1 diabetes 
VN1R55P - 
RNLS 
rs10509540 (?) 0.71 1 x 10-28 1.33 
SMIM20 - RBPJ rs10517086 (A) 0.3 5 x 10-10 1.09 
UBASH3A* rs11203203 (?) NR 2 x 10-9 NR 
BACH2* rs11755527 (?) NR 5 x 10-8 NR 
RPL32P23 - 
RBM17 
rs12251307 (?) NR 1 x 10-13 NR 
CLEC16A rs12708716 (?) NR 2 x 10-16 NR 
ZFP36L1 rs1465788 (?) 0.71 2 x 10-12 1.16 
PTPN2* rs1893217 (?) NR 4 x 10-15 NR 
IFIH1* rs1990760 (?) NR 7 x 10-9 NR 
SIRPG* rs2281808 (?) 0.64 1 x 10-11 1.11 
GSDMB rs2290400 (?) 0.5 6 x 10-13 1.15 
ERBB3 rs2292239 (?) NR 2 x 10-25 NR 
PTPN22* rs2476601 (?) NR 9 x 10-85 NR 
GAB3* rs2664170 (G) 0.32 8 x 10-9 1.16 
RPS14P1 - IL10* rs3024505 (?) 0.83 2 x 10-9 1.19 
CTLA4* rs3087243 (?) NR 1 x 10-15 NR 
SH2B3* rs3184504 (?) NR 3 x 10-27 NR 
PRKD2 rs425105 (?) 0.84 3 x 10-11 1.16 
KIAA1109 rs4505848 (?) NR 5 x 10-13 NR 
CD69* rs4763879 (A) 0.37 2 x 10-11 1.09 
IL27* - NUPR1 rs4788084 (G) 0.42 3 x 10-13 1.09 
LINC01550 - 
C14orf177 
rs4900384 (G) 0.29 4 x 10-9 1.09 
RPL39P23 - 
COBL 
rs4948088 (?) 0.95 4 x 10-8 1.3 
RPS3AP51 - 
LIF* 
rs5753037 (T) 0.39 3 x 10-16 1.1 
GLIS3 rs7020673 (?) 0.5 5 x 10-12 1.14 
MIR4686 - 
ASCL2 
rs7111341 (?) NR 4 x 10-48 NR 
CTRB2 - CTRB1 rs7202877 (G) 0.1 3 x 10-15 1.28 
CCR7* - 
SMARCE1 
rs7221109 (?) 0.65 1 x 10-9 1.05 
SKAP2 rs7804356 (?) 0.76 5 x 10-9 1.14 
HLA-DRA* rs9268645 (?) NR 1 x 10-
100 
NR 
CENPW rs9388489 (G) 0.45 4 x 10-14 1.17 
EFR3B rs478222 (?) 0.59 4 x 10-9 1.22 
LMO7 rs539514 (?) 0.5 6 x 10-11 1.43 
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LINC00574 - 
RPL12P23 
rs924043 (?) 0.85 8 x 10-9 1.35 
NAA25 rs17696736 (G) NR 6 x 10-18 NR 
C1QTNF6 - 
SSTR3 
rs229541 (T) 0.43 2 x 10-8 1.11 
CTSH rs3825932 (T) 0.68 3 x 1015 1.16 
PHTF1 rs6679677 (A) NR 1 x 10-40 NR 
HLA-DQA1* rs9272346 (G) NR 6 x 10-
129 
NR 
LOC399716 rs947474 (G) 0.19 4 x 10-9 1.1 
UBASH3A* rs9976767 (C) NR 2 x 10-8 1.16 
IGF2, IGF2-AS, 
INS-IGF2 
rs1004446 (C) 0.65 4 x 10-9 1.61 
IKZF4* rs1701704 (C) 0.35 9 x 10-10 1.25 
HLA-DQB1* - 
MTCO3P1 
rs2647044 (A) 0.13 1 x 10-16 8.3 
CLEC16A rs2903692 (G) 0.62 7 x 10-11 1.54 
CUX2 rs1265564 (?) NR 1 x 10-16 1.45 
IL2RA* rs61839660 (?) NR 5 x 10-9 1.6 
CEP76 - PTPN2* rs2542151 (C) 0.16 1 x 10-14 1.3 
CD226* rs763361 (A) 0.47 1 x 10-8 1.16 
TYK2* rs2304256 (C) 0.71 4 x 10-9 1.16 
MEG3 rs941576 (A) 0.57 1 x 10-10 1.11 
RPS26 - ERBB3 rs11171739 (C) 0.42 1 x 10-11 1.34 
CLEC2D* rs3764021 (C) 0.47 5 x 10-8 1.57 
Autoimmune hyperthyroidism 
FCRL3* rs3761959 (A) 0.4 2 x 10-13 1.23 
Un rs6832151 (G) 0.35 1 x 10-13 1.24 
HLA-DPA2* rs2281388 (T) 0.32 2 x 10-65 1.64 
TSHR rs12101261 (T) 0.64 7 x 10-24 1.35 
NPM1P33 - 
CTLA4* 
rs1024161 (T) 0.69 2 x 10-17 1.3 
HCG22 - 
C6orf15 
rs4947296 (C) 0.14 4 x 10-51 1.77 
HLA-S* - MICA* rs1521 (T) 0.79 2 x 10-65 1.92 
HLA-DQB1* - 
MTCO3P1 
rs6457617 (T) 0.45 7 x 10-33 1.4 
RNASET2 - 
MIR3939 
rs9355610 (G) 0.47 7 x 10-10 1.19 
C6orf10 rs2273017 (A) 0.51 2 x 10-22 1.53 
HLA-W* - MICD rs3893464 (G) 0.36 2 x 10-20 1.53 
HLA-J*, ZNRD1-
AS1 
rs4313034 (T) 0.83 2 x 10-15 1.67 
ABCF1* rs3132613 (C) 0.25 2 x 10-13 1.43 
MUC22 rs4248154 (C) 0.54 1 x 10-13 1.38 
ITPR3 rs9394159 (T) 0.53 4 x 10-12 1.36 
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MLN - 
LINC01016 
rs4713693 (T) 0.65 7 x 10-13 1.4 
SLAMF6* rs1265883 (C) 0.1 2 x 10-18 1.34 
TG rs2294025 (T) 0.19 8 x 10-9 1.16 
LINC01550 - 
C14orf177 
rs1456988 (?) 0.53 5 x 10-9 1.12 
C1QTNF6 rs229527 (?) 0.71 5 x 10-20 1.23 
GPR174 - 
KIF4CP 
rs5912838 (?) 0.58 2 x 10-33 1.32 
ABO rs505922 (?) 0.53 2 x 10-10 1.14 
 
Supplementary table 1: Regions associated with type 1 diabetes and autoimmune 
hyperthyroidism identified by genome wide association studies. Only those reaching 
genome wide significance are recorded (i.e. p value < 5 x 10-8). NR - not recorded 
(data not provided by study).[1] 
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Gene Disease/trait(s) dbSNP ID 
(strongest risk 
allele) 
Odds 
Ratio 
p-Value Reference 
AIRE Rheumatoid arthritis rs2075876 (A) 1.18 4 x 10-9 [2] 
IL2RA Multiple sclerosis; 
Crohn's disease 
rs12722489 (C) 1.23; 
1.11 
4 x 10-8;  
3 x 10-9 
 
[3, 4] 
IL2RA Inflammatory 
biomarkers 
rs7911500 (NR) NR 5 x 10-9 [5] 
IL2RA Inflammatory bowel 
disease 
rs12722515 (C) 1.102 4 x 10-10 [6] 
IL2RA Type 1 diabetes rs61839660 (NR) 1.6 5 x 10-9 [7] 
IL2RA Type 1 diabetes 
autoantibodies 
rs12722495 (A) 1.61 1 x 10-38 [8] 
IL2RA Vitiligo rs706779 (A) 1.27 3 x 10-9 [9] 
IL2RA Rheumatoid arthritis rs706778 (T) 1.1 5 X 10-
14 
[10] 
IL2RA Alopecia areata; 
Multiple sclerosis 
rs3118470 (G) 1.41; 
1.12 
2 X 10-
12; 3 X 
10-11 
[11, 12] 
IL2RA Response to anti-
retroviral therapy 
rs12722486 (NR) 38.2 2 X 10-9 [13] 
IL2RA Multiple sclerosis rs7090512 (G) 1.19 5 x 10-20 [12] 
IL2RA Type 1 diabetes rs12251307 (NR) NR 1 x 10-13 [14] 
STAT3 Multiple sclerosis rs2293152 (C) 1.22 4 x 10-8 [3] 
STAT3 Multiple sclerosis rs744166 (G) 1.15 3 x 10-10 [15] 
STAT3 Crohn's disease rs744166 (A) 1.18 7 x 10-12 [16] 
STAT3 Multiple sclerosis rs9891119 (C) 1.11 2 x 10-10 [12] 
STAT3 Crohn's disease rs9891119-(A) 1.37 2 x 10-15 [17] 
STAT3 Inflammatory bowel 
disease 
rs12942547 (A) 1.103 6 x 10-22 [6] 
 
Supplementary table 2: Genome wide associations identified within the seven genes 
causing autoimmune polyendocrinopathy. All reach genome wide significance (<5 x 
10-8). Where multiple associations were found for the same SNP all data is listed in 
the same order. Genes mapped by National Center for Biotechnology information. NR 
– not recorded (data not provided by study). 
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Trial name Brief description ClinicalTrials.gov 
Identifier 
Immune Disorder 
HSCT Protocol 
Assessing the possibility reduced 
intensity immunosuppression in 
patients with disorders of immune 
function including IPEX syndrome 
NCT01821781 
Reduced Intensity 
Conditioning for 
Hemophagocytic 
Syndromes or 
Selected Primary 
Immune 
Deficiencies 
Testing the efficacy of 
intermediate conditioning in 
patients with primary 
immunodeficiencies including 
IPEX syndrome 
NCT01998633 
Treosulfan and 
Fludarabine 
Phosphate Before 
Donor Stem Cell 
Transplant in 
Treating Patients 
with Non-malignant 
Inherited Disorders 
Testing whether a new 
conditioning regimen with 
reduced intensity can result in 
favourable outcomes in patients 
with non-malignant diseases 
requiring bone marrow transplant, 
specifically using Treosulfan and 
Fludarabine. 
NCT00919503 
Reduced Intensity 
Conditioning in 
Patients Aged ≤35 
With Non-Malignant 
Disorders 
Undergoing UCBT, 
BMT, or PBSCT 
(RIC HSCT NMD) 
Aim to demonstrate the efficacy 
of reduced intensity conditioning 
regimen for bone marrow 
transplant long term. 
 
NCT01962415 
CAMB/MAT2203 in 
Patients with 
Mucocutaneous 
Candidiasis (CAMB) 
Dose-titration trial to study the 
efficacy, safety and 
pharmacokinetics of oral 
cochleate amphotericin B in 
patients with chronic 
mucocutaneous candidiasis. 
NCT02629419 
Genetic Basis of 
Primary 
Immunodeficiencies 
The evaluation of patients with 
primary immunodeficiency 
disorders to identify patients with 
mutations in certain genes, 
including STAT1. 
NCT00001788 
Detection and 
Characterization of 
Infections and 
Infection 
Susceptibility 
Screening study to identify 
patients with immune disorders 
for further evaluation. 
NCT00404560 
Natural History of 
Individuals with 
Immune System 
Problems That Lead 
to Fungal Infections 
Long term study of people with 
immune system problems that 
lead to fungal infections 
NCT01386437 
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Studies of Disorders 
with Increased 
Susceptibility to 
Fungal Infections 
The collection of biological 
samples to study immune system 
disorders that make people 
susceptible to fungal infections 
NCT01222741 
 
Supplementary table 3: Studies/clinical trials currently recruiting patients with 
monogenic autoimmune and immunodysregulatory disorders. Taken from 
www.ClinicalTrials.gov (date accessed: 25/05/2016). Search terms; AIRE, APECED, 
APS1, IL2RA, CD25, FOXP3, IPEX, LRBA, ITCH, Chronic Variable 
Immunodeficiency, Primary Immunodeficiency Autoimmune, STAT1, STAT3, 
Monogenic Autoimmune, Congenital Autoimmune. 
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Introduction Part 1 – post script 
Since the publication of the review in this chapter (part 1) an additional genetic 
syndrome of autoimmunity that includes diabetes has been reported (caused by 
heterozygous mutations in TNFAIP3), and new knowledge on the clinical 
manifestations associated with pathogenic variants in AIRE and STAT1 has been 
identified by studies of large series.  This post script summarises this new knowledge. 
TNFAIP3 
Behcet-like familial autoinflammatory syndrome (OMIM #616744 (1)) is caused by 
autosomal dominant mutations in TNFAIP3 (2). In the original report from Zhou et al 
11 affected individuals from 6 unrelated pedigrees with variable degrees of 
autoinflammatory disorders were found to harbour loss of function mutations in 
TNFAIP3. Whole exome sequencing was used to search for causative mutations in 
two unrelated pedigrees and screening of an additional 150 phenotypically similar 
patients identified a further 4 families. None of the mutation carriers in the original 
report had endocrinopathy. Since the original report an additional 9 affected individuals 
from 4 families have been identified (3-6). Most families reported have had protein 
truncating variants (9/10) in TNFAIP3. The mutation was inherited from affected 
parents in 5 families. 
The median age of onset of Behcet-like familial autoinflammatory syndrome is 8.5 
years, later than most other monogenic syndromes than include autoimmune diabetes. 
The most common feature in the patients with TNFAIP3 mutations so far reported is 
oral and/or genital ulcers that are refractory to treatment (17/20 individuals, 85%). 
Gastrointestinal symptoms, including gastritis and ulcers were present in 7 individuals 
(35%) and inflammatory arthritis was also present in 7 affected patients (35%). As with 
other forms of monogenic disease, as new patients are identified the phenotypic 
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spectrum observed has widened. One patient reported has autoimmune 
lymphoproliferative disease and transicent hepatic dysfunction, and another had 
diabetes and intrerstitial lung disease. It seems likely that TNFAIP3 mutations are 
underrecognized due to this wide phenotypic variability, and the clinical similarity to 
Behcets syndrome in many cases. Identifying additional patients will therefore improve 
the understanding of this disorder and the disease manifestations associated with it. 
The observed phenotype in these patients resembles Behcets disease (OMIM 
%109650), a polygenic autoinflammatory disorder associated with the HLA B51 
haplotype, as well as non-HLA loci (7, 8). 
TNFAIP3 limits inflammatory processes by inhibiting NF-κβ, which regulates immune 
responses to infection (9, 10). Loss of inhibition results in unchecked NF-κβ signalling 
in the immune system and therefore uncontrolled inflammation (11). This is the first 
monogenic autoinflammatory disorder to include diabetes as part of the disease 
spectrum. The innate immune system can activate the adaptive immune system via 
cytokine signalling and this may underlie the organ specific autoimmunity observed in 
one individual (12).  
APS1 
Autoimmune polyendocrine syndrome type 1 (APS1, also known as Autoimmune 
polyendocrinopathy-candidiasis-ectodermal dystrophy [APECED]; see introduction 
part 1) commonly features chronic mucocutaneous candidiasis, hypoparathyroidism 
and adrenal insufficiency as part of a syndrome of autoimmunity and 
immundysregulation. Presentation with 2/3 of this classic triad is clinically diagnostic. 
The majority of knowledge of this rare disorder comes from studies of European 
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patients, most of whom (>80%) are homozygous for the founder mutations 
p.Arg257Ter or p.Tyr82Cys.  
Ferre et al. studied a large (n=35) series of North American patients longitudinally to 
define the clinical features in this population, who harboured a more diverse set of 
mutations in AIRE (13). They found that the classic diagnostic diad took longer to 
present, typically appearing 7.4 years after the first symptom. The most common non-
classical feature in this population was urticarial eruption (in 23/35, 66%), contrasting 
to previous reports where it was present only sporadically. Non-endocrine 
manifestations were more common in this cohort compared to previous reports, 
including urticarial eruption (66%), hepatitis (43%%) and intestinal dysfunction (80%). 
Ferre et al. therefore suggest new diagnostic criteria including urticarial eruption, 
intestinal dysfunction and enamel hypoplasia are used; the incorporation of these 
would have enabled diagnosis ~4 years earlier in these American individuals. The 
reasons for the different phenotype observed are not clear, but may include the 
different genotypes observed in this cohort compared to Europeans or environmental 
factors. Alternatively, the systematic evaluation employed may have allowed for 
recognition of manifestations that otherwise go unnoticed/unreported. 
STAT1  
Toubiana et al. followed a large international case series (274 individuals from 167 
families) with gain of function (GOF) variants in STAT1 (see introduction part 1)(14). 
Their study widened the clinical manifestations associated with GOF STAT1 and 
identified the aspects of disease associated with higher mortality. 98% of the patients 
studied had chronic mucocutaneous candidiasis (CMC), in keeping with previous 
reports, and the authors also suggested that GOF STAT1 variants were the most 
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common cause of CMC as it was present in ~50% of 400 individuals referred to the 
corresponding authors clinical laboratory for testing. Almost three quarters (74%) of 
the individuals studied had bacterial infections and 38% had viral infections, which was 
not previously recognised as a major component of the disease. Cerebral aneurisms 
and malignancies were both reported in 6% of individuals, resulting in a high burden 
of mortality in these individuals. The combined susceptibility to fungal, bacterial and 
viral infections led one commentator to suggest this disease is classified as a 
combined immunodeficiency rather than a candida-alone related disease (15). 
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Introduction Part 2 
  
76 
 
ADDITIONAL CAUSES OF MONOGENIC AUTOIMMUNITY WITHOUT DIABETES 
AS A REPORTED FEATURE; 
Eight other monogenic disorders which can include autoimmune diseases have been 
identified, as classified by the International Union of Immunological Societies (in 
section IV, diseases of immune dysregulation, syndromes with autoimmunity) (1). 
None of these disorders have been reported to include diabetes as a feature, however 
as additional patients are discovered and the associated phenotype is further 
characterised diabetes may become part of the spectrum of phenotypes associated 
with these disorders. The individual disorders are discussed below. 
CTLA4 (CD152) - ALPS type V (OMIM 616100) 
Heterozygous mutations in CTLA4 (cytotoxic T-lymphocyte-associated protein 4) were 
simultaneously reported by two separate groups looking for novel causes of familial 
autoimmune lymphoproliferative syndrome in 2014 (2-4). The variable syndrome of 
autoimmunity in the 21 affected individuals (from 10 families) most commonly included 
autoimmune enteropathy (15/21, 71%), lymphocytic infiltration of tissues (13/21, 62%) 
and autoimmune haematological diseases (12/21, 57%). Organ specific autoimmunity 
was also reported, with autoimmune thyroid disease in 2 individuals and type 1 
diabetes in an otherwise unaffected carrier. The immunophenotype is variable but was 
reported to include hypogammaglobulinaemia, CD4+ lymphopenia, low levels of 
CD45+ naïve T-cells and progressive loss of circulating B cells in some individuals. 
The regulatory T cells of affected individuals showed reduced expression of FOXP3 
and IL2RA (3). 
CTLA4 is constitutively expressed by Tregs and can be expressed by CD4+ and CD8+ 
effector T cells and functions as a potent suppressive receptor molecule (5-7). It 
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competes with CD28 to bind with CD80/86 and prevent co-activation of T effector 
cells(8). Upon binding of CD28, the receptor ligand complex undergoes 
transendocytosis whereby CD28 molecules are stripped from the effector T cell and 
internalised within the regulatory T cell (9). Suppression is therefore maintained after 
cell:cell contact. Expression of CTLA4 is induced by binding of the T cell receptor to 
CD28, resulting in progressive suppression over time with peak expression seen at 
48-72hr after activation (5). LRBA is essential for post-translational regulation of 
CTLA4 whereby it prevents CTLA4 containing vesicles from trafficking to lysosomes 
for degradation (see introduction part 1, section on CVID-8)(10). 
Immunosuppression results in clinical improvement. One patient in the literature  was 
responsive to therapy with abatacept (11), a CTLA4 mimetic which improved 
symptoms and increased the number and function of FOXP3+ regulatory T cells. Other 
individuals may therefore benefit from therapy with abatacept. HSCT has been 
reported in 8 individuals (12), 6 are currently alive and well, 1 died due to transplant 
related mortality and 1 individual died from diabetic keto-acidosis 2.5 years after 
HSCT. Both deceased individuals had full donor engraftment. 
The age of onset of patients reported in the two large original reports ranged from 2 to 
40 years however subsequent reports have identified individuals with onset in the 
neonatal period (11). Multiple unaffected carriers of pathogenic CTLA4 variants have 
been identified, with the oldest being 77 years (3), though some of these had 
autoimmune disease (e.g. type 1 diabetes) which may be related to impaired CTLA4 
function. Taken together this suggests that the penetrance of CTLA4 deficiency is 
more variable compared to other forms of monogenic autoimmunity. It may be due to 
the proposed mechanism of haploinsufficiency, whereby some functional CTLA4 
exists, as well as undefined genetic modifiers, environmental factors or the stochastic 
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nature of T cell receptor generation by V(D)J recombination. The true clinical picture 
of CTLA4 deficiency is still emerging and as more individuals are identified may 
broaden, as seen in other monogenic autoimmune disorders.  
Autoimmune lymphoproliferative syndromes (OMIM: #601859) 
First clinically recognised by Canale and Smith in 1967 (13), autoimmune 
lymphoproliferative syndrome (ALPS) is characterised by childhood presentation of 
non-malignant lymphadenopathy which may have associated hepatosplenomegaly 
and autoimmunity (14). The symptoms may wax and wane and can spontaneously 
improve in the second decade of life. The autoimmunity in these patients is usually 
directed at blood cells (e.g. haemolytic anaemia and autoimmune cytopenias) and 
individuals have an increased risk of lymphoma (both Hodgkin and non-Hodgkin). 
ALPS is a genetically heterogeneous condition; mutations in 6 genes are known to 
cause ALPS, two of which (KRAS and NRAS) are caused by somatic mutations. The 
below section summarises the four known forms of inherited ALPS. Approximately 
20% of patients with ALPS do not have a mutation in the known genes (15). 
FAS – type IA (OMIM #601859) 
Genetically characterised by Fisher et al Cell 1995 (16), ALPS type 1A is dominant 
disorder caused by mutations in the FAS gene and is an example of a RASopathy. 
Haploinsufficiency of FAS leads to defective apoptosis and expansion of antigen-
specific lymphocyte populations and lymphoproliferation. Heterozygous mutations in 
FAS are identified in 65-75% of individuals with ALPS, however it can also be 
autosomal recessive or somatic (17-19). The only curative treatment is haematopoietic 
stem cell transplantation, usually only undertaken in the most severe cases(20). FAS 
encodes a death receptor on the surface of cells and leads to apoptosis. Upon binding 
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its ligand (FASL), FAS forms the death-inducing signalling complex (DISC) which 
activates caspase-8 leading to DNA degradation, membrane blebbing and eventual 
cell death (21). 
FASL – type IB (OMIM #601859) 
FASL encodes the FAS ligand, a transmembrane protein expressed on cytotoxic 
lymphocytes. It binds to the FAS receptor (FASR) inducing it’s trimerisation. This 
results in a signalling cascade resulting in apoptosis of the target cell. There have been 
three reported cases of ALPS caused by dominant or recessive mutations in the FASL 
gene, with recessively inherited mutations seemingly resulting in a more severe 
phenotype with earlier onset (22-24). 
CASP10 – ALPS type II (OMIM #603909) 
Four individuals with ALPS but without mutations in FAS or FASL have been identified 
who harboured heterozygous mutations in the CASP10 gene encoding caspase 10 
(25, 26). This encodes cysteine-aspartic acid protease 10 which is important for 
cleaving numerous protein targets during apoptosis and is essential for FAS induced 
apoptosis. It normally exists as inactive proenzyme that is itself cleaved by the FAS 
induced death domain to become active.  
PRKCD – ALPS type III (OMIM #615559) 
ALPS type III, caused by autosomal recessive mutations in PRKCD, has been 
identified in five individuals from three families (27-30). It is characterised by significant 
lymphadenopathy, recurrent infections and variable autoimmune manifestations that 
can include membranous glomerulonephritis and hypothyroidism. The 3 siblings 
identified by Belot et al. also had systemic lupus erythematous (SLE), likely due to 
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defective B cell apoptosis leading to unchecked production of pathogenic antibodies 
associated with SLE.  
PRKCD encodes protein kinase C-δ, a member of the serine-threonine-specific protein 
kinases (31). It is ubiquitously expressed and phosphorylates a range of proteins 
involved in numerous cell signalling networks. Mouse studies showed protein kinase 
C-δ is essential for peripheral B cell development and a critical regulator of immune 
homeostasis, negatively regulating B cell proliferation (32). It also has role in self-
antigen induced B cell tolerance induction and upon cellular DNA damage, mediates 
apoptosis(33). Lymphocyte accumulation results from a combination of impaired 
apoptosis and excessive proliferation.  
OTHER ‘ORPHAN’ DISORDERS 
There are also a further 3 genetic disorders that cause syndromes of autoimmunity 
but that have only been identified in a single family and therefore do not meet the 
established criteria for a Mendelian disease (34). These are briefly discussed below.  
TPP2 (OMIM *190470) 
Stepensky et al. identified a homozygous frameshift mutation in TPP2 in two siblings 
who were the result of consanguineous union (35). Both siblings presented with early-
onset Evans syndrome (co-occurrence of autoimmune thrombocytopenia and 
autoimmune haemolytic anaemia) at 21 and 18 months and had lymphadenopathy. 
One developed intermittent splenomegaly and had recurrent viral infections 
(cytomegalovirus and varicella zoster) and was successfully treated with 
haematopoietic stem cell transplantation. The other sibling died from acute haemolytic 
crisis at the age of 3 years. The full function of TPP2 is under investigation, but the 
functional studies presented by Stpensky and colleagues and murine studies  indicate 
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that it is essential for the survival of lymphocytes and prevents them reaching 
senescence (36), allowing them to continue to fight infection and create diverse ranges 
of antigen receptors.  
FADD (OMIM #613759)  
In 4 affected members of a large consanguineous family with ALPS, severe recurrent 
infections (both bacterial and viral), liver disease, encephalopathy and cardiac 
malformations Bolze et al. identified a homozygous missense variant in FADD 
(encoding Fas-associated death domain protein) that co-segregated with the disease 
(37). FADD is an adaptor protein that mediates signalling for tumor necrosis factor 
receptors containing death-domains (38). The mechanism underlying the ALPS in 
these individuals is thought to be similar to FAS and FASL ALPS, whereby defective 
apoptosis leads to unchecked proliferation of lymphocytes. The recurrent and severe 
infections in these patients is likely due to the loss of FADD signaling in type 1 
interferon antiviral immunity (39, 40). The developmental defects were suggested to 
be due to FADD having a role in embryonic development, although no direct evidence 
for this is available.  
CASP8 (OMIM #607271) 
Chun et al. identified homozygous CASP8 mutations in two siblings from a 
consanguineous pedigree with ALPS and immunodeficiency (leading to recurrent 
infections and poor response to vaccination) (41).  CASP8 (caspase-8) is a member 
of the cysteine-aspartic acid protease family, all of which are essential for apoptosis. 
The finding that individuals homozygous for a mutation in CASP-8 not only have ALPS 
but also have a defect in T-, B- and natural killer cell activation leading to 
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immunodeficiency was the first observation that CASP8 has additional functions 
outside apoptosis. 
NEONATAL DIABETES 
Neonatal diabetes (NDM) is defined as diabetes with onset before the age of 6 months 
and has an incidence of approximately 1/100,000 live births (42). It is a highly 
heterogeneous disorder, with 24 distinct genetic causes identified to date (table 1) (43-
45). The mechanisms underlying these genetic causes broadly fit into three 
categories; defects in glucose sensing/metabolism by the β-cell; defects in the 
development of the pancreas and defects in the immune system leading to β-cell 
autoimmunity. Notable exceptions are autosomal recessive mutations in EIF2AK3 and 
IER3IP1 which cause aberrant protein trafficking by the endoplasmic reticulum (ER) 
and dominant INS mutations that cause missfolding of the insulin protein. For all three 
this results in ER stress and β-cell death (46). Clinically, NDM can be divided into 
transient and permanent forms. Transient NDM is most commonly caused by 
methylation defects in the 6q24 locus (table 1 legend) and remits in the first months of 
life, however may relapse as the child grows and insulin requirement increases (47).  
Screening of all known genes by targeted next generation sequencing has meant that 
a genetic diagnosis is possible in >82% of individuals (43). More than 45% of 
individuals with neonatal diabetes have an activating mutation in the potassium 
channel subunits Sur1 and Kir6.2 (encoded by the ABCC8 and KCNJ11 genes, 
respectively). A rapid genetic diagnosis is crucial for these individuals as it can enable 
personalised therapy; treatment with sulphonylurea tablets improves glycaemic 
control and removes the need for insulin injections (48). Furthermore, patients with 
recessively inherited mutations in SLC19A2 can be treated with thiamine which 
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improves their anaemia and results in improved glycaemic control and/or lower insulin 
requirement (De Franco, Diabetes, in press). A genetic diagnosis can also explain 
additional non-pancreatic features and ameliorate the need for further diagnostic 
testing and may anticipate the onset of additional features allowing for early-
intervention and monitoring. Mutations in 3 genes result in neonatal diabetes as part 
of a variable syndrome of autoimmunity (IL2RA, FOXP3, & STAT3). These are further 
discussed in the introduction part 1.  
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Gene Additional features Inheritance 
pattern 
6q24 locus IUGR, macroglossia, umbilical hernia, neurological features Varied* 
ABCC8 Developmental delay +/- epilepsy Autosomal dominant/ 
recessive 
EIF2AK3 Skeletal dysplasia, liver dysfunction Autosomal recessive 
FOXP3 Autoimmune enteropathy, eczema, autoimmune thyroiditis, other 
autoimmune manifestations 
X-linked recessive 
GATA4 Exocrine insufficiency, congenital heart malformations Autosomal dominant 
GATA6 Exocrine insufficiency, congenital heart malformations, 
neurological defects, hypothyroidism, gut and hepatobiliary 
malformation 
Autosomal dominant 
GCK - Autosomal recessive 
GLIS3 Hypothyroidism Autosomal recessive 
HNF1B Exocrine insufficiency, renal cysts Autosomal dominant 
IER3IP1 Microcephaly, epilepsy Autosomal recessive 
IL2RA Eczema, autoimmune enteropathy, recurrent infections, other 
autoimmune manifestations 
Autosomal recessive 
INS - Autosomal dominant/ 
recessive 
KCNJ11 Developmental delay +/- epilepsy Autosomal dominant 
MNX1 Sacral agenesis, neurologic defects Autosomal recessive 
NEUROD1 Cerebellar hypoplasia, sensorineural deafness, 
visual impairment 
Autosomal recessive 
NEUROG3 Congenital malabsorptive diarrhoea Autosomal recessive 
NKX2-2 Corpus callosum agenesis Autosomal recessive 
PDX1 Exocrine insufficiency Autosomal recessive 
PTF1A Exocrine insufficiency, cerebellar agenesis (coding mutations) Autosomal recessive 
RFX6 Intestinal atresia and/or malrotation, gall bladder agenesis Autosomal recessive 
SLC19A2 Thiamine-responsive megaloblastic anaemia, sensorineural 
deafness 
Autosomal recessive 
SLC2A2 Hepatorenal glycogen accumulation, renal dysfunction, impaired 
utilization of glucose and galactose 
Autosomal recessive 
STAT3 Autoimmune enteropathy, thyroid dysfunction, pulmonary 
disease, juvenile-onset arthritis, short stature 
Autosomal dominant 
ZFP57 IUGR Autosomal recessive 
Table 1: Genetic causes of neonatal diabetes. IUGR – intrauterine growth retardation. * - 
NDM associated with the 6q24 locus is caused by overexpression of imprinted genes at this 
locus. Three distinct inheritance mechanisms are associated; 1. Paternal uniparental disomy 
of chromosome 6; 2. Duplication of the paternal 6q24 locus; 3. Methylation defect of the 
maternal region resulting in overexpression. Adapted from De Franco & Ellard 2015 (43). 
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MATURITY-ONSET DIABETES OF THE YOUNG (MODY) 
Maturity-onset diabetes of the young (MODY) is a monogenic disorder accounting for 
1.1-4.2% of diabetes that is diagnosed before the age of 25 years (49-52) and has a 
population minimum prevalence of 1.08/10,000 in the UK (53). MODY is classically 
defined as a non-syndromic beta cell defect with a monogenic aetiology, is pancreatic 
autoantibody negative and has young onset in slim individuals (54). Patients are 
usually non-insulin dependent and generally have a family history suggesting 
dominant disease. To date, 11 causative genes have been identified as causing this 
classical description of MODY (GCK, HNF1A, HNF1B, HNF4A, CEL, ABCC8, 
KCNJ11, RFX6, INS, NEUROD1 & PAX6) (54). Heterozygous mutations in HNF1A 
are the most common aetiology, accounting for ~52% of MODY in white Europeans 
(53). 
A genetic diagnosis can improve treatment in these individuals; patients with HNF1A 
or HNF4A MODY are highly sensitive to low dosage sulphonylureas and often have 
better control of their diabetes when switching for insulin injections to tablets (55).  
Patients with MODY caused by activating mutations in ABCC8 or KCNJ11 are likely 
to respond to high-dose sulphonylurea treatment as seen in NDM, though as this form 
of MODY is rare empirical data is not available and further study is warranted. Patients 
with heterozygous mutations in glucokinase (encoded by GCK) can usually come off 
treatment altogether as their blood glucose is only slightly raised above normal, 
remains stable over their lifetime and does not cause micro/macro vascular 
complications associated with other forms of diabetes (55). 
TYPE 1 DIABETES  
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Type 1 diabetes results from specific autoimmune destruction of the pancreatic β-cells 
(56). This leads rapidly and progressively to total insulin deficiency and patients 
require life-long insulin injections to maintain normal blood sugar levels. Type 1 
diabetes is a polygenic disease - to date 61 loci have been identified by GWAS as 
associated with type 1 diabetes (57). The presence of these genetic risk factors is 
necessary, but not sufficient, to cause disease. More than half of the genes so far 
identified have a role in the function of the immune system (introduction part 1 and 
supplementary material) (58). Variation in the HLA region at chromosome 6p21 infers 
the greatest risk to the development of type 1 diabetes. In particular, the HLA class II 
DR and DQ encoding loci infer high risk, with the strongest predisposing haplotypes 
being DR3 and DR4 (58). HLA class II molecules present antigens at the surface of 
cells. Compound heterozygosity for DR3/DR4 has a synergistic effect, likely due to the 
presence of heterodimers of the DQ subunits, meaning four different DQ molecules 
are present at the cell surface.  
In the classic model of T1D pathogenesis (figure 1), genetically predisposed 
individuals have immunological infiltration of the islets (insulitis) bought on by a 
precipitating environmental event. This leads to a preclinical asymptomatic stage in 
which β-cell mass declines and then to the onset of symptoms (polydipsia, polyuria, 
increased huger and fatigue) as insulin production becomes insufficient to maintain 
normal blood glucose levels (59). In 13-80% of cases, the initial symptoms are not 
recognised and patients present with diabetic ketoacidosis, a medical emergency 
which requires immediate treatment (59, 60).  
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Figure 1: the classical model of type 1 diabetes pathogenesis. Adapted from 
Atkinson 2001. a – A genetically predisposed individual with normal β-cell mass. b – 
A precipitating environmental event/trigger leads to the induction of autoimmunity and 
infiltration of the pancreatic islets by leukocytes. β-cells are sensitive to injury. c – As 
β-cell mass declines, first phase insulin response is lost and glucose intolerance 
begins to develop, though individuals are usually asymptomatic. d – Further decline in 
β-cell mass leads to overt symptoms of diabetes. e - β-cells are drastically reduced 
and may be completely absent. Patients require lifelong total replacement of 
endogenous insulin. 
 
The incidence of T1D varies greatly, from 0.1/100,000 per year in China to 37/100,000 
in Finland (61) and there is evidence that some second-generation immigrant 
populations moving from low incidence to high incidence countries have an increased 
risk of T1D than their original country’s population, which increases with more time 
spent in the new country (62). This provides strong evidence that environmental 
factors have a role in the pathogenesis of T1D (56).  
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A variety of environmental factors/exposures have been implicated in the 
pathogenesis of type 1 diabetes with perhaps the strongest evidence for a role of viral 
infection in the induction of islet autoimmunity. A large population-based study of 
approximately 300,000 infants in Germany showed that risk of developing type 1 
diabetes by age 8 years was increased in infants developing respiratory tract infections 
in the first 6 months of life, especially when caused by viruses (63). Insights from the 
TEDDY study have also temporally linked respiratory infection to the age of initiation 
of islet autoimmunity, defined as autoantibody positivity (64). Furthermore, 
immunohistochemical staining of pancreata from individuals with new onset diabetes 
has shown that the enteroviral capsid protein vp1 is significantly more common in 
cases than age matched controls (65). Other environmental factors implicated in the 
aetiology of type 1 diabetes include adverse life events in childhood (66), the duration 
of breastfeeding and timing of weaning and nutrition (67). 
Since its first application in 1922 (68), the only treatment for type 1 diabetes has been 
life-long insulin injections and careful monitoring of blood sugar levels. Recent 
advances in treatment have focussed on the introduction of insulin pumps and 
continuous glucose monitoring, which automatically monitor blood glucose and 
administer insulin automatically (69, 70), as well as flash monitoring devices which use 
a Bluetooth enabled implant and small device to easily monitor glucose levels without 
the need to draw blood. There are also on-going trials and research programs which 
are focussing on intervening in the pre-symptomatic stage of diabetes development in 
order to reduce or reverse β-cell loss (71). The ‘holy-grail’ of treatment for patients with 
type 1 diabetes and complete loss of β-cell mass is islet transplantation, whereby 
healthy islets containing functional β-cells are implanted into patients with long-
standing diabetes. More than 1500 individuals have undergone this procedure 
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worldwide, and the procedure is becoming more viable for increasing numbers of 
patients (72). Problems around immunological rejection of the transplanted islets and 
complications arising due to continued immunosuppression have limited its adoption, 
although it has passed a phase 3 trial (73). Work is underway to derive functional β-
cells from patient derived stem cells, removing the prospect of rejection and need for 
immunosuppression (74). There is hope that in the future implantation of patient-
derived β-cells will be possible and type 1 diabetes will no longer be a life-long disease. 
Study of the cellular pathology of type 1 diabetes in humans has been limited as very 
few samples (approximately 200) from recent onset patients exist (75). All come from 
cases where recently diagnosed patients died, as biopsy of the pancreas is not 
feasible; a recent study where researchers resected part of the pancreas of individuals 
with new-onset type 1 diabetes was terminated prematurely due to severe 
complications bought on by the procedure (76). Animal models have therefore been 
extensively employed to study the pathogenesis of type 1 diabetes. 
The NOD mouse model 
The Non-Obese Diabetic (NOD) mouse (also known as the NOD/ShiLtJ mouse) has 
been widely used as a model organism to study the pathology of type 1 diabetes. 
Approximately 90% of female mice and 52% of males develop insulin requiring 
diabetes by the age of 30 weeks, with the median age of onset in females 18 weeks 
(77). There are broad similarities between human T1D and NOD mice; both develop 
diabetes early in life, both produce autoantibodies against insulin and the disease has 
strong association with the HLA class II molecules in both murine and human disease. 
Histologically, infiltration of mouse β-cells by leukocytes is evident from around 3 
weeks of age and shows some similarities to that observed in human disease (78). 
90 
 
The NOD mouse model has been invaluable to furthering understanding of type 1 
diabetes, however key differences in the physiology of the immune system (79) 
pancreas (both macro- and microscopically) (80) and the immunopathology of insulitis 
exist (81). Furthermore, disease prevention/delay in NOD mice is possible by the 
application of over 125 therapies, none of which have been translated to treating 
human type 1 diabetes (59).  
BIOMARKERS 
Biomarkers are quantifiable and objective molecular signatures which are indicative of 
a biological state or disease and can be measured robustly and in a reproducible 
manner (82, 83). In human healthcare, biomarkers are broadly categorised as either 
prognostic or predictive. Prognostic biomarkers are associated with outcome 
regardless of treatment and indicate the incidence or progression of disease, for 
example the measurement of serum triglyceride and LDL cholesterol to predict the 
likelihood of cardiovascular disease (84). They may also be useful as a diagnostic aid, 
for example thyroid peroxidase antibody can be used to determine the aetiology of 
thyroid disease (85). Predictive biomarkers provide information on the likelihood of 
treatment response for example in the testing of the activating BRAF V600E mutation 
in melanoma. The identification of the mutation predicts treatment response to 
selective BRAF inhibitors which give improved survival and reduced disease 
progression (86). Biomarkers are also commonly used as a surrogate endpoint in 
clinical trials of novel therapeutics. 
An ideal biomarker will be easily obtained from the patient/study participant and be 
minimally invasive (i.e. presence in urine/blood is preferable to presence in a tissue 
biopsy). It should also be cost effective to assay, with high sensitivity/specificity for the 
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disease or condition being tested and a high level of reproducibility across centres. A 
rapid turnaround time from testing to result is beneficial, and therefore if a novel 
biomarker is amenable to automation and can be tested in common widely-adopted 
systems this will desirable. The biomarker should also perform consistently between 
different genders and ethnicities (87). 
Biomarkers in autoimmune type 1 diabetes 
Previous studies have shown that biomarkers are useful to distinguish monogenic 
diabetes and type 2 diabetes (T2D) from autoimmune type 1 diabetes (T1D) (88, 89). 
For example, the presence of either glutamate decarboxylase (GAD) and islet antigen-
2 (IA2) autoantibodies are sensitive and specific (>0.57 and >0.99, respectively) for 
differentiating T1D from non-autoimmune monogenic diabetes, although their utility as 
a biomarker reduces relative to increasing time post-diagnosis. This is probably due 
to the reduce concentration of the antibodies in serum which reflects the cessation of 
the autoimmune process as all beta-cells are destroyed with time (90). Islet 
autoantibodies also have some use in predicting progression to diabetes in relatives 
of patients with T1D; positivity for at least two islet autoantibodies infers a 61% risk of 
developing T1D over 10 years (91). 
The production of C-peptide can be used to measure endogenous insulin secretion in 
patients with diabetes after the honeymoon period, differentiating between T1D and 
T2D or monogenic diabetes and also monitoring progression to insulin deficiency in 
T1D (89). This is important as treatment strategy relies on correct classification – T2D 
and maturity onset diabetes of the young (MODY) can be treated with oral 
hypoglycaemic agents in the majority of cases, whereas autoimmune diabetes 
requires insulin treatment.  
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Whilst pancreatic autoantibodies and/or c-peptide may be useful in differentiating 
monogenic autoimmune diabetes from MODY or T2D, their utility in distinguishing 
between T1D and monogenic autoimmune diabetes is less useful. As diabetes in 
monogenic autoimmunity is likely to result from the lymphocytic infiltration and 
destruction of the pancreatic islets, islet auto-antibodies are often present in 
individuals with monogenic autoimmune disease (45, 92, 93). Similarly to T1D, C-
peptide is also unlikely to be detectable in these individuals as the disease progresses. 
Furthermore, most patients require insulin in full replacement doses suggesting 
complete loss of pancreatic beta cells. 
Biomarkers in monogenic autoimmunity 
Some subtypes of monogenic autoimmunity have biomarkers which can be used to 
indicate the underlying genetic aetiology. The majority of individuals with IPEX 
syndrome, caused by hemizygous mutations in FOXP3, can be identified by flow 
cytometry by the absence of FOXP3+CD25+CD4+ T cells (regulatory T cells) (94). 
However, in a small number of cases with IPEX syndrome a normal number of 
regulatory T cells is observed (95). The reason for this difference in the immunological 
profile of patients with IPEX is not fully understood, and further studies assessing the 
sensitivity and specificity of this measure as a biomarker are warranted.  
A further example is seen with the absence of LRBA expression in individuals with 
common variable immunodeficiency-8 (CVID-8; caused by biallelic LRBA mutations). 
This approach was recently successfully employed to identify patients for genetic 
testing (96). In a cohort of 84 patients with a phenotype suggesting CVID-8, 24 had no 
expression of LRBA and in 14 of those recessive mutations in LRBA were identified. 
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Autoantibodies against harmonin and villin have been shown to be useful biomarkers 
for identifying patients with IPEX syndrome. Of 13 IPEX patients tested, 12 were 
positive for anti-harmonin antibodies and 6 for anti-villin antibodies. None of the age 
matched controls (n=321) or patients with an IPEX-like phenotype but no mutation in 
FOXP3 (n=14) were above the reference range (97). Non-specific Immunoglobulin E 
(IgE) can also aid in the identification of individuals with IPEX syndrome, with >90% of 
patients having raised serum IgE concentrations, some with levels 100x the upper limit 
of the normal reference range (98). In addition, autoantibodies to type 1 interferons 
have been shown to be highly specific (>99.5%) and sensitive (86%) to identify 
patients with Autoimmune Polyendocrinopathy Syndrome type 1 (APS1) caused by 
biallelic AIRE mutations (93, 99, 100). 
Why are they needed?  
Identifying affordable and specific biomarkers for further types of monogenic 
autoimmunity could enable selective genetic testing, reducing the time to diagnosis 
and cost. Furthermore, the introduction of gene panel tests has increased the 
identification of variants of uncertain significance and as such information provided by 
the analysis of biomarkers which supports a clinical diagnosis will aid in variant 
interpretation. This is especially true for variants identified in individuals from ethnic 
groups which are under-represented in large sequence variant databases. 
GENETIC RISK SCORES 
Common diseases often have a complex aetiology involving multiple genetic risk 
factors which, in combination with environmental factors, lead to the onset of disease. 
These polygenic diseases have varying heritability, with the total heritability of T1D 
estimated to be up to 88% based on twin concordance studies (101). 
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Individual ‘hits’ identified by genome-wide association studies (GWAS) each have a 
small contribution to disease risk but in combination can be used to derive a genetic 
risk score (also known as a polygenic risk score, polygenic score or genome-wide 
score) for a patient. This can provide an estimate of the risk of disease development 
or can be used to stratify patients with overlapping phenotypes. This is particularly true 
for diabetes, where patients with similar clinical features at presentation (i.e. raised 
blood glucose, increased thirst and urination) can have distinct aetiologies and are 
responsive to specific treatments.  
Polygenic risk of type 1 diabetes 
GWAS have identified >50 loci that contribute to the risk of developing T1D (57). The 
HLA DR locus confers the strongest risk with compound heterozygotes for the 
DR3/DR4 haplotype having the greatest odds ratio of 48.18, meaning those carrying 
this combination of HLA haplotypes are >48x more likely to develop type 1 diabetes 
than those with neither (table 1) (102). Of the loci outside of the HLA region, the 
PTPN22 loci has the largest effect, with an odds ratio of 1.96 (102). 
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HLA DR 
allele(s) 
Odds ratio 
Weight 
 
(ln(OR)) 
DR3/DR4 48.18 3.87 
DR3/DR3 21.12 3.05 
DR4/DR4 21.98 3.09 
DR4/X 7.03 1.95 
DR3/X 4.53 1.51 
 
Table 1: Odds ratios of HLA haplotypes conferring high risk for type 1 diabetes. 
‘X’ refers to any HLA DQ allele that is not DR3 or DR4. Odds ratios taken from Winkler 
et al. 
 
To generate a genetic risk score genotyping for the target SNPs is undertaken and the 
weighted odds ratios (ln(OR)) multiplied by the number of risk alleles (0, 1 or 2) at that 
loci. The total number is divided by the number of alleles to achieve a single score 
wherein each risk allele has a log-additive effect (103). This number can then be 
compared to large control cohorts to estimate the likelihood of a patient having a 
disorder – for example in T1D the score can be compared to the range of scores of 
gold standard WTCCC T1D patients and non-diabetic controls.  
The T1D genetic risk score (T1D-GRS) has proven to be useful in distinguishing T1D 
from T2D (103) in young people, where discrimination is becoming increasing complex 
with rising obesity rates increasing the incidence of type 2 diabetes in those under 30. 
Patel et al used a similar approach to show that the T1D-GRS could distinguish non-
autoimmune monogenic diabetes from T1D, which has important applications both in 
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clinical practise as well as in research settings to look for novel monogenic diabetes 
genes (104). In MODY the T1D-GRS is currently in clinical use in combination with 
biomarkers and clinical features to select patients for testing of the known genes (105). 
The correct classification of diabetes subtype at diagnosis allows for patients to be 
placed on the most effective treatment early on and may inform families and clinicians 
of recurrence risk. 
Conclusion 
Biomarkers are effectively used in diagnosing existing types of monogenic 
autoimmunity and can help select some patients for sequencing of known genes. The 
established biomarkers for T1D (islet autoantibodies and C-peptide) can differentiate 
T1D from non-autoimmune monogenic diabetes but are unlikely to be effective to 
identify monogenic autoimmune from T1D as both have autoimmune destruction of 
pancreas. Genetic risk scores have proven utility in the identification of T1D from 
young-onset T2D and in identifying T1D from non-autoimmune monogenic diabetes. 
Correct classification of diabetes allows for the most effective treatment to be utilised 
early on in disease course. 
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This chapter summarises the methods used throughout this thesis. Each published 
data chapter also contains information on specific methodologies used for that 
chapter. 
 
Immunoglobulin testing 
To perform immunoglobulin testing (chapters 1, 2, 3 and 4) plasma was separated 
from whole blood in EDTA blood tubes. This was performed by the Exeter Molecular 
Genetics laboratory and the Royal Devon and Exeter Hospital biochemistry 
department. Briefly, samples were centrifuged at 1300g for 8 minutes and the resulting 
plasma layer was aliquoted into additional tubes and stored at -80oC. Plasma was 
converted to serum by the addition thrombin to remove fibrinogen and then calcium 
chloride to induce clotting [56]. 
Automated Immunoglobulin (Ig) measurement was performed on an ImmunoCAP 
1000 instrument (Phadia, Uppsala, Sweden), which uses an enzyme-linked 
immunosorbent assay (ELISA). This involves using covalently bonded antibodies 
against the analyte of interest to specifically bind the analyte, in this case an 
immunoglobulin. Enzyme-labelled antibodies against the analyte are then added 
forming a complex. The substrate for the enzyme is then added and the product of its 
digestion measured. Thus, a quantitative measurement of the analyte can be 
achieved. General assays were used for the measurement of total IgE (Chapter 4) and 
specific assays were used for the measurement of anti-glutamic acid decarboxylase, 
anti-islet antigen-2 and anti-zinc transporter 8 antibodies (RSR, Cardiff, UK) (Chapters 
1, 2 and 3). 
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DNA extraction and quantification  
 
DNA extraction from whole blood leukocytes was used in chapters 1, 2 and 3. Most of 
this was performed by the Exeter Molecular Genetics laboratory and the Royal Devon 
and Exeter Hospital. The process was largely automated on the ChemagicSTAR 
instrument (Perkin Elmer, Waltham MA, USA). Briefly, this involved lysis of the 
leukocyte cells from EDTA-whole blood then binding of the nucleic acids to magnetic 
beads. Successive washes to remove cell components and other contaminants was 
performed on the beads before a final elution step into Tris-EDTA buffer. 
Quantitation was initially performed by UV-Vis spectrophotometry on the NanoDrop 
8000 (Thermo Scientific, Waltham MA, USA). This measures the absorbance of light 
at 260nm and 280nm to determine the concentration of nucleic acids within the 
sample. It can also give an estimation of purity by the ratio of absorbance at 
260/280nm and 260/230nm – with a 260/280nm ratio of 1.8 indicative of highly pure 
DNA against RNA and a 260/230 ratio of between 2.0 and 2.2 is indicative of pure 
nucleic acid against protein.  
As UV-Vis spectrophotometry is non-specific for DNA and applications such as droplet 
digital PCR (chapter 3) and Next Generation Sequencing (chapters 1, 2 and 3) require 
highly accurate quantitation of double stranded DNA (dsDNA), further quantification 
was performed with the Qubit Fluorometer (Thermo Scientific, Waltham MA, USA). 
This assay uses a specific intercalating dye that binds to dsDNA and fluoresces only 
when bound. The measured fluorescence was therefore compared to a standard curve 
created from samples with known concentration to obtain an accurate concentration 
of dsDNA. 
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Polymerase Chain Reaction (PCR) 
 
Polymerase chain reaction, followed by Sanger sequencing was used throughout this 
thesis to confirm findings from Next Generation Sequencing, screen genes where a 
specific phenotype indicated testing or for the testing of family members to confirm 
carrier status. Polymerase chain reaction amplifies a region of the DNA sample by 
several orders of magnitude, meaning that after around 35 cycles, millions of copies 
of the target region are present. It relies on DNA polymerase which creates a 
complimentary copy of the template within the target region. Specific primers for the 
relevant genomic regions (coding regions -50 and +10 to capture branch sites and 
canonical splice sites) were designed in silico using primer3plus software, the NGRL 
SNPcheck tool and NCBI primer BLAST to ensure specificity [57]. An M13 tail was 
added to all primers to enable high-throughput Sanger sequencing to be undertaken 
(table 1) 
 
M13 primer Sequence (5’ – 3’) 
Forward TGTAAAACGACGGCCAGT 
Reverse CAGGAAACAGCTATGACC 
 
Table 1: M13 primer sequences. The M13 sequence was added to all PCR primers 
to incorporate the sequence into the resulting amplicons. 
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Droplet digital PCR (ddPCR) 
 
Digital droplet PCR was used in chapters 1 and 3 to confirm putative mutations 
identified by targeted NGS. The BioRad ddPCR protocol is a technique based on 
partitioned polymerase chain reaction. The sample and reagents are partitioned into 
~20,000 individual nanolitre droplets such that each droplet acts as an individual 
reaction (figure 1A). This means that the reaction can be measured as thousands of 
individual amplification events within a single genomic sample and the mosaicism of 
variants and copy number of deletions/insertions can be accurately and absolutely 
quantified (figure 1B). The reaction incorporates fluorescent dyes which can be 
detected to determine the presence/absence of the target defined by the PCR primers.  
Briefly, the sample is quantified using the Qubit fluorometer and diluted to 4ng/µL 
before adding to a mastermix containing a TaqMan reporter dye, polymerase and 
assay-specific primers. The sample and droplet generation oil are loaded into a 
cassette and droplets are then generated using the BioRad Droplet Generator. The 
reaction is then run on a thermocycler and when complete is placed into the droplet 
reader. This pulls the droplets in single file past a detector to detect the presence or 
absence of the intercalated dye and thus the target sequence. 
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Figure 1 ddPCR. A: Droplet digital PCR can offer absolute quantification as each 
droplet can be counted as a separate reaction within a single well. B: Data from the 
confirmation of an LRBA exon 30 deletion identified in a proband by targeted NGS. 
The proband has 19 positive droplets, in keeping with the false positive rate due to 
non-specific amplification by the PCR primers. Both parents have ~50% positive 
droplets compared to the normal control. 
 
  
A B 
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Dideoxy chain terminator sequencing (Sanger sequencing) 
 
Dideoxy chain terminator sequencing (Sanger sequencing), as pioneered by Frederick 
Sanger and colleagues in 1977, remains the gold standard for the detection of single 
nucleotide polymorphisms and small insertions and deletions within DNA and was 
used in chapters 1, 2 and 3. Usually used following PCR, it involves the use of chain-
terminating fluorescently labelled di-deoxynucleotides to prevent elongation of the 
complementary strand by DNA polymerase. When used through multiple cycles, this 
creates a series of DNA fragments which differ in size by one nucleotide. Each 
fragment has a fluorescently labelled nucleotide at its 3’ end and a capillary 
electrophoresis machine (3730 DNA analyser, Applied Biosystems, Waltham MA, 
USA) can be used to separate the fragments by length. The fragments are passed in 
front of an excitatory laser and the fluorescence emitted is read by a detector. Thus, 
an image (electropherogram) is formed of the sequence which can be compared to 
the reference sequence.  
Next Generation Sequencing 
Massively parallel high throughput sequencing (Next Generation Sequencing, NGS) 
has revolutionised the way in which human molecular genetic research is performed. 
Using this methodology enables vast amounts of sequencing data to be generated, 
with a single NextSeq500 run generating approximately 120 billion bases of data in 
~24 hours. This compares to approximately 700 thousand bases of data generated in 
a similar timeframe by Sanger sequencing. 
This technique has been utilised in this thesis to test multiple genes, including in 
combination with in-solution hybridisation to test all coding genes (exome sequencing), 
and for the custom targeted capture of genetic regions of interest (chapters 1, 2 and 
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3). We utilised the Illumina sequencing by synthesis method on an Illumina HiSeq 
2500 (Exeter Sequencing Service, University of Exeter) or NextSeq 500 (in house) for 
exome sequencing and targeted NGS.  
Custom Targeted Next Generation Sequencing 
In order to rapidly assess the multiple genes causing monogenic autoimmune disease, 
as well as rule out the known causes of monogenic diabetes, in-solution hybridisation 
to biotinylated RNA baits complementary to the target region was used, relying on a 
customised version of the Agilent SureSelect protocol (figure 2; Chapters 1, 2, 3 and 
4; [58]). In brief, this involved fragmenting DNA samples to ~200bp, repairing the ends 
of the fragments to blunt ends, the addition of an adenosine base to the end of each 
fragment, ligation to adaptors containing universal primer sequences, illumina 
sequencing compatible hybridisation regions and unique molecular barcodes of 6bp, 
and a PCR step to enrich the sample for adapted molecules. Samples were then 
multiplexed (12-plex) and hybridised overnight with the biotinylated RNA baits to 
capture adapted fragments within the region of interest. Capture on streptavidin coated 
beads followed by washing and amplification of the captured fragments was performed 
before QC analysis and pooling for sequencing. A list of the genes in our custom 
targeted panel is provided in appendix 1. 
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Figure 2: Stylised diagram of SureSelect enrichment protocol for exome 
sequencing and targeted NGS. 1. Genomic DNA is fragmented to ~200bp. 2. 
Adapter sequences are added that include a patient specific indexing sequence and 
Illumina sequencer hybridisation regions. 4. Adapted fragments are hybridised 
overnight to biotinylated RNA baits specific for the target sequence. 5. Hybridised 
DNA is captured on streptavidin coated paramagnetic beads which are magnetically 
separated and purified. 6. After amplification and quantification, the captured library 
is sequenced. 
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Exome Capture 
Exome sequencing (chapter 3) is a targeted sequencing method that captures the 
majority of the coding regions of the genome. While massively parallel sequencing is 
cheaper per-base than dideoxy chain terminator sequencing, the cost of whole 
genome sequencing remains prohibitively expensive and the storage, processing and 
analysis of data is cumbersome. Moreover, the ~1% of the human genome that 
encodes proteins has been extensively characterised meaning interpretation of 
sequence variation in this region is easier. Exome sequencing therefore offers a cost-
effective strategy to identify Mendelian disease genes. Exome sequencing was used 
based on the Agilent SureSelect protocol (see targeted sequencing above and figure 
2), using the exome capture library all-exon v5 or v6 (total region targeted: 50 or 60Mb 
respectively, details available at http://www.genomics.agilent.com/en/SureSelect-
DNA-Target-Enrichment-Baits-NEW/SureSelect-Human-All-Exon-V6/?cid=AG-PT-
124&tabId=AG-PR-1308). 
Massively parallel high throughput sequencing (Illumina) 
Massively parallel high throughput sequencing for both the custom targeted capture 
panels and exome sequencing was undertaken on either the HiSeq 2500 instrument 
or NextSeq500 instrument (Illumina, San Diego CA, USA). Adapted fragments (the 
sequencing library) are washed across a flow cell which contains covalently bonded 
oligonucleotides which are complementary to the ends of the adapters to hybridise the 
library to the flow cell. Clonal amplification is used to create thousands of identical 
copies of each of the fragments in a discrete space, termed clusters. Fluorescently 
labelled nucleotides which have reversible chain terminating regions are then added 
to the flow cell and an image taken of the growing DNA molecules between each 
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addition. This allows for the base that is added to be measured and a read of the 
sequence to be generated.  
Bioinformatics analysis 
To analyse the large quantities of data generated by next generation sequencing 
specialised computer hardware and software is required. An overview of a generic 
pipeline for the analysis of NGS data is given in figure 3 with a brief description of each 
step, and specific information on the pipelines used in this thesis is included in sections 
below. 
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Figure 3: overview of bioinformatics pipeline. A brief description of the individual 
steps is given, as well as the software/tool used. The underlying code of the specific 
pipeline used to analyse data can be found at 
[https://github.com/matt0johnson/tNGS_v5] 
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Targeted NGS pipeline 
This pipeline was initially developed by Hana Lango-Allen (University of Exeter 
Medical school, Exeter, UK), with ongoing maintenance and additions to the code by 
Andrew Parrish and Garan Jones, Thomas Laver and Matthew Johnson (University of 
Exeter Medical school, Exeter, UK and Royal Devon and Exeter NHS Trust, Exeter, 
UK). It utilises the core steps outlined in figure 3 however includes the following 
additional analyses; 
i) Copy number variation analysis using ExomeDepth software [59] 
ii) Parsing of the data into a customised and accessible format which includes 
relevant detail for analysis and key metrics for the sample 
iii) Calling of variants only in regions of interest to minimise incidental findings 
 
Exome pipeline 
This pipeline was primarily developed by Matthew Wakeling (University of Exeter 
Medical School, Exeter, UK). It is similar to the tNGS pipeline but includes the following 
information; 
i) Homozygosity mapping by looking for blocks of homozygous single nucleotide 
variants to identify regions putatively identical by descent 
ii) Analysis of relatedness of parent-proband trios to ensure correct identification 
of de novo variants 
iii) Analysis of off-target reads (those not in coding regions) to look for large 
structural variants and karyotype changes 
iv) Contamination analysis by looking at the balance of heterozygous calls (true 
heterozygous calls should have read depths of approximately 50%).  
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Type 1 Diabetes Genetic Risk Score (T1D-GRS) 
To generate the T1D-GRS (chapter 1) samples were first genotyped for the top 10 risk 
SNPs/alleles (table 2) either by Sanger sequencing, targeted NGS or externally by 
LGC genomics’ proprietary KASP assay (Middlesex, UK). The resulting genotypes 
were then scored based on their weighted risk (ln(odds ratio)) and allele count (0, 1 or 
2). The scores were summed and divided by the total number of alleles to achieve a 
log additive risk score. This was compared to controls (WTCCC type 1 diabetes or 
non-diabetic control cohorts) to provide an indication of the likelihood of patients 
having type 1 diabetes or a monogenic cause. 
SNP(s) Gene/allele Odds Ratio Weight 
rs2187668, 
rs7454108 
DR3/DR4-DQ8 48.18 3.87 
DR3/DR3 21.12 3.05 
DR4- DQ8/DR4-
DQ8 21.98 3.09 
DR4-DQ8/X 7.03 1.95 
DR3/X 4.53 1.51 
rs1264813 HLA_A_24 1.54 0.43 
rs2395029 HLA_B_5701 2.5 0.92 
rs3129889 HLA_DRB1_15 14.88 2.7 
rs2476601 PTPN22 1.96 0.67 
rs689 INS 1.75 0.56 
rs12722495 IL2RA 1.58 0.46 
rs2292239 ERBB3 1.35 0.3 
rs10509540 C10orf59 1.33 0.29 
 
Table 2: top 10 risk SNPs for type 1 diabetes and their weighted risk. 
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Statistical analysis 
Statistical analyses were undertaken in Stata 14 (Statacorp, TX, USA) and the tests 
used are detailed in each chapter. These included parametric and non-parametric 
tests as appropriate. 
Ethical approval 
Specific ethical approval was not required for this thesis as the studies herein were 
undertaken using samples from the Exeter beta cell research bank with ethical 
approval from the North Wales Ethical Committee, who specialise in genetic studies 
into rare diseases.  
Patient recruitment and follow up 
Referrals were taken for all patients with diabetes that was diagnosed in the first six 
months of life, or where diabetes was diagnosed in a patient before the age of 5 years 
and an additional autoimmune disease was present, also diagnosed before 5 years.  
To obtain accurate clinical information from the patients a bespoke request form was 
designed and used to collect information from clinicians about incident and prevalent 
cases of multiple early-onset autoimmune disease (available at 
http://www.diabetesgenes.org/content/early-onset-diabetes-and-autoimmunity and 
appendix 2). This allowed for standardised information to be collected, while also 
allowing for free text to be added. The samples are securely stored in Exeter Molecular 
Genetics laboratory at the Royal Devon and Exeter NHS foundation trust. 
 
Clinical information was collated in a password protected database stored on the on 
the Royal Devon and Exeter NHS foundation trust’s secure servers. Follow up and 
correspondence was by email enabling rapid communication of results and new 
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clinical manifestations. For international referrals consent was taken and held locally 
by the referring clinician, and for UK referrals consent was obtained as part of the 
Exeter beta cell research bank (http://www.diabetesgenes.org/content/genetic-beta-
cell-research-bank). 
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ABSTRACT  
Aims/hypothesis 
Identifying patients suitable for monogenic autoimmunity testing and gene discovery 
studies is challenging: early-onset type 1 diabetes mellitus (T1D) can cluster with 
additional autoimmune diseases due to shared polygenic risk and islet and other organ 
specific autoantibodies are present in patients with both monogenic and polygenic 
aetiologies. We aimed to assess if a type 1 diabetes genetic risk score (T1D-GRS) 
could identify monogenic autoimmune diabetes and be useful to prioritise patients for 
gene discovery studies.  
Methods 
We studied 79 patients with diabetes and at least 1 additional autoimmune disease 
diagnosed before 5 years. We screened all patients for variants in  7 genes known to 
cause monogenic autoimmunity that can include diabetes (AIRE, IL2RA, FOXP3, 
LRBA, STAT1, STAT3, STAT5b). We genotyped all patients for the top 10 risk alleles 
for T1D, including HLA and non-HLA loci, to generate a T1D-GRS. 
Results 
47% (37/79) of individuals had mutations in the monogenic autoimmunity genes. The 
T1D-GRS was lower in these patients compared to individuals without mutations in 
these genes (median 9th vs. 49th centile T1D controls (p<0.0001). Age of diabetes 
diagnosis and T1D-GRS combined to be highly discriminatory of monogenic 
autoimmunity (ROC-AUC: 0.88). Most patients without a mutation in a known gene 
had a high T1D-GRS, suggesting they have polygenic clustering of T1D and additional 
autoimmunity and should not be included in gene discovery studies. 
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Conclusions 
We have shown that the T1D-GRS can identify patients likely to have monogenic 
autoimmunity helping both diagnostic testing and novel monogenic autoimmunity gene 
discovery. Patients with monogenic autoimmunity have a different clinical course to 
those with polygenic type 1 diabetes (T1D) and can respond well to therapies targeting 
the underlying genetic defect.  
KEYWORDS 
Monogenic autoimmune diabetes, Genetic Risk Score, Type 1 diabetes, Gene 
discovery 
 
ABBREVIATIONS 
• AITD – autoimmune thyroid disease 
• CD – coeliac disease 
• GRS – genetic risk score  
• IPEX – immunodysregulation, polyendocrinopathy, enteropathy, X-linked     
syndrome 
• NGS – next generation sequencing 
• T1D – type 1 diabetes mellitus 
• T2D – type 1 diabetes mellitus 
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Monogenic autoimmune disease often presents with very early-onset diabetes. 
For example, hemizygous mutations in FOXP3 cause IPEX (Immunodysregulation, 
polyendocrinopathy, enteropathy, X-linked) syndrome, which presents in the neonatal 
period with diabetes, protein-losing enteropathy and severe eczema [1] and patients 
with infantile-onset multisystem autoimmune disease due to dominant gain-of-function 
STAT3 mutations or common variable immunodeficiency 8 with autoimmunity due to 
recessively inherited LRBA mutations may present with neonatal diabetes [2, 3].  
While some patients harbour a causative mutation in a single gene, the clustering of 
very early-onset diabetes with autoimmune disease is often due to a strong polygenic 
risk resulting from shared predisposing genetic loci. It is well established that the HLA-
DR3 haplotype is associated with the development of type 1 diabetes mellitus (T1D) 
[4] and coeliac disease (CD) through its strong linkage with the HLA-DQ2 haplotype 
[5]. Outside the HLA region the IL2RA polymorphism rs706778 is associated with 
increased risk of T1D, autoimmune thyroid disease (AITD) and CD, as well as other 
paediatric-onset autoimmune disorders [6].  
The phenotypic overlap between the two groups means identifying patients for testing 
is difficult using clinical features or biomarkers. While islet auto-antibodies are highly 
discriminatory of T1D against type 2 diabetes (T2D) and maturity onset diabetes of the 
young (MODY) [7, 8], they are often present in patients with monogenic autoimmunity. 
For example, multiple islet autoantibodies are present in more than half of individuals 
with IPEX syndrome [9]. Moreover, as it is thought that these patients have 
autoimmune destruction of the pancreatic β cells [10], serum C-peptide levels and 
treatment type or dose is also likely to be similar in the two groups.  
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The type 1 genetic risk score (T1D-GRS) is calculated by genotyping the top risk 
alleles and summing their effective weight to assign a numerical score to the patient 
that can be compared to control samples [11]. It was recently shown to be highly 
discriminatory of non-autoimmune monogenic diabetes and T2D from T1D [11, 12]. 
We sought to determine if the T1D-GRS could distinguish between monogenic 
autoimmunity and polygenic clustering of autoimmune disease. Our results show that 
it performs better than clinical features or biomarkers in this patient group.  
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RESEARCH DESIGN AND METHODS 
Study cohorts 
Patients with early-onset autoimmunity 
We studied 79 patients diagnosed with diabetes and >1 additional autoimmune 
disorder before the age of 5 years referred to Exeter Molecular Genetics laboratory 
between 2005-2017(table 1). All patients had previously been screened for all known 
monogenic diabetes genes [13]. Clinical information was supplied by the referring 
clinician from the patient’s medical notes.  
T1D controls 
As previously described [12], we used T1D controls from the Wellcome Trust Case 
Control Consortium (WTCCC) [14]. These 1963 patients from the WTCCC T1D cohort 
have a clinical diagnosis of T1D, were diagnosed before 17 years and insulin treated 
from diagnosis.  
Methods 
Genetic Testing 
We used targeted next generation sequencing (NGS) as previously described [13] to 
test the 7 genes known to cause monogenic diabetes with autoimmunity (AIRE, IL2RA, 
FOXP3, LRBA, STAT1, STAT3, STAT5b) in 79 individuals. All putative mutations were 
confirmed by Sanger sequencing or digital droplet PCR (primers available on request). 
T1 Genetic Risk Score 
In order to generate a T1D-GRS we genotyped the top 10 SNPs with the largest effect 
size as previously described, including both HLA and non-HLA regions [11, 12] 
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(supplementary table S1) by targeted NGS, Sanger sequencing (primer sequences 
available on request) or the KASP assay (LGC Limited, Middlesex, UK).  
Statistical analysis 
Logistic regression and receiver operating characteristic (ROC) curve analysis was 
used to assess the discriminatory power of biomarkers, clinical features and the T1D-
GRS. Parametric (t test) and non-parametric (Mann-Whitney U) tests were used for 
continuous variables and the Fishers Exact test was used to compare categorical 
variables. Statistical analyses were performed in Stata 14 (StataCorp LP, College 
Station, TX). 
Antibody testing 
Antibody testing for anti-Glutamic Acid Decarboxylase (GAD), anti-Zinc Transporter 8 
(ZnT8) and anti-Islet Antigen 2 (IA-2) was performed as previously described when 
serum was available (n=43) [8]. 
Ethical approval 
The study was approved by the Genetic Beta Cell Research Bank, Exeter, U.K. with 
ethical approval from the North Wales Research Ethics Committee, U.K.  
138 
 
RESULTS 
Molecular genetics 
A mutation in a known monogenic autoimmunity gene was identified in 47% (37/79) of 
the individuals with diabetes and >1 autoimmune disorder diagnosed before 5 years; 
25 males had a hemizygous mutation in FOXP3, 8 patients had recessively inherited 
mutations in LRBA, two had recessively inherited IL2RA mutations and two patients 
had heterozygous gain-of-function STAT3 mutations. 12 of these patients have been 
reported previously [2, 3, 15]. The remaining 42 patients have early-onset multiple 
autoimmunity but do not have a mutation in a known gene. The group of individuals 
with “unknown aetiology” will either have a polygenic predisposition to diabetes and 
other autoimmune disease or a monogenic cause of autoimmunity, which includes 
diabetes, which has not been described to date. 
The T1D-GRS is lower in monogenic autoimmunity than in patients with multiple 
autoimmune disease of unknown aetiology 
Patients with confirmed monogenic autoimmunity had a markedly lower median T1D-
GRS than those with early-onset autoimmunity of unknown aetiology (9th v 49th centile 
of T1D p = <0.0001); figure 1. Patients with unknown aetiology had a similar median 
T1D-GRS as the T1D controls (49th v 50th T1D centile p = 0.63).  
The likelihood of identifying monogenic autoimmunity increases with 
decreasing T1D-GRS 
When the entire cohort of 79 patients was split into quartiles that were defined by the 
T1D controls the likelihood of identifying monogenic autoimmunity decreased as the 
T1D-GRS increased. 69% (29/42) with a score below the 25th centile had a mutation 
in a known gene whilst 0% (0/11) with a T1D-GRS above the 75th centile had a 
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mutation in a known gene (Figure 2B). 79% (11/14) of those below the 5th centile had 
a mutation in a known gene and 0% (0/8) above the 95th centile had a mutation in a 
known gene (data not shown).  
Most of those with unknown aetiology are likely to have polygenic clustering of 
type 1 diabetes and additional autoimmunity 
The 42 patients who do not have a known cause of monogenic autoimmunity have a 
similar distribution between the four T1D-GRS quartiles as seen in T1D controls 
(p=0.38, figure 2A). This would fit with the majority of the patients, where a known 
cause was not found, having polygenic Type 1 diabetes. The 37 patients with 
confirmed monogenic autoimmunity were most likely to have a low T1D-GRS: 78% 
(29/37) of those with monogenic autoimmunity were in the first quartile of T1D-GRS 
while none (0/37) were in the fourth quartile (figure 2B, p<0.0001).  
Those with monogenic autoimmunity developed diabetes earlier and had 
broadly different clinical features to those with unknown aetiology 
Clinical features of those with and without a known cause of monogenic diabetes are 
shown in table 1. The patients with confirmed monogenic autoimmunity were typically 
diagnosed earlier than those with unknown aetiology (5 weeks [IQR: 1-18] vs. 36 
weeks [IQR: 26-44], p<0.0001). A similar proportion of patients had a positive result 
for at least one of anti-GAD, IA-2 or ZnT8 autoantibodies: 44% (8/18) with mutation 
and 44% (11/25) unknown aetiology p = 1.00). When restricted to patients positive for 
>1 islet autoantibody (n=19), the GRS was lower in those with monogenic 
autoimmunity (0.558 [IQR: 0.528-0.613] vs. 0.716 [IQR: 0.670-0.819], p = 0.0005). 
Insulin dose and the median number of autoimmune features were similar. 
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Organ specific disorders showed different frequencies in the two groups (Table 1, 
overall p = 0.0002). Patients with  monogenic autoimmunity were more likely to have 
autoimmune enteropathy (p=0.01 OR 3.8 [95% CI 1.3-10.8]) or glomerulonephritis 
(p=0.008 OR17.5 [95% CI 0.95-323.0]) and less likely to have thyroid disease (AITD) 
and/or coeliac disease (CD)) compared to patients with autoimmunity of unknown 
aetiology (p=0.001, OR 5.3 [95% CI 1.8-16.6]) The clustering of T1D, coeliac and 
thyroid disease in those without a known cause of monogenic autoimmunity is likely 
to reflect the shared predisposition resulting from HLA-DR3 for Type 1 diabetes, 
thyroid disease and coeliac disease. Of the patients with diabetes and AITD or CD, 
18/25 (72%) of those with unknown aetiology and 3/8 of those with a monogenic 
aetiology carry at least one copy of DR3 (supplementary table S2).  
A combination of clinical features and T1D-GRS is highly discriminative of 
monogenic autoimmunity 
The T1D-GRS was highly discriminatory for identifying those with monogenic 
autoimmunity against those with unknown aetiology (figure 3). Receiver operating 
characteristic (ROC) curve analysis gave a ROC area under the curve (ROC-AUC) for 
the T1D-GRS of 0.80 (95% CI: 0.70-0.90). Age of diagnosis had similar ROC-AUC 
(0.79 [95% CI: 0.69-0.90], p = 0.91) and when these 2 features were combined the 
discrimination improved against the T1D-GRS alone (ROC-AUC 0.88 [95% CI: 0.80-
0.95], p = 0.04).   
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DISCUSSION 
We have shown that a T1D-GRS can be used to discriminate patients most likely to 
have a mutation in a monogenic autoimmune gene and could be used to prioritise 
patients for gene discovery studies and, in combination with clinical features, genetic 
testing. Patients with confirmed monogenic autoimmune disease have a markedly 
lower T1D-GRS than those with isolated Type 1 diabetes or Type 1 diabetes 
associated with other autoimmune disease, even when both conditions are diagnosed 
very young.   
The T1D associated antibodies have no discriminatory value, being present both in 
patients with and without monogenic autoimmunity. Whilst pancreatic autoantibodies 
have been previously shown to be specific (>57%) and highly sensitive (>99%) for 
discriminating T1D from non-autoimmune monogenic diabetes [8], we did not observe 
this in our cohort as monogenic autoimmunity often leads to autoantibody production. 
When islet autoantibodies were present, the T1D-GRS was lower in those with 
confirmed monogenic autoimmunity than in patients with an unknown aetiology (0.558 
v 0.716). There is evidence that autoantibodies to harmonin and villin are diagnostic 
markers for patients with IPEX syndrome [16], however we were unable to test this in 
our patients with hemizygous FOXP3 mutations. C-peptide testing is useful for 
identifying type 2 diabetes and MODY from T1D [17], however as monogenic 
autoimmunity is likely to result in destruction of the pancreatic beta cells (as evidenced 
by post-mortem histological studies of  individuals with IPEX syndrome [15, 18, 19])  it 
is unlikely to be useful in this patient group and we were unable to assay serum C-
peptide in our patients. The T1D-GRS (ROC-AUC: 0.80) gave similar discrimination 
of monogenic autoimmunity from unknown aetiology than clinical features (ROC-AUC 
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Age of diagnosis: 0.79) and a combination of these two features gave the best 
discrimination (ROC-AUC 0.88). 
The overlap in clinical features may preclude their use to identify patients with 
monogenic autoimmunity. Age at diabetes onset was a good discriminator between 
the two patient groups, however the range of age of diabetes diagnosis overlapped 
(monogenic autoimmunity: 0-83 weeks, unknown aetiology: 1-258 weeks). While 
autoimmune enteropathy and CD showed different prevalence in those with and 
without a mutation (Table 1) both groups included patients with CD and autoimmune 
enteropathy. Furthermore, at the onset of symptoms these disorders can be 
challenging to distinguish clinically, particularly in very young patients.  
Those with confirmed monogenic autoimmunity were less likely to have AITD or CD in 
addition to T1D than those with an unknown aetiology (22% vs 60%, OR 5.33). This 
is driven by the strong predisposing HLA allele DR3 (through linkage with DQ2) in 
keeping with previous studies on shared HLA risk for these disorders [20]. The same 
effect does not appear to modulate disease in monogenic autoimmunity as none of 
the 5 individuals carrying the highest risk alleles for concurrent T1D and CD - DR3/DR3 
and DR3/DR4 [20] - have CD, and only 3/14 with DR3/X has CD or AITD. Further 
study of a larger group of patients is needed to confirm this effect as it may be that 
they go on to develop CD or AITD later in childhood. We have selected patients with 
an extreme phenotype (diabetes and >1 autoimmune disease diagnosed before 5 
years) hence we have found the extreme genotypes, both for monogenic and 
polygenic disease. 
This study provides evidence that the polygenic risk of developing autoimmune 
diabetes does not affect the development of diabetes in patients with monogenic 
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autoimmunity. Previous reports of individuals with monogenic autoimmunity have 
shown that many patients do not develop diabetes, for example 70% of those reported 
with gain-of-function STAT3 mutations are not diabetic [2, 21, 22]. The known risk 
alleles are not modifying the phenotype in these patients as the polygenic risk of 
developing autoimmune diabetes in our cohort of with diabetes is similar to healthy 
controls (p=0.162, data not shown). Further study of non-diabetic patients with 
monogenic autoimmunity is warranted.  
We propose that the T1D-GRS could be used to prioritise patients for gene discovery 
studies. Our results suggest that a cut-off based on the 25th centile of T1D controls 
would be suitable to guide selection of patients for initial discovery as the majority in 
this group have a monogenic cause. Furthermore, there was a small enrichment of 
individuals in the first quartile of the unknown patients (figure 2A) suggesting some 
patients in this group may have monogenic autoimmunity. These novel causes may 
be mutations in genes not previously associated with disease or deep-
intronic/regulatory mutations in known genes. Identifying these novel aetiologies will 
further the understanding of the adaptive immune system and could provide new 
therapeutic targets as knowledge of the underlying pathway defect can allow 
personalised therapies. This is already happening for patients with recessive LRBA 
mutations who can be treated with abatacept which replaces the lost receptor 
molecule [23] and patients with IPEX syndrome who are amenable to hematopoietic 
stem cell transplantation which, if performed early, can prevent the onset of organ-
specific autoimmunity. Furthermore, identifying novel aetiologies will assist with 
research by preventing patients with monogenic disease from taking part in clinical 
trials aimed at those with a polygenic aetiology.  
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The numbers of patients with monogenic autoimmune disease available to study in 
our cohort is low (n=37) however, to our knowledge, this is the largest series of patients 
with monogenic autoimmune diabetes described in the literature to date. Interestingly 
we did not identify any patients with autoimmune polyendocrine syndrome type I 
(APS1) due to biallelic AIRE mutations. The onset of autoimmune diabetes in APS1 is 
typically later (30-50 years) [24, 25] and the specific clinically defining features, namely 
chronic mucocutaneous candidiasis and hypoparathyroidism, mean their identification 
may present less of a challenge. 
Seven of the 10 genotyped SNPs in this T1D-GRS cover loci that are associated 
(positively or negatively) with >1 autoimmune disease (supplementary table S1) 
however some variants that predispose to multiple clinically distinct autoimmune 
disorders were not included in our panel. A recent meta-analysis of associations with 
childhood onset autoimmune disease, including T1D, identified 22 loci which 
associated with two or more of the disorders in our patient group [6]. A GRS tailored 
for regions with pleiotropic effects could offer higher discrimination of polygenic 
clustering of autoimmune disease and monogenic autoimmunity. 
In conclusion we have demonstrated that the T1D-GRS is useful to discriminate 
clustering of early-onset type 1 diabetes with autoimmunity from monogenic 
autoimmune disease and could be used to prioritise patients for gene discovery 
studies and follow up genetic testing. Identifying these patients can allow for targeted 
treatment, inform families and clinicians of the likely clinical course and increase 
understanding of the human immune system.  
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Table 1: Summary of the main clinical and demographic features of the cohort. 
*Either the result of consanguineous union or from regions with a high rate of 
consanguinity as previously described. †IQR = Inter-quartile range. ‡IPEX syndrome, 
caused by hemizygous mutations in FOXP3, is an X-linked recessive disorder and 
therefore only presents in males, hence the bias toward males in those with confirmed 
monogenic autoimmunity. 
Clinical/demographic 
feature 
Monogenic 
autoimmunity (n=37) 
Unknown 
aetiology (n=42) 
p 
value 
Consanguineous* 19/37 (51%) 11/42 (26%) 0.04 
Male: Female ratio 31:6 25:17 0.03‡ 
Diabetes characteristics 
Median age of diabetes 
diagnosis, weeks (range) 
5 (0 - 83) 36 (1 - 252) <0.001 
Median insulin dose 
(U/Kg/Day) 1.0 (0.6-1.2) 0.8 (0.5-1.1) 0.33 
Islet autoantibody status (n = 43) 
Positive for >1 antibody  8/18 (44%) 11/25 (44%) 1.00 
GAD positive 5/18 (28%) 8/25 (32%) 1.00 
IA2 positive 2/18 (11%) 2/25 (8%) 1.00 
ICA positive 2/18 (11%) 3/25 (12%) 1.00 
ZnT8 positive 1/18 (5%) 0/25 (0%) 0.42 
Additional autoimmune diseases  
Median number of 
additional disorders 
(IQR†) 
2.0 (1.0 – 2.0) 1.5 (1.0 – 2.0) 0.51 
Autoimmune enteropathy 16/37 (43%) 7/42 (17%) 0.01 
Coeliac disease 2/37 (5%) 12/42 (29%) 0.008 
Autoimmune thyroid 
disease (Hypo-
/hyperthyroidism) 
6/37 (16%) 17/42 (40%) 0.025 
Autoimmune 
haematological disease 
(Thrombocytopenia, 
lymphoproliferative 
disease 
or  hepatosplenomegaly) 
5/37 (14%) 6/42 (14%) 1.00 
Atopic dermatitis 6/37 (16%) 5/42 (12%) 0.75 
Alopecia 0/37 (0%) 3/42 (7%) 0.24 
Glomerulonephritis 6/37 (16%) 0/42 (0%) 0.008 
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Figure 1: Boxplot of the T1D-GRS in confirmed monogenic autoimmunity, 
patients with unknown aetiology and T1D controls. The central line within the box 
represents the median and the upper and lower limits of the box represent the 
interquartile range. The whiskers are the most extreme values within 1.5x the 
interquartile range from the 1st and 2nd quartiles. Those with confirmed monogenic 
autoimmunity have a lower median score than T1D controls, while those with unknown 
aetiology have a similar score to the T1D controls.  
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Figure 2: The T1D-GRS in patients with monogenic autoimmunity and patients 
with unknown aetiology. A) The proportion of patients with early-onset multiple 
autoimmunity of unknown aetiology (n= 42) in each quartile based on T1D controls. 
There is an over-representation of individuals with a low T1D-GRS, suggesting there 
are novel monogenic causes remaining to be found in our cohort. B) The proportion 
of patients with confirmed monogenic autoimmunity (n=37) in each quartile based on 
T1D controls. The proportion of patients with a confirmed monogenic cause was higher 
in patients with a low T1D-GRS. 
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Figure 3: Receiver Operating Characteristic (ROC) curve T1D-GRS and T1D-GRS 
combined with age of diabetes diagnosis in the discrimination of patients with 
monogenic autoimmunity from those with unknown aetiology (n=79). The 
dashed line shows T1D-GRS (AUC: 0.80 [95% CI: 0.70-0.90]) and the black line 
shows T1D-GRS combined with age of diabetes diagnosis (AUC: 0.88 [95% CI: 0.80-
0.95]). For age of diabetes diagnosis alone (AUC: 0.79 [95% CI: 0.69-0.90]) and the 
presence of autoantibodies (AUC 0.49, [95% CI: 0.34-0.65]) data not shown. 
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Supplementary table S1: SNPs used for the T1-GRS calculation. Disease 
associations taken from www.gwascatalog.com. 
SNP(s) Gene Odds Ratio Weight 
Autoimmune  
disease associations 
rs2187668, 
rs7454108 
DR3/DR4-DQ8 48.18 3.87 
Type 1 diabetes,  
Coeliac disease,  
Autoimmune thyroid disease,  
Autoimmune hepatitis 
DR3/DR3 21.12 3.05 
DR4- DQ8/DR4-DQ8 21.98 3.09 
DR4-DQ8/X 7.03 1.95 
DR3/X 4.53 1.51 
rs1264813 HLA_A_24 1.54 0.43 
Type 1 diabetes,  
Myasthenia gravis 
rs2395029 HLA_B_5701 2.5 0.92 
Type 1 diabetes,  
Psoriasis 
rs3129889 HLA_DRB1_15 14.88 2.7 
Type 1 diabetes (protective), 
Multiple sclerosis 
rs2476601 PTPN22 1.96 0.67 
Type 1 diabetes,  
Autoimmune thyroid disease 
Crohn’s disease, 
Myasthenia gravis, 
Systemic lupus 
erythematosus, 
Rheumatoid arthritis 
rs689 INS 1.75 0.56 
Type 1 diabetes 
rs12722495 IL2RA 1.58 0.46 
Type 1 diabetes,  
coeliac disease, 
Systemic sclerosis 
rs2292239 ERBB3 1.35 0.3 
Type 1 diabetes 
rs10509540 C10orf59 1.33 0.29 
Type 1 diabetes 
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Supplementary table S2: HLA DR3 status of patients with coeliac disease and 
autoimmune thyroid disease in those with confirmed monogenic autoimmunity 
and unknown aetiology. X = any HLA allele other than DR3. 
 Monogenic autoimmunity (n=37) Unknown aetiology (n=42) 
 
Coeliac 
disease 
(n=2) 
Autoimmune 
thyroid 
disease 
(n=6) 
Either/ 
both 
(n=8) 
Coeliac 
disease 
(n=12) 
Autoimmune 
thyroid 
disease 
(n=17) 
Either/  
both 
(n=25)  
DR3/DR3 0 0 0 4 2 6 
DR3/X 1 2 3 7 9 16 
X/X 1 4 5 1 6 7 
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ABSTRACT 
Immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, 
caused by hemizygous variants in FOXP3, is challenging to manage for clinicians and 
represents a devastating diagnosis for families. Classically IPEX was thought to be 
severe and fatal in infancy for most cases, however recent studies have identified 
patients with a milder clinical course. The only curative treatment for IPEX is 
haematopoietic stem cell transplantation (HSCT), however the risks associated with 
this procedure, especially in infants with severe autoimmunity, mean the decision to 
transplant is fraught with difficulty. We collected clinical and genetic information on a 
cohort of patients with IPEX syndrome (n=48) referred to our centre since 2005. We 
sought to identify genotype/phenotype relationships or clinical characteristics that 
could predict prognosis or identify patients who had a milder clinical course. We did 
not find evidence of a genotype/phenotype relationship, as patients with missense or 
null variants did not consistently differ in their presentation, disease severity or 
prognosis, and patients with the same variant had disparate clinical features. 
Furthermore, presenting feature (diabetes or enteropathy) did not predict clinical 
outcome. We also report the longest surviving male with a FOXP3 mutation, who is in 
his seventh decade of life, despite his grandson having the classical features of IPEX 
in infancy. The decision to undertake HSCT should therefore be based on individual 
clinical need and not on the variant identified or family history.                       
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INTRODUCTION 
Immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome is 
a severe and complex condition of autoimmunity with onset usually in the first months 
of life. IPEX was first reported in 1982 in a large non-consanguineous pedigree with 
multiple affected males [1]. Enteropathy is the most common clinical manifestation 
(>90% of patients) and is the presenting feature in >50% of individuals [2, 3]. Diabetes, 
often diagnosed in the neonatal period, is present in ~70% of patients and severe 
atopic dermatitis is also seen in ~70%. The estimated prevalence of IPEX syndrome 
is <1/1 million live births [4], though this is likely to be an underestimate; many affected 
individuals will not receive a genetic diagnosis due to the high rate of mortality and 
disparity in the availability of genetic testing around the world. 
In 2000 the causative gene for IPEX was identified as forkhead-box P3 (FOXP3) [5]. 
Since its implication in IPEX syndrome >75 disease-causing variants have been 
reported [6]. The loss of regulatory T cells and/or their inability to supress inappropriate 
immune reactions underlies the disease; FOXP3 is the master transcription factor of 
the regulatory T cell (Treg) lineage, important not only for their development but also 
for their continued suppressive function [7]. Tregs are essential for maintaining 
immune tolerance, removing or deactivating T cells reactive to autoantigens and 
suppressing inappropriate inflammation.  
Classically, a clinical diagnosis of IPEX was made based on pathognomonic features 
(enteropathy, diabetes and atopic dermatitis) and subsequently confirmed by genetic 
testing. Due to reductions in cost and improvements in speed and accuracy of genetic 
testing a genetic diagnosis of IPEX can pre-empt a clinical diagnosis [8]. Recent 
reports have shown that the clinical manifestation of IPEX syndrome is highly variable, 
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ranging from prenatal death caused by foetal hydrops [9, 10] to diabetes with 
enteropathy that resolved spontaneously in the 3rd decade of life [11]. Furthermore, 
the use of gene panel tests for diseases with clinical overlap is identifying patients with 
disease causing variants that do not have the classically associated phenotype [12]. 
Rather than representing atypical cases these are likely to represent the true spectrum 
of IPEX which was previously under-recognised.  
Making a genetic diagnosis of IPEX syndrome can improve treatment for patients. The 
only curative treatment for IPEX syndrome is haematopoietic stem cell transplantation 
(HSCT) and there is evidence that those receiving transplantation early (<5.5 years) 
have significantly greater chance of survival than those who undergo transplantation 
later in life [13]. If undertaken before the onset of specific autoimmune manifestations 
HSCT can prevent irreversible damage to target tissues such as the pancreatic islets. 
Despite improvements in patient outcomes after HSCT, the procedure still has 
substantial mortality risk; approximately 1 in 6 (16%) patients undergoing HSCT do 
not survive to 200 days’ post-transplant [14].  
Taken together, the increased speed to diagnosis and recognition of atypical ‘milder’ 
cases pose a problem for clinicians involved in the management of patients with IPEX. 
Genetic counselling for families is challenging as whilst it can inform on recurrence 
risk, it cannot accurately predict clinical phenotype of individual patients. A genetic 
diagnosis of IPEX syndrome may lead to increased psychological stress for families, 
as the disease was thought to be fatal in infancy and information available generally 
pertains to severe cases that have been recognised by the classical phenotype. 
Furthermore, for patients with a milder clinical course and who may survive to 
adulthood the benefits of HSCT may not outweigh the risk of the procedure. A genetic 
diagnosis may now occur before a clinical diagnosis of IPEX such as when patients 
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have presented with isolated diabetes. The decision to undertake HSCT may therefore 
be taken before the full clinical course of the patient has been understood. 
We report the largest series of probands with IPEX syndrome to date (n=48). We 
aimed to determine if the type of mutation (i.e. missense vs protein truncating 
mutations) or clinical characteristics that could be used to predict prognosis in patients 
with IPEX syndrome and therefore inform medical management.  
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METHODS 
Study population 
48 patients with a clinical diagnosis at referral of either isolated neonatal diabetes 
(NDM; n=20), IPEX syndrome (n=21), early-onset autoimmune disease (n=5) or a 
history of multiple affected male foetuses (n=2) were referred to the Exeter Molecular 
Genetics Laboratory between 2005 and 2017. Clinical information was initially taken 
from the patients genetic testing request form. Further information was requested from 
the referring clinician when results were reported and detailed follow up was requested 
for this study. 
Molecular genetics 
Where a clinical diagnosis of IPEX syndrome was made prior to referral, rapid 
screening of the FOXP3 gene was performed by Sanger sequencing (n=21). When 
patients had isolated neonatal diabetes or the onset of multiple autoimmunity was 
outside infancy (>12 months) comprehensive panel testing of genes causing neonatal 
diabetes and monogenic autoimmune diabetes was undertaken by targeted next 
generation sequencing (NGS) as previously described (methods section 6.1 and [15]). 
All putative disease-causing variants found by targeted NGS were confirmed by 
Sanger sequencing. Where samples were available family member testing was 
undertaken to assess co-segregation. 
Novel/rare variant interpretation 
All novel variants identified were classified using the American College of Medical 
Genetics guidelines [16]. Variants which were classified as pathogenic or likely 
pathogenic were included in this study. 
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Immunoglobulin testing 
Where serum samples (n = 16) were available immunoglobulin E (IgE) testing was 
performed in house as previously described [17]. 
Statistical analysis 
The appropriate non-parametric (Gehan-Breslow-Wilcoxon and Wilcoxon rank) tests 
were used for continuous variables and the Fishers exact test was used to compare 
categorical variables. Statistical analyses were performed in Stata 14 (StataCorp LP, 
College Station, TX). 
Ethical approval 
The study was approved by the Genetic Beta Cell Research Bank, Exeter, U.K. with 
ethical approval from the North Wales Research Ethics Committee, U.K. 
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RESULTS 
Disease causing variants in FOXP3 
We report 34 different disease causing variants in the FOXP3 gene identified in 48 
probands and 2 family members. Seventeen novel variants were identified in 18 
individuals and were all classified as pathogenic or likely pathogenic (table 1). In the 
30 remaining patients, we identified 17 previously reported disease causing variants 
(see table 1 for HGMD/ClinVar identifiers).  
Clinical characteristics of patients  
In 2 families, genetic testing was undertaken on a foetal DNA sample due to a history 
of multiple spontaneous miscarriages of males (patient 1) and foetal hydrops (patient 
2). Most of the remaining individuals presented with either diabetes (n=32, 70%) or 
enteropathy (n=11, 24%). Three patients (7%) presented with autoimmune 
hypothyroidism, recurrent severe sepsis and respiratory insufficiency, respectively. 
The age of presentation was similar for those presenting with diabetes or enteropathy 
(4 weeks [IQR 2-12] vs 4 weeks [IQR 0.3-16] respectively, p = 0.86). The median age 
of latest follow up was 1.33 years (IQR: 0.5-5.33).  
The most common clinical feature was diabetes in 38/46 individuals (83%; table 1). 
Enteropathy was seen in 28 individuals (61%) and atopic dermatitis was seen in 20/46 
(43%). Common additional features were anaemia (haemolytic [n=2] and of unknown 
type [n=8]); 10/46, 22%), hypothyroidism (9/46, 20%),  recurrent infections (9 
individuals) and nephrotic disease (9/46, 20%). Rarer features included, pulmonary 
disease (6 individuals) and alopecia (2 individuals). In the 21 patients where 
measurement of IgE was undertaken (16 tested internally) 18 (86%) had values above 
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the age specific reference range in keeping with previous reports of patients with IPEX 
syndrome having raised IgE.  
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Demographic information Variant details Clinical features 
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1 UK NA NA p.Asp213fs c.636_646del Novel NA NA         ND   NA 
2 UK NA NA p.Arg397trp c.1189C>T 
CM010059; 
RCV000012160.2 
NA NA         ND   NA 
3 Argentina 
3180 
(38) 
1y 4m p.Arg337Gln c.1010G>A CM0911379 Diabetes 5w ✓ ✓    ✓  
2266 
[2-97] 
 
Insulin, 
meprednisone, 
tacrolimus, 
azathioprine 
Died 
aged 
1y 4m 
4 Bulgaria 
3420 
(39) 
2y 6m p.Arg337Gln c.1010G>A CM0911379 
Recurrent 
infections 
<1y ✓ ✓ ✓    ✓  *Raised 
Hydronephrosis, 
Joint hyperflexibility, 
Macroglossia, 
Eosinophilia. 
 
Died 
aged 
2ys 
6m 
5 UK ND (ND) 5y p.Arg337Gln c.1010G>A CM0911379 Enteropathy <4y  ✓ ✓    ✓ 
34000 
[2-97] 
Hepato-
splenomegaly 
HSCT undertaken, 
age unknown 
Died 
aged 
5ys 
6 Finland 
4300 
(40) 
22y p.Arg337Gln c.1010G>A CM0911379 Diabetes 2w ✓ ✓      ✓ ND 
Growth hormone 
deficiency 
diagnosed at 5y, 
Epilepsy 
Curative BMT 
undertaken at 18y. 
Now healthy, on 
full replacement 
insulin dose 
Alive 
7 Venezuela 
3000 
(38) 
8m p.Arg337Gln c.1010G>A CM0911379 Diabetes 4w ✓ ✓ ✓     ✓
259 [2-
34] 
Died from 
disseminated 
intravascular 
coagulation at 8 
months of age 
Methotrexate and 
insulin therapy for 
diabetes 
Died 
aged 
8m 
8 Germany 
1590 
(38) 
1y 6m p.Pro339Ala c.1015C>G 
CM086632; 
RCV000387030.1 
Diabetes 1w ✓ ✓  ✓     ND 
Developmental 
delay 
 
Died 
aged 
1y 6m 
9 UK ND (ND) 12 w p.Ile346Thr c.1037T>C CM1110994 Enteropathy 1d  ✓ ✓      ND   Alive 
10 UK 
3050 
(ND) 
1y 4m p.Arg347His c.1040G>A CM086633 Diabetes 8w ✓        ND 
Polydactyly, delayed 
dentition 
 Alive 
11 Ukraine 
3880 
(40) 
6m p.Arg347His c.1040G>A CM086633 Diabetes 4w ✓    ✓    ND 
Respiratory 
insufficiency and 
diaphragmatic 
hernia at birth 
 
Died 
aged 
6m 
12 Turkey 
3300 
(39) 
1y 6m p.Arg347His c.1040G>A CM086633 Diabetes 4w ✓       
45 [2-
34] 
  Alive 
13 Australia 
3928 
(39) 
5y 4m p.Arg347His c.1040G>A CM086633 Diabetes 8w ✓        ND   Alive 
14 Morocco 
3200 
(39) 
8m p.? c.1044+4A>G CS003179 Diabetes 5d ✓ ✓ ✓      ND   
Died 
aged 
8m 
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15 UK ND (ND) 7m p.Ala349Thr c.1054G>A Novel Enteropathy 6m  ✓       *Raised 
Alopecia, pancreatic 
exocrine 
dysfunction, 
metaphyseal 
chondrodysplasia 
 
Died 
aged 
11w 
16 India 
1700 
(36) 
30y p.Ile363Leu c.1087A>C Novel Diabetes 6w ✓        ND 
b12 deficiency 
(without evidence of 
celiac disease) 
 Alive 
17 UK ND (ND) 9m p.Met370Val c.1108A>G RCV000414229.1 
Respiratory 
insufficiency 
5m   ✓    ✓ ✓
2396 
[2-34] 
  Alive 
18 Vietnam 
2400 
(41) 
4 w p.Pro378Leu c.1133C>T Novel Diabetes 2w ✓   ✓ ✓    ND   Alive 
19 India ND (ND) 2m p.Ala384Thr c.1150G>A 
CM010058; 
RCV000012163.1
3 
Diabetes 1w ✓        ND   Alive 
20 India 
3600 
(39) 
4m p.Ala384Thr c.1150G>A 
CM010058; 
RCV000012163.1
3 
Hypothyroidis
m 
1d ✓  ✓ ✓     ND   
Died 
aged 
4m 
21 UK ND (ND) 25y p.Ala384Thr c.1150G>A 
CM010058; 
RCV000012163.1
3 
Diabetes 2w ✓ ✓ ✓ ✓   ✓ ✓ *Raised Malnutrition  Alive 
22 
South 
Africa 
2500 
(32) 
4y 2m p.Arg386His c.1157G>A CM109690 Enteropathy 1w  ✓ ✓  ✓  ✓  *Raised 
Hepatosplenomegal
y, 
Thrombocytopenia, 
presented as 
neonate with 
hyperinsulinaemia 
which 
spontaneously 
resolved after 3 
weeks 
Prednisolone 
(effective), then 
rituximab, 
tacrolimus and oral 
steroids. Curative 
HSCT undertaken 
at 10mo. 
Alive 
23 Pakistan 
2600 
(37) 
3 w p.Asn388Ser c.1163A>G Novel Diabetes 1w ✓ ✓       ND 
Exocrine pancreatic 
deficiency 
 
Died 
aged 
6m 
24 Canada ND (ND) 7m p.Arg397Gln c.1190G>A CM109691 Enteropathy 16w  ✓       ND   Alive 
25 
Netherland
s 
ND (ND) 18y p.Glu399Lys c.1195G>A Novel Diabetes 11m ✓ ✓ ✓     
0.1 [2-
214] 
IgA deficiency, 
muscle weakness 
 Alive 
26 
Czech 
Republic 
2400 
(36) 
25y p.Val408Met c.1222G>A CM0911380 Diabetes 1d ✓     ✓   ND   Alive 
27 El Salvador ND (ND) 23 w p.Val408Met c.1222G>A CM0911380 Diabetes 7w ✓        ND   Alive 
28 Germany 
3720 
(40) 
9y p.Val408Met c.1222G>A CM0911380 Diabetes 3w ✓ ✓  ✓     ND 
Developmental 
delay 
 Alive 
29 Turkey 
4300 
(38) 
14 w 
p.Glu412_Arg4
20del 
c.1234_1260d
el 
Novel Diabetes 9w ✓ ✓ ✓  ✓  ✓  ND Thrombocytopenia  Alive 
30 Sri Lanka ND (40) 1y 3m p.Glu412Asp c.1236G>C Novel Diabetes 18w ✓     ✓   ND  
Prednisolone for 
nephrotic 
syndrome 
Died 
aged 
2ys 
31 Guatemala 
2720 
(38) 
23 w p.Arg414fs c.1240del Novel Enteropathy 9w ✓ ✓ ✓ ✓   ✓  *Raised   
Died 
aged 
5m 
168 
 
32 Israel 
2000 
(38) 
2m p.Cys424Tyr c.1271G>A CM078706 Diabetes 1w ✓    ✓ ✓  ✓ ND 
Persistent metabolic 
acidosis 
 Died 
aged ? 
33 UK ND (ND) 6 w p.Asn426fs 
c.1276_1286d
el 
Novel Enteropathy 2d  ✓ ✓     
4899 
[2-34] 
Osteopenia, left 
ventricle 
hypertrophy 
 
Died 
aged 
<3ys 
34 USA 
2995 
(38) 
14y p.? c.210+2T>C Novel Enteropathy 4y ✓ ✓   ✓    ND 
hypogonadism 
secondary to 
malnourishment 
 
Died 
aged 
14ys 
35 UK ND (ND) 9m p.Leu76fs c.227delT CD013979 Diabetes 1d ✓ ✓  ✓   ✓  ND 
Apnoea and 
bradycardia, 
osteopenia, 
seizures, cerebral 
haemorrhage 
 
Died 
aged 
9m 
36 UK ND (ND) 2y p.? c.-23G>A Novel Enteropathy 3w ✓ ✓ ✓     
>1000 
[2-34] 
Rhinitis, failure to 
thrive 
Partially curative 
HSCT undertaken 
at 2 years 
Alive 
37 Australia 
4000 
(40) 
20y p.Phe102fs c.305delT Novel Diabetes 6m ✓        ND 
Mild gastritis at 17y. 
Raised LFTs, 
diagnosed with 
primary sclerosing 
cholangitis at 19y. 
Had recurrent boils, 
now resolved. 
Ursofalk for liver 
disease, 
mesalazine for 
gastritis 
Alive 
38 USA 
3180 
(40) 
8m p.Thr108Met c.323C>T CM066087 Diabetes 25w ✓       
2950 
[2-34] 
  Alive 
39 USA 
2390 
(39) 
8m p.Ser181Thr c.542G>C Novel Diabetes 1d ✓  ✓     
6.3 [2-
34] 
Milk protein allergy  Alive 
40 Indonesia 
3600 
(39) 
2y 4m p.Lys250del c.748_750del CD096416 Diabetes 5m ✓ ✓ ✓ ✓ ✓   
7173 
[<144] 
 
Immunosuppressiv
e (prednisolone 
then cyclosporine) 
Alive 
41 Indonesia 
2400 
(36) 
2y 2m p.Lys250del c.748_750del CD096416 Diabetes 2w ✓ ✓   ✓   
>10,00
0 (<45) 
Hepatosplenomegal
y, Developmental 
delay 
 Alive 
42 Iran 
2150 
(38) 
4y 5m p.Glu251del c.751_753del 
CM003191; 
RCV000012166.1
1 
Diabetes 2w ✓ ✓    ✓  ✓
2089 
[2-199] 
  Alive 
43 Sri Lanka 
2900 
(40) 
9y 10m p.Glu251del c.751_753del 
CM003191; 
RCV000012166.1
1 
Diabetes 9m ✓  ✓  ✓ ✓   ND 
Chronic cutaneous 
candidiasis, 
Alopecia 
 Alive 
44 USA 
4307 
(37) 
4y p.Met256Val c.766A>G Novel Diabetes 7w ✓  ✓   ✓   ND 
Inflammatory 
arthritis, eosinophilia 
 Alive 
45 
Netherland
s 
3850 
(41) 
9y 2m p.Met256Val c.766A>G Novel Diabetes 10m ✓  ✓   ✓  
0.1 [2-
696] 
  Alive 
46 Iran 
3150 
(40) 
14 w p.? c.816+7G>C CS107134 Enteropathy 1d ✓ ✓    ✓   ND 
Hypoxic brain injury 
at birth 
 
Died 
aged 
3m 
47 USA 
2865 
(38) 
6y 1m p.Glu323Lys c.967G>A Novel Enteropathy 5w ✓ ✓ ✓    ✓ 
>3000 
[2-34] 
 Curative HSCT 
undertaken at 6mo 
Alive 
48 Vietnam 
3500 
(39) 
10m p.Phe331Val c.991T>G Novel Diabetes 12w ✓ ✓  ✓    
730 
[<130] 
  
Died 
aged 
10m 
Table 1: Clinical and genetic characteristics of 48 probands with FOXP3 variants. ND – no data available. NA – not applicable as testing 
performed on foetal DNA. Variants are described based on HGVS guidelines and refer to FOXP3 transcript NM_014009.3.
169 
 
Identifying FOXP3 disease-causing variants before clinical IPEX 
Twenty patients were referred with diabetes in the absence of any notable 
additional clinical manifestations at referral. Of these, 8 (40%) went on to develop 
the classical features of IPEX syndrome after a genetic diagnosis was made and 
within the first 12 months of life. The time from referral to diagnosis was faster in 
those with classical IPEX at referral (n=21) compared to those with isolated 
diabetes (n=20) (5.3 weeks v 21.6 weeks, p=0.001). The median age at referral 
was similar in the two groups (34.7 weeks v 58.3 weeks, p=0.51).  
No evidence for a genotype/phenotype relationship  
Variant type (protein truncating [n=9], in-frame deletions [n=5] or missense 
[n=34]) did not predict clinical presentation or development of the classic features 
of IPEX syndrome (figure 1). The proportion of different variant types was the 
same in those with isolated diabetes at testing and those with other features 
indicative of IPEX syndrome (p=0.239). The spectrum of variant types was also 
the same in those who presented with diabetes compared to those presenting 
with enteropathy (p=0.361). Mortality rates for those with missense variants 
(12/34 deceased) and those with protein truncating variants (6/9 deceased) were 
similar (p=0.24), including when considering only those with limited clinical 
information (last update <2 years, p=0.08). 
Assessment of a larger group of patients with IPEX syndrome is warranted to 
increase statistical power, as the number of patients with protein truncating and 
in-frame deletion mutations is low. Furthermore, studies to assess the function of 
the missense mutations by DNA binding assays could be performed to identify 
missense variants that are hypomorphic and retain some function against those 
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that abrogate FOXP3 function completely, as these may represent a separate 
group which are skewing these results. 
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Figure 1: Proportion of patients with phenotypic characteristics by their 
variant type. Black bars show patients with missense variants (n=33). Grey bars 
show patients with protein truncating variants. None of the phenotypes/clinical 
characteristics show significant difference between the two groups. 
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Furthermore, and in keeping with previous published cases of IPEX syndrome, 
identical disease causing variants were identified in patients with disparate clinical 
features. For example, the phenotype associated with the p.Val408Met variant ranged 
from diabetes and nephrotic syndrome at 25 years (patient 26) to classical IPEX 
syndrome (including neonatal diabetes, autoimmune enteropathy and hypothyroidism) 
diagnosed in infancy (patient 28).  
Variation in presentation within the same family 
Even in members of the same family with the same variant, there was wide variation 
in the clinical presentation and severity of disease between affected males (figure 2). 
The proband (patient 13, 3:iii) presented with neonatal diabetes, eczema (which 
subsequently resolved) and chronic diarrhoea resulting in a clinical diagnosis of IPEX 
syndrome. Genetic testing identified the previously reported missense variant 
p.Arg347His. Family member testing identified that his mother and aunt were carriers 
of the variant; his male cousin had also inherited the variant. This cousin was affected 
with isolated eczema in infancy which resolved spontaneously. He is currently clinically 
well and free from any conditions associated with IPEX at the age of 10 years. 
Intriguingly, testing of the maternal grandparents identified the variant in the maternal 
grandfather who had been affected with eczema which resolved in infancy and was 
diagnosed with ulcerative colitis aged 13 years. His colitis is currently described as 
manageable with treatment, and his symptoms reportedly do not affect his day to day 
life. He is currently 61 years old which, to our knowledge, makes him the oldest 
surviving male carrier of a FOXP3 variant.  
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Figure 2: Clinical manifestations in a family with a FOXP3 variant. The proband 
(3:iii, patient 13) has classical IPEX syndrome diagnosed in infancy. His cousin (3:ii), 
who is also a variant carrier, had eczema in infancy that resolved spontaneously. 
Strikingly, the 61-year-old maternal grandfather has the variant and had eczema in 
infancy which resolved and had ulcerative colitis diagnosed at age 13. 
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Milder clinical course despite predicted loss of FOXP3 
One patient with a protein truncating variant (PTV) (c.305delT, p.Phe201fs), predicted 
to result in the complete loss of FOXP3, had a milder clinical course having presented 
with isolated diabetes at 6 months (figure 3). Routine antibody screening identified 
persistently positive tissue transglutaminase antibody and, due to a history of lethargy 
and abdominal pain, the patient underwent a ileocolonoscopy and upper 
gastrointestinal (GI) endoscopy at age at 17 years. This identified patchy inflammation 
and a diagnosis of gastritis was made. Villous atrophy, found in most cases of IPEX-
associated autoimmune enteropathy, was not present. The patient also had abnormal 
liver function test results from age 17 and a diagnosis of primary sclerosing cholangitis 
was made at age 19, which is responding well to treatment with ursodeoxycholic acid. 
The patient is currently clinically stable at 23 years and has had improvement in his 
liver function and GI symptoms.  
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Figure 3: clinical course of patient 37 (c.305del). a – diagnosis of neonatal 
diabetes. b – onset of GI symptoms and positive tissue transglutaminase antibody 
result. c – diagnosis of gastritis and abnormal liver function detected. d – diagnosis of 
primary sclerosing cholangitis. 
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Presenting feature does not predict clinical course 
Having diabetes as the presenting feature did not predict a different clinical course 
compared to those who presented with enteropathy (table 2). A similar proportion of 
those presenting with diabetes (n=32) and those presenting with enteropathy (n=11) 
developed classical IPEX within the first 12 months of life (19/32, 59% v 6/11, 55%; 
p=1.00). The distribution of other clinical features (atopic dermatitis, hypothyroidism, 
anaemia, glomerulonephritis, recurrent infections and pulmonary disease) was also 
similar in the two groups (p = 0.55). Eighteen patients are deceased in our cohort, 
highlighting the clinical complexity and severity of IPEX syndrome. Mortality rates were 
similar for those presenting with diabetes compared to those presenting with 
enteropathy (10/32 v 4/11 deceased by age 5, p=0.61). 
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Clinical/demographic 
feature 
All patients                   
(n=46) 
Diabetes 
presenting 
feature 
(n=32) 
Enteropathy 
presenting 
feature (n=11) 
Demographic features 
Median age at onset of 
1st disease/weeks [IQR] 
4 [0.1-14] 4 [2-12] 4 [0.3-16] 
Median age at referral or 
follow up/years [IQR] 
1.3 [0.5-5.3] 1.5 [0.7-9.2] 0.6 [0.3-5] 
Median time ref to 
dx/weeks [IQR] 
11.7 [2.3-25.1] 17.1 [6-36.1] 1.9 [1-12.9] 
Median birthweight/g  
(gestation/weeks) n=31 
3165 (39) 3180 (39) 2865 (38) 
Clinical features 
Classical IPEX* 31 (67%) 20 (63%) 9 (82%) 
Diabetes 39 (85%) 32 (100%) 5 (45%) 
Autoimmune 
enteropathy 
28 (61%) 16 (50%) 11 (100%) 
Atopic dermatitis 20 (43%) 10 (31%) 7 (64%) 
Hypothyroidism 9 (20%) 7 (22%) 1 (9%) 
Anaemia 10 (22%) 8 (25%) 2 (18%) 
Nephrotic disease 9 (20%) 8 (25%) 1 (9%) 
Recurrent infections 9 (20%) 3 (9%) 4 (36%) 
Pulmonary disease 6 (13%) 5 (16%) 0 (0%) 
Hyper IgE 18/19 (95%) 9/10 (90%) 9/9 (100%) 
 
Table 2: clinical features of patients with disease-causing variants in FOXP3. 
*classical IPEX is defined as 2 or more of enteropathy, diabetes and atopic dermatitis. 
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DISCUSSION 
We report 34 distinct disease-causing variants in FOXP3 in 48 families, the largest 
series of IPEX patients to date. We have shown that clinical presentation does not 
predict clinical course or prognosis, and did not find evidence of phenotype-genotype 
relationships in IPEX syndrome as the type of variant identified (i.e. missense or 
protein truncating) did not predict clinical phenotype. 
We observed highly variable clinical manifestations in our cohort, however most 
patients had diabetes and/or enteropathy in keeping with previous reports of IPEX 
syndrome. A higher proportion of our cohort had diabetes compared to previous 
reports [1, 2]. This is likely to be due to referral bias as we actively recruit patients with 
either neonatal diabetes and/or early-onset autoimmune diabetes for research-funded 
genetic testing (www.diabetesgenes.com). Enteropathy was reported in 61% of our 
cohort (28/46), lower than previous reports of IPEX where >90% have enteropathy [1, 
2]. This is likely to reflect the increasing recognition of the variability in IPEX syndrome. 
We did not observe any correlation between the genotype of patients and their 
phenotype; those with missense variants did not have different clinical features or 
prognosis to those with protein truncating variants. The mortality rate for missense 
variants and PTVs was similar (p=0.24). This is in keeping with previously reported 
patients where data on mutation type and survival was available (n=65; missense 
21/44 deceased vs PTV 8/21 deceased, p=0.56) (3). Previous studies have identified 
a normal number of Tregs in some patients with missense or small in-frame deletions 
in FOXP3 [3, 4]. These were proposed to result in residual FOXP3 function, although 
further studies on different patients with the same variants did not detect FOXP3+ 
Tregs [5], and the observed phenotype was not consistently milder in these patients. 
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The resulting disease manifestations in IPEX must therefore depend on more than the 
function of FOXP3 and the Treg compartment. 
We have identified the oldest surviving patient with IPEX syndrome reported to date 
(figure 1) (current age 61). He had eczema in infancy which resolved and episodes of 
anaemia, and has a diagnosis of ulcerative colitis which is reportedly managed well 
with treatment. His grandson, patient 13, presented with neonatal diabetes at 8 weeks 
leading to genetic testing and went on to develop enteropathy in infancy. The variant 
this family carries is the p.Arg347His variant that has been previously described as 
causing a milder form of IPEX syndrome, though some patients have classic features 
in infancy [3, 4, 6-10]. 
The variability in phenotype is not restricted to patients with missense variants. We 
identified a frameshift variant in patient 36 which is predicted to result in complete loss 
of FOXP3 via nonsense mediated decay. Despite this, the patients’ only feature until 
19 years of age was diabetes (diagnosed at 6 months) and he is clinically stable at the 
age of 23 years. A previously reported patient with a PTV spanning the same base 
(c.304_305del, p.Phe102fs) had severe IPEX syndrome (enteropathy, atopic 
dermatitis, autoimmune haemolytic anaemia and neonatal diabetes) diagnosed before 
the age of 6 months which was successfully treated by HSCT [11].  
IPEX syndrome was classically defined as a triad of early-onset diabetes, autoimmune 
enteropathy and severe atopic dermatitis with additional immunodysregulatory 
features. Our study, along with other recent reports, has extended the phenotype 
which now ranges from fatal autoimmunity with prenatal onset to isolated diabetes in 
adulthood [8, 12, 13]. These cases represent a spectrum of disease associated with 
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variants in FOXP3 and it is likely that IPEX syndrome is under-recognised; patients 
without severe disease in infancy are unlikely to undergo genetic testing. 
The wide variability of clinical manifestations, even in families with the same variant, 
and lack of features predictive of prognosis means a genetic diagnosis can be 
distressing for families and medical management is challenging for clinicians. The 
decision to undertake HSCT in patients with IPEX carries substantial risk and 
prognosis cannot accurately be predicted by genetic or clinical information. Treatment 
must therefore remain based on the clinical condition of the patient. An early genetic 
diagnosis can facilitate careful monitoring of the patient’s clinical condition and allow 
the search for a matched donor to begin before possible progression of disease, even 
if the prognosis of the patient remains unknown. A genetic diagnosis for families allows 
genetic counselling to inform them of recurrence risk and will facilitate pre-natal 
testing, however prediction of prognosis for individuals affected is not possible. 
Whilst we report the largest single cohort of patients with IPEX syndrome, the numbers 
are still relatively low and longitudinal data on clinical course is not available for many 
patients (average age at follow up; 1.33 years [IQR: 0.5-5.33]). A longitudinal study of 
the patients with IPEX syndrome that survive into adulthood may offer better insights 
into the clinical course and identify characteristics of patients with milder disease. This 
has been beneficial for patients with autoimmune polyendocrine syndrome type 1 
(APS1) caused by biallelic variants in AIRE [14-17]. Studies of patients with APS1 
across their lifetime have enabled optimal treatment and follow-up strategies to be 
proposed and identified a putative association with disease course and human 
leukocyte antigen (HLA) alleles. 
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In conclusion, whilst faster and more comprehensive genetic testing can allow for rapid 
treatment intervention, as more atypical cases are identified the medical management 
and decision to undertake HSCT for patients with IPEX has become increasingly 
difficult. We did not find evidence for a genotype/phenotype relationship in our cohort, 
in keeping with previous reports, and clinical presentation did not predict prognosis. 
The decision to intervene with HSCT cannot be made based on FOXP3 genotype or 
clinical presentation alone and must be undertaken based on individual clinical need. 
Further studies of the factors which dictate clinical phenotype in IPEX syndrome are 
warranted. 
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ABSTRACT  
Young-onset autoimmune diabetes associated with additional autoimmunity usually 
reflects a polygenic predisposition but rare cases result from monogenic autoimmunity. 
Diagnosing monogenic autoimmunity is crucial for patients’ prognosis and clinical 
management. We sought to identify novel genetic causes of autoimmunity presenting 
with neonatal diabetes (NDM; diagnosis <6 months). 
We performed exome sequencing in a patient with NDM and autoimmune 
lymphoproliferative syndrome and his unrelated, unaffected parents and identified 
compound heterozygous null mutations in LRBA. Biallelic LRBA mutations cause 
Common Variable Immunodeficiency-8, however NDM has not been confirmed in this 
disorder.  We sequenced LRBA in 169 additional patients with diabetes diagnosed <1 
year without mutations in the 24 known NDM genes. We identified recessive null 
mutations in 8 additional probands, of which 3 had NDM (<6 months). Diabetes was 
the presenting feature in 6 of 9 probands. Six of 17 (35%) patients both born to 
consanguineous parents and with additional early-onset autoimmunity had recessive 
LRBA mutations.  
 LRBA testing should be considered in patients with diabetes diagnosed <12 months, 
particularly if they have additional autoimmunity or are born to consanguineous 
parents. A genetic diagnosis is important as it can enable personalized therapy with 
abatacept, a CTLA4 mimetic, and inform genetic counselling. 
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Clustering of diabetes with early-onset autoimmunity in very early childhood is usually 
due to a combination of extreme polygenic risk and environmental exposure. Rarely, 
a mutation in a single gene is the aetiological cause and the identification of the 
underlying monogenic defect can give important insights into mechanisms of beta-cell 
autoimmunity and pathways of immune tolerance[1, 18-30]. Due to significant clinical 
overlap, discriminating patients with causative mutations in a single gene from those 
with a polygenic aetiology remains a challenge.  
A prompt diagnosis of monogenic autoimmunity is crucial as it informs clinical 
management and targeted therapies may be possible. FOXP3 mutations in males 
cause Immunodysregulation, Polyendocrinopathy, Enteropathy, X-Linked (IPEX) 
syndrome[1] which can be treated with a haematopoietic stem cell transplant (HSCT).  
If performed early HSCT can cure the life-threatening enteropathy as well as prevent 
the onset of autoimmune-mediated diabetes[31]. In an individual with polyarthritis, 
scleroderma and autoimmune haemolytic anaemia resulting from an activating STAT3 
mutation, treatment with tocilizumab, a monoclonal antibody against IL-6, resulted in 
marked improvement in their symptoms[32].  Patients with Common Variable 
Immunodeficiency-8 (CVID-8), caused by recessively inherited mutations in 
Lipopolysaccharide-responsive Beige-like Anchor protein (LRBA), can be successfully 
treated with Abatacept, a mimetic for CTLA-4. CTLA-4 is a potent suppressive receptor 
that acts as an immune checkpoint and is post-translationally regulated by LRBA.  [18].  
Monogenic autoimmune disease often presents extremely early; for example, 
mutations in the STAT3, FOXP3 or IL2RA genes commonly present with neonatal 
diabetes[1, 30, 33]. Mutations in LRBA typically presents with severe autoimmune 
disease early in childhood and diabetes is a feature in 22% of patients, however 
neonatal diabetes has not been confirmed [19]. 
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We identified biallelic mutations in LRBA in an individual with neonatal diabetes 
diagnosed at 7 weeks and additional early-onset autoimmunity of unknown cause. We 
go on to show that this is a relatively common aetiology of neonatal or infancy-onset 
diabetes when patients have additional early-onset autoimmune disease and are born 
to consanguineous parents.   
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RESEARCH DESIGN AND METHODS 
Gene discovery using exome sequencing: The initial case presented in diabetic 
keto-acidosis (blood glucose concentration: 53 mmol/L) at the age of seven weeks 
and developed thrombocytopenia and autoimmune lymphoproliferative disease aged 
three years. To define the genetic aetiology, having excluded all 24 known causes of 
neonatal diabetes, we used exome sequencing and trio analysis of the proband and 
his unaffected, unrelated parents to search for de novo heterozygous mutations and/or 
compound heterozygous mutations. Exome sequencing was performed using 
Agilent’s SureSelect Human All Exon kit (v5) with paired end 100bp read length 
sequencing undertaken on an Illumina HiSeq 2500. For single nucleotide variant 
identification, the resulting reads were aligned to the hg19 reference genome 
according to GATK[34, 35] best practice guidelines. An in house script was used to 
remove synonymous variants, those outside the coding region or conserved splice 
site, and variants present in dbSNP131 or the ExAC database with a MaF greater than 
0.1%, as previously reported[30]. We used the R software package ExomeDepth[36] 
to detect copy number variation. Coverage and read depth data for the trio is provided 
in supplementary table S1. 
Follow up testing in selected neonatal/infancy onset diabetes: In our cohort of 
1561 patients diagnosed with diabetes before the age of 12 months, 169 did not have 
a mutation in a known gene and were screened for mutations in LRBA (figure 2). Of 
these, 54 patients were consanguineous and within this group 17 individuals had 
autoimmune disease. Autoimmune disease was also present in 25 of 116 non-
consanguineous patients. Consanguineous unions were defined as previously 
described [37], either known related parents (n=25) or patients who were from regions 
with high levels of consanguineous unions (n=29)[37].  The additional autoimmune 
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disease was diagnosed before 5 years and included hypothyroidism (15/42), Coeliac 
disease/autoimmune enteropathy (16/42) and inflammatory arthritis (3/42) (further 
details are provided in supplementary table S2).  
The 24 known causes of neonatal diabetes had been previously excluded by next 
generation-sequencing [30, 38], and methylation specific MLPA (MRC Holland) in all 
169  patients. Targeted next generation sequencing of the 58 exons and flanking 
intronic regions of LRBA (NM_006726.4) was performed as previously described[39] 
in the 169  patients with diabetes diagnosed before 1 year. Putative mutations were 
confirmed by Sanger sequencing or by droplet digital PCR (details available on 
request). When available samples from affected siblings and unaffected parents 
underwent mutation testing. Clinical information was collected from the patient’s 
medical records by the referring clinician. All subjects and/or their parents gave 
informed consent for genetic testing.  The study was approved by the Genetic Beta 
Cell Research Bank, Exeter, U.K. with ethical approval from the North Wales Research 
Ethics Committee, U.K. 
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RESULTS 
Molecular Genetics 
We initially searched for de novo mutations in the proband and unrelated, unaffected 
parent trio.  This identified four coding variants in the proband, all of which were 
present in the Exome Aggregation Consortium (ExAC) database[40] of >60,000 
patients not diagnosed with any severe paediatric disease (see supplementary table 
S3). We considered these unlikely to be causative and switched our analysis to look 
for recessive causes. 
We identified compound heterozygous mutations in LRBA and PKHD1L1. The two 
novel null mutations in LRBA (p.D1053fs*2; c.3156del and p.S2659*; c.7976C>G) 
were considered likely to be pathogenic as bi-allelic mutations in this gene are known 
to cause  Common Variable Immunodeficiency-8 (CVID-8)[24]. Variants in PKHD1L1 
have not been associated with Mendelian disease and there are 549 individuals in the 
ExAC database (controls without severe paediatric disease) with homozygous loss of 
function mutations [40], suggesting that loss of PKHD1L1 does not cause childhood-
onset disease.   
Whilst diabetes has been reported as a feature in 11/57 patients[18-29] with LRBA 
mutations,  only two patients were diagnosed before the age of one year; one at 4 
months and one at 7 months. The median age of diabetes diagnosis in the other 
patients was two years (range 1-9 years). LRBA encodes the Lipopolysaccharide-
responsive beige-like anchor protein - an essential post-translational regulator of the 
CTLA-4 receptor involved in the suppression of regulatory T cells[18]. 
Sequence analysis of LRBA in 169 patients diagnosed with diabetes before 12 months 
identified homozygous null mutations in eight additional probands and one affected 
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sibling (see table 1, figure 1, supplementary figure S2). All mutations introduce 
premature termination codons (3 nonsense, 4 frameshifts, 2 mutations affecting 
splicing and one whole exon deletion) and are predicted to result in complete loss of 
the LRBA protein. Carrier status was confirmed in parents when samples were 
available (see figure 1).  
Table 2 shows the distribution of individuals with LRBA mutations by age of diabetes 
diagnosis and parental consanguinity. Interestingly the highest proportion of those with 
a mutation were diagnosed with diabetes between 6 and 12 months. We identified 
LRBA mutations in 9 of 1561 patients diagnosed with diabetes before 12 months, 
giving a minimum prevalence of 0.6% in our cohort (Table 2).  
Seven of 54(13%) consanguineous patients had LRBA mutations whilst a mutation 
was identified in only 2 of 25 (8%) non-consanguineous patients with additional 
autoimmunity. Strikingly, when the criteria of consanguinity and additional 
autoimmunity were combined, 6 of 17 (35%) patients harboured mutations in LRBA 
(figure 2). Using these two criteria therefore greatly increased the likelihood of 
identifying an LRBA mutation.  
Clinical characteristics 
The proband presented in severe diabetic ketoacidosis at the age of seven weeks 
(blood glucose 53 mmol/L). He was treated with a full replacement dose of insulin, was 
negative for anti-GAD antibodies and had a HbA1c prior to his death of 7.0% (53 
mmol/mol). Thrombocytopenia and autoimmune lymphoproliferative disease were 
reported at the age of three years with additional features including right hemiparesis 
and neuromotor retardation also noted at this time. The patient died shortly before his 
fourth birthday due to an intracranial haemorrhage caused by thrombocytopenia.  
197 
 
Detailed follow up after genetic analysis revealed the proband’s three elder siblings 
had also died in childhood at another hospital; two older sisters died at ages 12 years 
and 3.5 years due to complications relating to immunodeficiency and his older brother 
died at the age of 6.5 years due to immunodeficiency and severe enteropathy. 
Diabetes was not reported in these individuals and DNA was not available for testing. 
This family history suggests the siblings were also compound heterozygous for the 
LRBA mutations, fitting with the inheritance pattern of LRBA. The parents were 
unaffected in keeping with previous reports that haploinsufficiency of LRBA does not 
cause CVID-8 [22, 23] 
All 10 patients with bi-allelic LRBA mutations were diagnosed with diabetes in the first 
15 months of life (median: 7.5 months, range: 6 weeks – 15 months) and four of these 
patients met the criteria for neonatal diabetes, having been diagnosed with diabetes 
before the age of 6 months. All had insulin doses suggesting full replacement was 
required (table 1). Positivity for anti-GAD antibodies (90 U/mL; normal range <25 
U/mL) was detected in just 1 of the 6 patients in whom pancreatic antibody screening 
for anti-GAD/IA2/ZnT8 antibodies was possible (table 1). This low prevalence of 
autoantibodies is in keeping with these patients having autoimmunity with a distinct 
mechanism to that seen in type 1 diabetes. 
In 6 of the 9 probands diabetes was the presenting feature. Autoimmune disorders 
were present in 8 of the 9 probands (table 1) and included haematological 
manifestations (5/8), autoimmune enteropathy (3/8) and hypothyroidism (1/8). The 
remaining proband is the result of a consanguineous union and has presented with 
diabetes at 9 months, which is still the only clinical feature at 2 years. In three patients, 
recurrent respiratory infections were reported. The prognosis was poor as three of the 
patients are deceased; the original proband died from a cerebral haemorrhage likely 
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caused by thrombocytopenia, a second patient developed complications associated 
with nephroblastoma and a third child died of sepsis (table1). 
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Conclusions 
We have identified 10 different loss of function LRBA mutations in nine probands and 
one sibling (figure 1 and table 1) with 4 cases having neonatal diabetes. This study 
increases the total number of genetic causes of neonatal diabetes to 25, and the 
genetic causes of severe early-onset autoimmunity that includes neonatal diabetes to 
4; the others being FOXP3 [1], IL2RA [33], and STAT3 [30].  
In our cohort of patients with diabetes diagnosed before 12 months, 0.6% have 
recessively inherited LRBA mutations. In contrast to other monogenic autoimmune 
diabetes subtypes the highest pick-up rate for LRBA mutations was in those 
individuals diagnosed with diabetes between 6 and 12 months. The combined criteria 
of autoimmune disease and consanguinity identified a high proportion of patients with 
LRBA mutations. Six of the 9 probands with LRBA mutations were suspected or 
proven to be consanguineous and have additional autoimmune disease. Using these 
criteria in our patients with infancy-onset diabetes we identified a causative mutation 
in 35% (6/17) of patients; (see figure 2). We therefore recommend testing for LRBA 
mutations is considered in all patients diagnosed with diabetes before the age of 12 
months, particularly those who have diabetes and additional autoimmunity and are the 
result of consanguineous union.  
Identifying LRBA mutations early is crucial as it may allow for the introduction of 
optimal treatment strategies before the disease progresses. Genetic testing of all 
causes of neonatal diabetes is now predominantly by targeted panels (e.g. [39, 41, 
42]) occurring immediately after the diagnosis of diabetes  with in the first 6 months of 
life[38].  Targeted sequencing should include LRBA as in all 4 probands with neonatal 
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diabetes this was the first feature of their multisystem autoimmune disorder and for 
one proband is currently the only feature at the age of two years.  
Recessive mutations in LRBA are a known cause of  Common Variable 
Immunodeficiency 8 (CVID-8, MIM #614700)[24] which often includes early-onset 
autoimmunity, immune dysregulation, recurrent infections and 
hypogammaglobinaemia with variable penetrance [18-29, 43]. Neonatal diabetes had 
not been observed as a feature of this disorder. The extra-pancreatic features 
observed in our cohort are at a similar prevalence to those reported in patients with 
biallelic LRBA mutations (supplementary Figure S1), consistent with a diagnosis of 
CVID-8.  
Five of the 6 patients in whom testing was possible were negative for pancreatic 
antibodies. This suggests that the mechanism of autoimmunity may be distinct to that 
observed in early-onset type 1 diabetes. It may be that the autoantigens which are the 
target of the immune response are as yet uncharacterised, that they are not islet 
specific, or that the autoimmunity is cell-based rather than antibody driven. Further 
work to elucidate the true mechanism underlying the development of diabetes in CVID-
8 is warranted and may give new insights into the pathophysiology of type 1 diabetes.  
All patients we describe have functionally similar bialleleic null mutations but despite 
this there is considerable variation in their phenotype. For example, patient 3 
presented with neonatal diabetes (diagnosed at 4 months) and has immunodeficiency, 
autoimmune lymphoproliferative disease, hepatosplenomegaly, lymphocytic 
interstitial pneumonia and recurrent chest infections diagnosed before the age of 8 
years, whereas patient 7 was diagnosed with diabetes at the age of 10 months and 
has coeliac disease, pernicious anaemia and subclinical hypothyroidism at the age of 
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26 years (see table 1).  The variable phenotype of patients with homozygous missense 
mutations seen in previous studies was not statistically different from those with 
protein truncating mutations; the age of onset of the first symptom is similar in both 
groups (median age of onset; missense mutations: 1.75 years versus nonsense 
mutations: 2 years, p = 0.79) [18, 22, 24, 25, 28]. It therefore seems likely that 
additional genetic and/or environmental factors influence the severity of the disease 
and the specific organs affected in these patients.  
The autoimmunity observed in patients with LRBA mutations is considered to result 
from the loss of an essential immune regulatory pathway and a reduction in the 
suppressive action of regulatory T cells, therefore a disruption of immune 
tolerance[18]. It was recently shown that LRBA prevents the lysosomal degradation of 
the CTLA-4 receptor, facilitating its trafficking to the surface of T cells during T cell 
receptor (TCR) stimulation[18]. CTLA-4 is a potent suppressor, blocking co-stimulation 
of the TCR and therefore negatively regulating immune responses [44]. A loss of LRBA 
therefore results in increased CTLA-4 degradation diminishing this inhibitory pathway 
on T-cell activation and resulting in unchecked activation of immunologic responses.  
Identifying the underlying genetic aetiology is clinically important for these patients as 
understanding the disease mechanism may allow the use of personalized therapy. 
Abatacept, a CTLA-4 mimetic that replaces the action of the lost suppressive receptor, 
has been used to treat 12 patients with LRBA mutations so far and all showed 
improvement in their autoimmune features[18, 22]. Therapy with abatacept had not 
been attempted in our patients at the time of reporting. HSCT is also an option for 
these patients, with successful outcome reported in 3 of 4 patients with LRBA 
mutations in whom it has been attempted[22, 27, 29]. 
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In conclusion, we have identified LRBA mutations in 9 probands with early-onset 
diabetes (< 1 year) of whom 8 had additional autoimmune features. In 4 of these 
patient’s diabetes was diagnosed before 6 months confirming the role of this gene in 
the aetiology of neonatal diabetes. As diabetes was the presenting feature in 6/9 
individuals we recommend that testing for LRBA mutations is considered in all patients 
with newly diagnosed neonatal diabetes, and in those with infancy onset (< 12 months) 
diabetes, especially when a recessive inheritance is suspected or additional 
autoimmune features are present. A genetic diagnosis is critical not only for 
counselling on recurrence risk but it can also allow for immunomodulatory agents such 
as abatacept to be considered as part of the treatment regimen. 
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Table 1 
Patient 1  2.1 2.2 3 4 5 6 7 8 9 
Genotype* 
p.D1053fs/p.S2659* 
(c.3156del/c.7976C>A) 
p.R2348* 
(c.7042C>T) 
p.R2348* 
(c.7042C>T) 
p.R1271* 
(c.3811C>T) 
p.? 
(c.5581-1G>A) 
p.M589fs 
(c.1764dup) 
p.P816fs 
(c.2447del) 
p.? 
(c.(4729+1_4730-
1)_(5171+1_5172-
1)del) 
p.? 
(c.5172-
2A>G) 
p.I1330fs 
(c.3988dup) 
Birth weight [g] 
(gestation 
[weeks]) 
2600 (35) 3200 (39) 
3200 
(unknown) 
2700 (40) 3200 (38) 2750 (39) 3200 (40) 2965 (40) 2970 (40) 3000 (40) 
Sex Male Male Male Male Female Female Male Male Female Male 
Current Age 
(years) 
Deceased 1 Deceased 8 Deceased 2 6 26 1 4 
Known 
consanguinity  
No Yes Yes Yes Yes Yes Yes No Yes Yes 
Ethnicity Turkish Moroccan Moroccan Omani Omani Iranian Egyptian Chinese Turkish Pakistani 
Diabetic features  
Age at onset 7 weeks 6 weeks 15 months 4 months 5 months 9 months 9 months 10 months 8 months 7 months 
Treatment (dose) Insulin (1U/kg/day) 
Insulin 
(1U/kg/day) 
Insulin 
(1.2U/kg/day) 
Insulin (1U/kg/day) 
Insulin 
(0.6U/kg/day) 
Insulin 
(0.7U/kg/da
y) 
Insulin (2U/kg/day) 
Insulin 
(0.6U/kg/day) 
Insulin 
(0.9U/kg/day) 
Insulin 
(1.7U/Kg/day) 
HbA1c† 
(mmol/mol) 
7.0% (53) 7.1% (54) 6.6% (49) (7.1% (54) 8.3% (67) ND ND 8.7% (72) 7.2% (55) ND 
Antibody Status GAD Negative 
GAD/IA2/Zn
T8 Negative 
ND GAD/IA2 Negative GAD positive ND ND GAD negative 
GAD/IA2 
Negative 
ND 
Immunodysregulatory features  
Haemato-logical 
disorders 
Thrombocytopenia; 
Autoimmune 
lymphoproliferative 
disease 
_ 
Thrombocytope
nia; 
Autoimmune 
lymphoprolifer
ative disease 
Agammaglobulinaemia
; Autoimmune 
lymphoproliferative 
disease 
_ _ 
Thrombocytopenia; 
Autoimmune 
haemolytic anaemia 
Pernicious anaemia _ _ 
Gastro-intestinal 
disorders 
_ 
Autoimmune 
enteropathy 
Autoimmune 
enteropathy; 
Hepatosplenom
egaly 
Hepatosplenomegaly 
Autoimmune 
enteropathy 
_ 
Episodes of 
diarrhoea 
Coeliac disease _ 
Chronic 
diarrhoea 
Endocrine 
disorders 
_ _ _ _ _ _ 
Autoimmune 
hypothyroidism 
TPO Ab positive 
(sub clinical 
hypothyroidism) 
_ _ 
Recurrent 
infections 
_ _ 
Died of septic 
shock 
following 
unknown 
infection 
Recurrent chest 
infections (Aspergillus 
spp.) 
_ _ Pneumonia _ 
Pneumonia; 
Otitis media 
URTI‡, 
septicaemia 
Other features  
  
Cleft lip; Developmental 
delay; Hemiparesis. Died 
from intracranial bleed 
_ _ 
Lymphocytic 
interstitial pneumonia 
Died from 
Nephroblastoma 
_ 
History of 
convulsions; 
Multiple cerebral 
infarctions 
Parenchymal 
calcification of 
kidneys 
_ 
 
_ 
 Table 1 – Clinical features of patients with LRBA mutations. *All mutations 
are homozygous unless otherwise indicated and are described according to 
HGVS guidelines based on the longest isoform, NM_006726.4. Disorders 
reported are based on the clinical diagnosis made by the patients’ physician and 
were not always confirmed by diagnostic investigations such as biopsies.   †Most 
recent HbA1c recorded. ‡Upper respiratory tract infections. ND – no data. TPO 
Ab – thyroid peroxidase antibody. 
  
  
 
<6 months 6-12 months <12 months 
 
Consang* 
Non-
consang† 
Consang 
Non- 
consang 
Consang 
Non- 
consang 
Total number 
of patients 
338 892 63 268 401 1160 
Number with 
other known 
genetic cause 
299 761 17 56 316 817 
Number LRBA 
tested in 
31 74 23 41 54 116 
Number of 
LRBA cases 
identified 
3 1 4 1 7 2 
Minimum 
prevalence 
(%) 
0.9% 0.1% 6.3% 0.4% 1.7% 0.2% 
 
Table 2: Minimum prevalence of LRBA mutations in our cohort of patients 
diagnosed with diabetes before 12 months. *Born to consanguineous 
parents. †Born to unrelated parents.   
  
 
 
Figure 1 – Family pedigrees of patients with LRBA mutations. Filled symbols 
represent affected individuals and dots within symbols represent heterozygous 
unaffected carriers. Double lines signify parents are related. Genotypes are 
provided below affected individuals and carriers. When no genotype is given, 
samples were unavailable for testing.  
 
  
  
Figure 2 – Flow diagram showing the testing strategy for LRBA screening 
in individuals diagnosed with diabetes diagnosed before 12 months of age. 
The pick-up rates of LRBA mutations, when individuals are sub-grouped 
according to consanguinity and additional autoimmune disease, are provided.  
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 Supplementary table S1: Exome sequencing metrics for family 1. 
Sample Proband Mother Father 
Genes targeted 21,522 
Size of targeted region (Kb) 50,621 
% of target at 10x coverage 93.6 96.6 95.6 
% of target at 20x coverage 79.2 89.8 86.0 
% of target at 0x coverage 1.0 1.0 0.9 
Mean coverage across target 46x 65x 56x 
 
  
 Supplementary table S2: Autoimmune features of the cohort tested for LRBA 
including the index patient (1) and sibling of a patient with a mutation (2.2). 
Individuals without autoimmune disease are not included (i.e. patient 5). 
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2.2 ✓ ✓     ✓          
3 ✓     ✓ ✓          
4   ✓                
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8         ✓          
9  ✓   ✓      
10     ✓              
11 ✓                  
12   ✓                
13     ✓              
14   ✓                
15           ✓        
 16 ✓     ✓            
17             ✓      
18   ✓ ✓              
19   ✓                
20   ✓                
21   ✓                
22 ✓   ✓              
23   ✓                
24     ✓              
25   ✓            ✓ ✓
26     ✓ ✓            
27     ✓              
28   ✓                
29   ✓                
30 ✓ ✓ ✓          ✓   
31     ✓       
 
     
32   ✓         
 
     
33     ✓              
34   ✓ ✓              
35             ✓      
36   ✓   ✓        ✓   
37   ✓     ✓          
38 ✓ ✓              ✓
39   ✓                
 40   ✓ ✓              
41 ✓ ✓ ✓              
42 ✓ ✓ ✓              
 
 Supplementary table S3: Heterozygous de novo variants identified from 
exome sequencing data in patient 1 
Gene Variant Consequence ExAC 
frequency 
OR4A16 NM_001005274.1:c.730G>A  
p.Val244Met 
Missense 0.002% 
TBP NM_003194.4:c.273_281del  
p.Gln93_Gln95del 
In-frame deletion 0.011% 
STK19 NM_032454.1:c.59dup  
p.Asn20Lysfs*16 
Frameshift 0.04% 
HNRNPCL1 NM_001013631.2:c.830C>T  
p.Ala277Val 
Missense 0.05% 
 
  
  
Figure S1: Features of CVID-8 in this cohort and previously identified 
patients. Hatched boxes represent individuals with neonatal diabetes 
(diagnosed <6 months). 
  
  
 
Figure S2 – Ideogram of LRBA protein showing functional domains and 
approximate location of mutations identified in our cohort. ConA-like: 
Concanavalin A (ConA)-like lectin binding domain; VHS: VPS (vacuolar protein 
sorting)-27, Hrs (hepatocyte growth factor-regulated tyrosine kinase substrate) 
domain and STAM (signal transducing adaptor molecule); PKA: Protein Kinase 
A; WD: structural motif of approximately 40 amino acids, often terminating in 
tryptophan-aspartic acid (W-D) dipeptides; BEACH: beige and CHS domain. 
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Immunoglobulin E in health and disease 
M. B. Johnson  
 Immunoglobulin E  
Immunoglobulin E (IgE) is the lowest abundance immunoglobulin in healthy 
individuals, accounting for less than 1 x 10-4% of total serum immunoglobulin [1]. 
Its physiological role is primarily in the defence against multicellular parasites, as 
demonstrated by the stimulation of specific IgE production by helminth infection 
and raised levels of serum IgE observed in people living in the tropics, where 
helminth’s are endemic [2]. Excess production of non-specific IgE is also 
associated with atopic diseases and hyper-IgE syndrome (HIES; also known as 
Job’s syndrome), caused predominantly by dominant negative mutations in 
STAT3 [3]. 
IgE is produced after class switching of B-cells into short lived plasma cells. This 
mostly occurs in germinal centres but also in extra-follicular space in secondary 
lymph nodes [4]. These plasma cells then produce IgE in the lymphatic system 
and periphery. IgE primes the IgE-mediated response by binding to Fc receptors 
found on the surface of mast cells and basophils. Fc receptors are also found on 
eosinophils, monocytes, macrophages and platelets in humans [5]. 
IgE in medicine 
Serum IgE is most commonly elevated in the context of allergic reactions[6]. Its 
use is limited in determining the specific allergen, other than in allergic 
bronchopulmonary Aspergillosis (ABPA) which is part of the diagnostic criteria 
[7]. Measurement of IgE may also be used to identify patients with severe atopic 
disease suitable for anti-IgE therapy with omalizumab and for monitoring efficacy 
and determining dosage [8] . Raised IgE is also used to identify primary 
immunodeficiencies such as HIES, Omenn syndrome and IPEX syndrome.  
Hyper IgE syndrome 
 HIES is a multisystem disorder that commonly includes increased levels of serum 
IgE (>2000 IU/L; >95%), severe eczema (100%), eosinophilia (93%) 
characteristic facial dysmorphism (83%), susceptibility to Staphylococcal 
infections (>90%) and abnormal dentition (72%) [9]. Heterozygous dominant-
negative mutations in STAT3 are the primary cause. The vast majority of 
mutations identified in STAT3 are missense, in keeping with a dominant negative 
mechanism of disease. Recessively inherited mutations in DOCK8 also causing 
an immunodeficiency syndrome with raised IgE in a smaller number of cases [10].  
Germline gain of function (GOF) mutations in STAT3 were recently identified as 
the cause of early-onset multisystem autoimmune disease (OMIM: 615952) [11, 
12]. This is characterised by the early-onset of multiple autoimmune diseases 
and contrasts to the phenotype associated with HIES, though severe eczema and 
dental anomalies may be present in both conditions.  
IgE in IPEX 
Previous studies have shown that the majority of patients with IPEX syndrome, 
caused by hemizygous mutations in FOXP3, have raised concentrations of serum 
IgE [13]. In our cohort of patients with IPEX syndrome, where serum was 
available and measurement was possible (n=16), 13/16 (81%) had serum IgE 
concentrations above the age specific reference range in keeping with previous 
reports (chapter 2 and table 1).  
The main differential diagnosis in non-consanguineous males with very early-
onset autoimmunity is hemizygous FOXP3 mutations or GOF STAT3 mutations. 
Our patients with FOXP3 mutations had significantly higher serum IgE than those 
with STAT3 mutations (median 2177.5 KU/L [IQR 152-3200] v 1 KU/L [IQR 0.7-
2], p=0.002, figure 1). Measurement of IgE could therefore be extremely useful in 
 this patient group to guide genetic testing. Moreover, in those without a mutation 
in the coding region of FOXP3, it could facilitate the identification of regulatory 
mutations or novel genetic aetiologies by suggesting which pathway is most likely 
to be affected. 
Patient Gene 
Age 
serum 
collected 
IgE concentration 
(KU/L) 
[reference range] * 
Interpretation 
1 FOXP3 0 2950 [2-34] Raised IgE 
2 FOXP3 0 259.4 [2-34] Raised IgE 
3 FOXP3 0 44.5 [2-34] Raised IgE 
4 FOXP3 0 557.8 [2-34] Raised IgE 
5 FOXP3 0 3000 [2-34] Raised IgE 
6 FOXP3 1 2266 [2-97] Raised IgE 
7 FOXP3 6 2089 [2-199] Raised IgE 
8 FOXP3 25 0.1 [2-214] Low IgE 
9 FOXP3 0 5.6 [2-34] Normal 
10 FOXP3 0 6.3 [2-34 Normal 
11 FOXP3 0 4899 [2-34] Raised IgE 
12 FOXP3 4 7173 [2-199] Raised IgE 
13 FOXP3 0 2396 [2-34] Raised IgE 
14 FOXP3 0 10000 [2-34] Raised IgE 
15 FOXP3 1 3400 [2-97] Raised IgE 
16 FOXP3 0 1000 [2-34] Raised IgE 
17 STAT3 0 0.5 [2-34] Low IgE 
18 STAT3 0 1 [2-34] Low IgE 
19 STAT3 0 1 [2-34] Low IgE 
20 STAT3 4 2 [2-199] Low IgE 
21 STAT3 7 2 [2-307] Low IgE 
22 STAT3 4 0.7 [2-199] Low IgE 
 
Table 1: IgE concentration for patients with hemizygous FOXP3 mutations 
and GOF STAT3 mutations. *age specific reference ranges taken from Martins 
et al. 
  
  
Figure 1: Boxplot showing serum IgE levels in patients with IPEX syndrome 
(n=16), healthy controls (n=1510) and patients with STAT3 GOF mutations 
(n=6). Serum IgE was significantly higher in patients with IPEX (median 2177.5 
KU/L) than healthy controls, and significantly lower in patients with STAT3 GOF 
mutations (median 1 KU/L).  
 STAT3 and IgE  
The pathogenic mechanism(s) that underlies the increased production of IgE in 
patients with HIES has not been fully resolved, in part due to knockout of STAT3 
in mice being lethal during embryonic development and the overlapping and 
pleiotropic nature of STAT signalling [14, 15]. Furthermore, whilst in the murine 
model IL-21 down-regulates IgE production via STAT3 signalling [16], IL-21 
increases production of IgE by human plasma cells in a STAT3 dependent 
manner [17].  
The pathogenesis of HIES is in part due to defective IL-10 signalling leading to a 
reduction in immune tolerance [18]. IL-10 also has a role in the suppression of 
IgE production [19]. The loss of STAT3 signalling may therefore increase IgE 
production by reducing IL-10 signalling. In patients with STAT3 GOF mutations, 
increased IL-10 signalling may underlie decreased IgE production, however 
empirical data to support this is not available. Further study of this area is 
warranted to elucidate the role of STAT3 in the production of IgE. Cells from 
patients with STAT3 GOF, in combination with those from patients with HIES, 
could offer an ideal experimental model for this.  
Regulatory T cells (Tregs) have a role in the regulation of IgE production. Tregs 
suppress antibody production by B-cells via IL-10 signalling and TGF-B 
(transforming growth factor beta) [20]. Reduced numbers or function of regulatory 
T cells may therefore underlie the increase in IgE seen in patients with IPEX 
syndrome. In previous reports of patients with STAT3 GOF mutations [21, 22], 6 
patients were reported to have reduced numbers of Tregs however their serum 
IgE concentration was not available. Further study is warranted to elucidate a 
possible connection between STAT3 GOF mutations, the Treg compartment and 
IgE production.  
 Further study of IgE in STAT3 GOF 
Since the publication of our manuscript ‘Low IgE is a useful tool to identify STAT3 
gain of function mutations’ (Chapter 4B) a response has been published by an 
international team of investigators following a larger cohort of patients with STAT3 
GOF [23]. The authors assessed the serum IgE concentration in an additional 23 
patients with either previously published mutations or in whom GOF was 
confirmed by luciferase reporter assay. They found that 9 of the patients had 
values above 2KU/L (mean 28.3KU/L, median <2KU/L) and conclude that low 
serum IgE is therefore less useful for identifying patients with STAT3 GOF 
mutations than our data suggested, with a sensitivity of 0.61 [95%CI 0.39-0.80].  
When the patients we report are included (n=6, table 1), the sensitivity of IgE 
<2KU/L is 0.69 [95%CI 0.49-0.84]. This is still too low to be clinically useful for 
guiding genetic testing. As the authors note, as additional patients with STAT3 
GOF mutations have been reported the phenotypic spectrum observed has 
increased. It may therefore be that patients with low IgE represent a distinct 
subgroup, or have mutations that affect STAT3 signalling in a specific way that 
denotes a change to IgE level, possibly via IL-10 signalling. Further study is 
needed to elucidate the mechanism that underlies aberrant IgE production in 
some individuals with GOF STAT3 mutations. 
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 To the Editor, 
Germline gain-of-function mutations (GOF) in STAT3 were recently identified as 
the cause of early-onset autoimmune disease (MIM: 615952). This rare 
monogenic autoimmune disorder commonly encompasses autoimmune 
haematological disorders (identified in 70% of patients), recurrent infections 
(60%) and autoimmune enteropathies (50%)[21, 22, 24]. The phenotype 
observed contrasts to that of patients with loss-of-function (LOF) STAT3 
mutations causing hyper-IgE (Job) syndrome, typically characterised by elevated 
immunoglobulin E (IgE), recurrent infections and eczema[25]. Identifying patients 
with STAT3 GOF mutations informs families and clinicians of prognosis and 
facilitates personalised treatment.  
There is substantial clinical variability between patients with GOF STAT3 
mutations and overlap in phenotype with other monogenic autoimmune disorders 
such as IPEX syndrome (immunodysregulation, polyendocrinopathy, 
enteropathy, X-linked; MIM: 304790) resulting from hemizygous loss-of-function 
FOXP3 mutations, and early-onset polygenic autoimmune disease. 
Distinguishing the specific genetic aetiology using clinical characteristics alone is 
not possible and genetic testing, often performed sequentially until a pathogenic 
mutation is found, is essential for accurate diagnosis.  
Genetic testing for STAT3 is expensive and available only in a limited number of 
specialist centres. An inexpensive and widely available test to identify patients 
most likely to harbour GOF STAT3 mutations is desirable as it will prevent 
inappropriate genetic testing. We assessed whether IgE would be a useful tool to 
aid in the identification of patients suitable for STAT3 sequencing. 
Total serum IgE concentration was measured by using the Immuno-CAP 1000 
instrument (Phadia) for both healthy reference samples (n = 1510) and STAT3 
 patient samples (n = 6). Calibration was performed with the 2nd International 
Reference Preparation 75/502 of Human Serum IgE from the World Health 
Organization[26]. Statistical analysis was performed in Stata®; specificity, 
sensitivity and binomial confidence intervals were calculated. The age of the 
patients with STAT3 GOF mutations ranged from 1-9 years, and the median time 
from the first clinical symptom to IgE testing was four years.  
Immunological assessment of individuals with STAT3 GOF mutations identified 
total serum IgE below the lower reference limit of age-matched controls in all six 
cases, (<2 KU/L, range 0.7-2 KU/L; See Figure 1) [24]. Using 2 KU/L as a cut off 
for the assay for identification against all age groups gave a sensitivity and 
specificity of 100% (95% CI: 54.1 – 100) and 97.2% (95% CI: 96.2-97.9), 
respectively.  
We have demonstrated that serum IgE, an inexpensive and widely available 
diagnostic test, is likely to be very useful to facilitate identifying patients suitable 
for STAT3 sequencing, and a 2 KU/L cut-off gives high sensitivity and specificity. 
The role we propose for IgE measurement is in patients with multi-system early-
childhood autoimmune disease in whom STAT3 GOF mutations are being 
considered. This is likely to be particularly helpful in distinguishing from multiple 
autoimmunity resulting from hemizygous FOXP3 mutations as more than 90% of 
patients with IPEX syndrome have increased serum IgE.  In this scenario raised 
IgE would be helpful to rule out STAT3 GOF mutations, reducing total genetic 
testing expenditure. In addition, despite recent advances in sequencing 
technologies, identifying pathogenic mutations from benign variants remains a 
challenge. Measuring IgE could be a tool to aid molecular geneticists in 
classifying STAT3 variants found by DNA sequencing; serum IgE concentration 
below 2 KU/L supports pathogenic GOF. 
 We have assessed IgE in a small number of patients with GOF STAT3 mutations 
(n=6) and assessment in further patients is required to increase confidence in the 
diagnostic utility, but it is notable that all six patients had IgE concentrations below 
the 1st centile of the reference population.  Two previous case series of patients 
with STAT3 GOF mutations measured IgE in a total of nine additional individuals 
(four of those previously reported are included in this study[21, 24]). One 
described two additional individuals with serum IgE below 2 KU/L[21], supporting 
our findings. The other reported more variability in IgE than we have observed 
(0.1-58.5 mg/dL; n=7)[22], but we were unable to ascertain reference interval, 
testing platform or comparable units to our assay for these individuals and 
therefore, unable to make a direct comparison to our findings[22]. A potential 
limitation of the diagnostic accuracy of IgE to identify patients with STAT3 GOF 
mutations is that an allergic response or parasitic infection may increase serum 
IgE. Given that allergies are relatively common (for example allergic rhinitis is 
present in >20% of the European population) this is an important consideration 
as this may decrease the performance of the test in these patients. In conclusion, 
total serum IgE concentration is an inexpensive and robust tool for determining 
which patients with multiple early-onset autoimmunity are likely to have a STAT3 
GOF mutation. In combination with the identification of clinical features of early-
onset autoimmune disease IgE concentrations could be assayed locally to 
facilitate appropriate, cost-efficient and rapid genetic testing. Further work is 
warranted to determine IgE in other subtypes of monogenic autoimmunity. 
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Figure 1: Boxplot of serum IgE concentrations in healthy controls and patients 
with STAT3 GOF mutations. P value determined using the Mann-Whitney test. 
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Conclusions 
  
 Identifying monogenic autoimmunity can lead to improved treatment for patients 
and gives clinicians and families knowledge on prognosis and recurrence risk. 
Discovering new causes of monogenic autoimmune diabetes can also give 
insights into beta-cell autoimmunity that could have wider implications for patients 
with polygenic type 1 diabetes. 
This section of this thesis will summarise the main findings of each chapter, give 
the impact of the results and suggest future avenues of research in monogenic 
autoimmunity. 
 
CHAPTER 1 - A TYPE 1 DIABETES GENETIC RISK SCORE CAN 
DISCRIMINATE MONOGENIC AUTOIMMUNITY WITH DIABETES FROM 
EARLY ONSET CLUSTERING OF POLYGENIC AUTOIMMUNITY WITH 
DIABETES 
 
Conclusions 
We showed that a genetic risk score using the top 10 risk alleles for type 1 
diabetes (T1D-GRS) could discriminate monogenic autoimmunity from patients 
who are likely to have polygenic clustering of diabetes and additional 
autoimmunity in whom a known monogenic cause was excluded. Identifying 
monogenic autoimmunity from the more common polygenic clustering of 
autoimmune diseases is a challenge as there is significant clinical overlap 
between these groups. Markers for autoimmune diabetes are useful for 
identifying non-autoimmune monogenic diabetes from type 1 diabetes, however 
islet autoantibodies (e.g. anti-glutamic acid decarboxylase antibody) are present 
in both monogenic and polygenic autoimmune diabetes, age of onset can be 
 similar, and insulin is usually required in full replacement doses for both groups. 
We showed that the T1D-GRS was a similar discriminator to age of diabetes 
diagnosis (ROC-AUC 0.80 vs 0.79) however when combined, discrimination 
improved beyond either alone (ROC-AUC 0.88, p=0.04). Specific clinical features 
such as coeliac disease or autoimmune enteropathy showed different prevalence 
in those with monogenic autoimmunity compared to those with unknown 
aetiology, but as these features were present in both groups they could not be 
used alone to guide testing or gene discovery. 
This study also provides evidence that the polygenic risk of developing diabetes, 
including that from the strongest predisposing HLA DR3 and DR4 haplotypes, 
does not influence the phenotype of patients with monogenic autoimmune 
disease. All the patients with monogenic autoimmunity had early-onset diabetes 
(diagnosed <5 years), however they had a similar range of T1D-GRSs as the 
population of non-diabetic controls. Our data also suggests there are novel 
monogenic aetiologies to discover in our cohort as there was a small enrichment 
of patients without monogenic disease in the lowest quartile of the type 1 diabetes 
controls, where most (79%) known monogenic autoimmunity was found. 
Impact of findings  
This study provided a genetic diagnosis to 37 families, informing the families and 
clinicians on prognosis and recurrence risk which ranges from <1% for de novo 
STAT3 mutations to 50% for male offspring of FOXP3 mutation carriers.  
It is important to identify monogenic autoimmunity as many forms genetic 
subtypes are suitable for targeted therapy. For example, abatacept can be used 
to treat patients with biallelic LRBA mutations [27] and anti-IL6 antibody therapy 
with tociluzumab for patients with GOF STAT3 mutations [22]. 
 Whilst there is some overlap in the range of T1D-GRS scores in individuals with 
polygenic and monogenic autoimmunity, which prevents this from being used as 
an exclusion test, the T1D-GRS can help to prioritise patients for routine genetic 
testing. This is important as it will help to prevent expensive genetic testing being 
undertaken on individuals who are most likely to have polygenic disease and will 
also preclude any anxiety experienced by families regarding the possibility of their 
child having an inherited disease.  
The T1D-GRS may prove useful in the selection of patients for gene discovery, 
particularly those with a score below the 25th centile of T1D controls. Where 
patients have novel or very rare variants of uncertain significance the T1D-GRS 
could assist with variant classification by suggesting the most likely aetiology. 
Future directions 
One future direction for this cohort of patients is to perform gene discovery in 
those without a causative variant in the genes tested and who have a low T1D-
GRS (<25th centile of T1D controls). The ideal strategy would be to perform whole 
genome sequencing to a high depth as this will capture >98% of the genome and 
allow for both coding variants and non-coding regulatory variants to be identified. 
The strategy of gene discovery studies will depend on family structure, with 
outbred patients (defined as having a coefficient of inbreeding [F] <0.0156 [28]) 
sequenced as trios to look initially for de novo or compound heterozygous 
variants and patients who are the result of consanguineous union (F > 0.0156) 
sequenced as singletons to look initially for homozygous variants. These new 
genetic causes may be a novel aetiological gene or mutations in as yet undefined 
intronic/regulatory regions. The power to identify new genetic causes will rely on 
the number of families sequenced, as confirming a new genetic cause depends 
 on identifying variants in the same gene/regulatory region in multiple unrelated 
pedigrees.  
Fine mapping of the HLA region could provide additional information on the 
genetic risk in patients without a known genetic cause, as has been evidenced 
by studies into coeliac disease [29]. This may also identify rare haplotypes that 
infer high risk and underlie the early-onset of diabetes and autoimmunity in 
patients without a confirmed monogenic cause. Furthermore, many loci that infer 
risk for multiple autoimmune diseases were not included in this study [30], and a 
genotyping assay that captures these pleiotropic loci may give better 
discrimination as it could identify patients whose disease phenotype does not fit 
their genetic predisposition. In addition, combining the T1D-GRS with genetic risk 
scores for other autoimmune diseases such as thyroid disease [31] and coeliac 
disease [32] could identify patients with a low T1D-GRS but whose non-diabetic 
disease manifestations fit with a polygenic aetiology. This could enable a more 
granular and individualised genetic risk to be ascertained, and could also enable 
assessment of genetic risk in patients without diabetes but with multiple early-
onset autoimmune diseases. 
 
CHAPTER 2 – GENOTYPE AND CLINICAL PHENOTYPE DO NOT PREDICT 
PROGNOSIS IN IPEX SYNDROME 
 
Conclusions 
We sought to identify genetic or clinical characteristics in patients with 
Immunodysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) 
syndrome to identify correlation with prognosis. We did not identify evidence of 
 phenotype-genotype relationships in IPEX syndrome; those with missense 
variants did not differ in their prognosis to those with protein truncating variants 
expected to result in the complete loss of FOXP3 protein. Moreover, individuals 
with the same missense mutation had highly variable phenotypes, even within 
the same family, and one patient with a protein truncating variant expected to 
result in the loss of FOXP3 survived to adulthood with a milder clinical course. 
The presenting feature (either enteropathy or diabetes) did also not predict a 
different prognosis or disease course in our large cohort of patients. 
Medical management for IPEX is challenging and the only curative therapy, 
haematopoietic stem cell transplantation (HSCT), has high mortality risk. Whilst 
many patients with IPEX syndrome die in infancy, some patients have a milder 
clinical course, even if they have the same mutation as those with severe forms. 
We showed that decisions on medical management cannot be based on 
presentation or genotype and must be based on individual clinical need. We also 
showed that while recurrence risk can be predicted by genetic testing, phenotype 
cannot.  
Furthermore, panel testing of genes with similar phenotypes is identifying more 
individuals with atypical clinical disease and is highlighting the true spectrum of 
IPEX. Understanding what causes this variability in phenotype could allow for 
better selection of patients for HSCT by identifying which patients are likely to 
progress quickly to severe disease and which patients are likely to have a milder 
clinical course where the risk of HSCT would be unlikely to outweigh the 
prognosis.  
Impact of findings 
 The 48 diagnoses provided in this study enabled prenatal diagnosis in 2 families 
and facilitated HSCT in 4 patients. Furthermore, it gave information for families 
and clinicians on recurrence risk; where the FOXP3 variant was carried by the 
unaffected mother each offspring has a 50% chance of inheriting the variant, with 
females being unaffected carriers and males being affected. We have studied the 
largest collection of families with IPEX syndrome to date. Even in this large 
cohort, we could not find evidence that presenting feature or genotype affected 
prognosis, suggesting that they do not have a role in disease progression. This 
paves the way for further studies into patients with IPEX syndrome to elucidate 
the cause of the highly variable phenotypes that are observed.  
Our study will also increase knowledge and recognition of the milder forms of 
IPEX, which were previously thought to be atypical rare forms. We suggest that 
IPEX is a more variable clinical disorder than previously understood and the 
criteria for testing of FOXP3 could be widened to include males with isolated 
early-onset diabetes, isolated autoimmune enteropathy or other autoimmunity in 
early childhood. Further recognition of atypical cases may allow for further study 
of the determinants of variability. We have identified the oldest surviving male 
with a FOXP3 mutation (current age 61 years) which may act to reassure families 
and clinicians that IPEX syndrome is not necessarily life limiting, particularly if the 
variant is hypomorphic, though this should be treated with caution due to the wide 
variability in prognosis. 
Future directions  
Publication of this work will disseminate the findings and show that, at least in this 
cohort, genotype and presentation do not dictate prognosis. Furthermore, 17 of 
the variants identified in our cohort are novel and their publication will assist in 
the classification of FOXP3 variants. Another key direction of research in IPEX 
 syndrome is to identify the genetic characteristics of these patients that may be 
involved in determining phenotype. For example, full HLA typing for these 
patients should be undertaken, as the risk of developing autoimmune diabetes is 
strongly associated with class II HLA alleles (particularly HLA DR4 and DR3) [33]. 
Furthermore, strongly protective haplotypes exist (e.g. HLA DRB1*15) that may 
influence the likelihood of the development of diabetes in these individuals [34]. 
Fine mapping of the HLA would be most desirable to identify rare alleles that may 
be having an effect, as has been shown for coeliac disease [29]. New long read 
sequencing technologies are enabling improved analysis and phasing of the 
highly polymorphic HLA region, and these would be ideal to study this cohort [35]. 
There are also >50 loci outside the HLA region that are associated with type 1 
diabetes, and genotyping of these may provide additional insights [36]. 
Histopathology of patients with autoimmune enteropathy has also shown that 
some individuals have overexpression of HLA DR molecules on enterocytes and 
inappropriate expression of class II HLA on crypt epithelia [37, 38]. Determining 
the regulatory networks that lead to this inappropriate expression may also 
identify hallmark genetic features that influence phenotype in IPEX syndrome.   
Functional work to assess the expression of FOXP3 in the individual with a 
protein truncating FOXP3 variant but a milder disease course would also be 
desirable. If, as predicted, he does not have expression of FOXP3, 
immunophenotyping to look for Treg-like lymphocytes (CD4+CD25+CD127low) 
[39] or atypical lymphocyte profiles would be useful to understand his milder 
phenotype. Indeed, immunophenotyping of all patients with hemizygous FOXP3 
mutations may give insight into the causes of their variable phenotypes. 
Longitudinal study or patients with IPEX would also be useful to further 
understand key clinical features that may be associated with a milder course, and 
 it would allow for prospective measurement of autoantibodies and 
immunophenotyping which, unlike genetics, are dynamic. This would be difficult 
for this very-rare disease as patients will be located throughout the world, 
however through collaboration with other international groups it would be possible 
to follow patients through life.  
We were not able to look in detail at geographic or socio-economic factors that 
may be influencing disease phenotype in patients with IPEX syndrome. It is well 
established that the proportion of specific autoimmune diseases varies by country 
and that incidence is increasing in many [40]. This is not explained by genetic 
variation alone and therefore looking at the autoimmune manifestations in 
patients with IPEX syndrome and correlating this to their country of origin may 
give insights into possible environmental factors that influence phenotype. 
 
CHAPTER 3 - RECESSIVELY INHERITED LRBA MUTATIONS CAUSE 
AUTOIMMUNITY PRESENTING AS NEONATAL DIABETES 
 
Conclusions 
We used exome sequencing for a patient with autoimmune lymphoproliferative 
disease and neonatal diabetes (NDM; diagnosed at 7 weeks) to look for novel 
causes of NDM and identified compound heterozygous mutations in LRBA, 
confirming the role of LRBA in neonatal diabetes. We then used targeted NGS to 
screen an additional 170 probands in whom the 24 known causes of NDM had 
been ruled out. This identified a further 8 probands and family member testing 
identified one affected sibling. Clustering of early-onset diabetes and additional 
autoimmunity is usually polygenic, however identifying monogenic autoimmunity 
 can facilitate personalised medicine. This is particularly true for patients with 
biallelic disease causing variants in LRBA, who are amenable to therapy with 
Abatacept which replaces the lost signalling from CTLA-4 that underlies their 
disease. 
Seven of the patients we report are consanguineous and 6 of these had additional 
autoimmune disease. In one patient, NDM was the only clinical feature at 2 years 
of age. We showed that, in our cohort, biallelic LRBA mutations have a minimum 
prevalence of 0.6% (9/1561) in patients diagnosed with diabetes before 12 
months, and of 6.3% (4/63) in patients who are the result of consanguineous 
union diagnosed with diabetes between 6-12 months. Combined selection criteria 
of consanguinity and autoimmune disease gave the highest pick up rate, with 
6/17 (35%) of patients found to have recessively inherited LRBA mutations. 
Impact of findings  
Our study led to a genetic diagnosis for 10 patients with early-onset 
autoimmunity. This also informed the families and clinicians of recurrence risk 
(25% to siblings <1% to offspring of patient). Identifying patients with recessively 
inherited LRBA mutations can facilitate targeted therapy. It has been shown that 
treatment with abatacept, an immunoglobulin-CTLA-4 mimetic, can improve 
symptoms in patients with LRBA mutations [27]. LRBA post-translationally 
regulates CTLA-4, a potent suppressive receptor, and abatacept replaces the lost 
CTLA-4 signalling in these individuals. Patients with LRBA mutations are also 
amenable to haematopoietic stem cell transplantation, and identifying these 
patients early, at the onset of disease, could allow for the search for a matched 
donor to begin before the disease progresses. None of our patients were treated 
with abatacept. Three patients died before a genetic diagnosis was made and the 
 cost of abatacept may have been prohibitive as many of our patients were from 
developing countries. 
This study confirms recessively inherited LRBA mutations as a cause of neonatal 
diabetes. It is now included on the Exeter Molecular Genetics laboratory’s custom 
targeted NGS panel meaning diagnoses are happening soon after presentation 
for patients with neonatal diabetes. We have also shown that recessively 
inherited LRBA mutations are a relatively common cause of diabetes and 
autoimmunity in our cohort of patients diagnosed before 12 months, and testing 
of LRBA should be considered in consanguineous patients with early-onset 
autoimmunity. We have increased the number of genetic causes of neonatal 
diabetes to 25, and causes of early-onset autoimmunity that incudes neonatal 
diabetes to 4. As one patient had isolated diabetes at the age of 2 years, LRBA 
should be included on genetic testing panels for neonatal diabetes. Furthermore, 
as LRBA is a highly polymorphic 58 exon gene, analysis by targeted NGS is 
preferable as it will require less precious DNA from these patients and rationalise 
data analysis.  
Future directions 
Assessment of the factors influencing the variability in phenotype observed, both 
in our cohort and in previous reports, is warranted. All our patients had protein 
truncating variants that would be predicted to result in the complete loss of LRBA 
by nonsense mediated decay. Despite this, the phenotype varied wildly with some 
individuals surviving to adulthood while others died in infancy. Furthermore, only 
11/57 (19%) of the previously reported patients have diabetes. While the high 
proportion of individuals with diabetes in our cohort represents referral bias, 
identifying the factors that determine whether patients with biallelic LRBA 
mutations develop diabetes will give insights into the mechanisms of beta-cell 
 autoimmunity that could have implications for patients with type 1 diabetes. Type 
1 diabetes has been classically thought of as a single aetiology, however there is 
growing evidence for heterogeneity [41]. If immunophenotyping of prospective 
cases of LRBA deficiency was performed in parallel with patients with newly 
diagnosed early-onset type 1 diabetes this could find heterogeneity in type 1 
diabetes. If some patients with type 1 diabetes display a similar 
immunophenotype to those with LRBA mutations, they may be amenable to 
therapy with abatacept to counter the autoimmune response to the beta-cells. 
Most patients with early onset diabetes and additional autoimmunity did not have 
a mutation in LRBA or the other 24 known causes of NDM (11/17 
consanguineous and 23/25 non-consanguineous patients). Further study of these 
patients to characterise the aetiology of their disease is warranted. Initially this 
could involve undertaking testing of the type 1 diabetes genetic risk score as 
employed in chapter 1. Whole genome sequencing to look for novel genetic 
aetiologies in those with low polygenic risk for type 1 diabetes could then be 
undertaken. In combination with immunophenotyping this could seek novel 
mutations in regulatory regions of the genome. Measurement of intracellular 
LRBA or cell-surface CTLA-4 expression could distinguish patients likely to have 
deep-intronic regulatory mutations around LRBA. Classifying these variants 
remains a challenge and analysis in combination with functional data would 
enable a guided approach. 
Longitudinal follow up of these patients may impart further knowledge of the 
disease course and prognosis for patients with recessively inherited LRBA 
mutations. At the time of publication none of our patients had undergone 
treatment with abatacept or HSCT, but follow up could enable further assessment 
of the efficacy of these treatments if they are employed. It is not known if early 
 intervention with abatacept or transplantation could improve the diabetes and 
lower insulin requirement in patients with biallelic LRBA mutations, and follow up 
of patients with diabetes undergoing treatment with abatacept could give new 
insights.  
 
CHAPTER 4 - LOW IgE IS A USEFUL TOOL TO IDENTIFY STAT3 GAIN OF 
FUNCTION MUTATIONS 
 
Conclusions 
We hypothesised that patients with gain-of-function (GOF) STAT3 mutations 
would have the reciprocal immunoglobulin phenotype of those with hyper-IgE 
syndrome (HIES) caused by loss of function (LOF) STAT3 mutations. All our 
patients (n=6) had serum IgE levels below the lower limit of the reference range 
(2KU/L; range 0.7-2KU/L). This is striking as all patients were below the 1st centile 
of healthy individuals, and the likelihood that this is by chance is therefore 
extremely small. We showed that 2KU/L had a specificity of 100% (95% CI: 54.1 
– 100) and sensitivity of 97.2% (95% CI: 96.2-97.9) to identify STAT3 GOF.  
We also tested serum IgE levels in our patients with hemizygous FOXP3 
mutations (chapter 4a) and showed that the 13/16 (81%) had raised serum IgE, 
in keeping with previous reports. The main differential diagnosis for non-
consanguineous males with early-onset multiple autoimmunity is STAT3 GOF 
mutations or hemizygous FOXP3 mutations, and the levels in our patients were 
significantly different (p=0.002) suggesting testing IgE could have utility to 
differentiate these phenotypically similar patients. 
 Impact of findings 
This study provides a method for identifying patients suitable for STAT3 genetic 
testing that is affordable and is readily available. It could therefore be used to 
screen patients before sending samples for genetic testing. It would also be 
useful to assess the pathogenicity of missense variants in STAT3 [11, 21, 22, 42]. 
For example, both disorders are associated with increased infections and atopic 
dermatitis. Measurement of Serum IgE could therefore be useful to characterise 
the nature of the variants identified without the need for time consuming functional 
studies. This would give knowledge on disease course, as patients with HIES do 
not develop organ specific autoimmunity whilst those with STAT3 GOF do.  
Furthermore, GOF STAT3 mutations are seen in malignancies (particularly large 
granular lymphocytic [LGL] leukaemia [43] and it may be that patients with STAT3 
GOF have a higher rate of LGL. Identifying and accurately characterising variants 
in STAT3 would therefore allow for monitoring for autoimmunity and potential 
malignancies. In patients without a coding mutation in FOXP3 or STAT3, raised 
serum IgE may suggest that there are uncharacterised intronic variants affecting 
FOXP3 and enable identification of novel regulatory loci. 
Since the publication of our manuscript, a response has been published [23]. This 
was a larger study of 23 individuals with STAT3 GOF mutations. The authors 
showed that low IgE is less useful to identify patients with STAT3 GOF mutations 
than our data suggested as they identified 6 patients with serum IgE levels above 
2KU/L. When combined with our patients IgE <2KU/L had a sensitivity of 0.69 
[95%CI 0.49-0.84] which is too low to guide genetic testing. Measurement of 
serum IgE to assist with the interpretation of novel missense variants in STAT3 
is still warranted as most patients with GOF have low IgE, and most with LOF 
have high IgE.  
 Future directions 
To further assess the usefulness of IgE for identifying STAT3 GOF mutations 
study of additional patients is warranted as the numbers are still low (n=29). The 
6 patients reported with IgE levels above 2KU/L may represent an atypical patient 
group or have variants which affect STAT3 function in a way that does not reduce 
IgE levels. The variants identified in the patients were not reported in the 
publication by Tangye et al, therefore further collaboration would be beneficial to 
correlate specific mutations with IgE levels. Functional work may also be 
beneficial to determine if the mechanism of increased STAT3 activation differs 
between some patients accounting for the diverse effects on IgE levels. It may 
also be beneficial to perform a sensitivity/specificity analysis of serum IgE level’s 
usefulness to identify patients with IPEX syndrome caused by hemizygous 
FOXP3 mutations from those with STAT3 GOF. Assessment of serum IgE in 
other forms of monogenic autoimmunity may identify common pathways of IgE 
regulation and improve knowledge of the complex nature of STAT3 signalling. 
 
  
 Final remarks 
 
The work that is collated within this thesis has focussed on the identification of 
patients with autoimmune diabetes as part of a syndrome of monogenic 
autoimmunity, and factors that influence the phenotypic variability observed in the 
known causes. To this end, it has identified biallelic variants in LRBA as a cause 
of autoimmunity that may present as neonatal or early-onset diabetes (chapter 
3); shown that a type 1 diabetes genetic risk score can be used to discriminate 
monogenic autoimmune diabetes from polygenic clustering of diabetes and 
additional autoimmunity (chapter 1); that the polygenic risk loci, including the 
established HLA DR3 and DR4 alleles, do not determine if patients with 
monogenic autoimmunity develop diabetes (chapter 1); and that genotype or 
presenting feature does not predict prognosis in patients with IPEX syndrome 
(chapter 2). 
The first step towards the work that has been compiled in this thesis was to 
identify the cohort of patients to study. This was less straightforward than initially 
thought; all of the clinical information regarding autoimmune diseases for these 
individuals, other than their diabetes phenotype, was stored either as free text in 
a database or was within scanned clinical notes stored for each patient. In order 
to improve this moving forward, I have added new fields to the existing database 
in order to easily identify historic cases and accurately record autoimmune 
diseases in new referrals. Furthermore, I have systematically stored the clinical 
information for these patients in a sister database that is set up to record 
immunological data. This has been invaluable in forming a resource for my on-
going work in gene discovery for monogenic diabetes. As most of the historic 
cases were referred for diabetes testing, clinical information on their additional 
autoimmunity was often not recorded in the original referral but was provided in 
 follow up correspondence. In order to improve this for future referrals I generated 
a bespoke autoimmunity request form (appendix 2) for prospective cases, which 
is already being used by clinicians to refer new patients from across the globe.   
Initially, testing for monogenic autoimmunity in our laboratory was sporadic, with 
only the FOXP3 and STAT3 genes tested for referrals where there was a strong 
suspicion of monogenic autoimmunity. Early in my PhD studies I added several 
other monogenic autoimmunity genes to our targeted NGS panel (for example 
LRBA, which I confirmed was a cause of autoimmune neonatal diabetes during 
my PhD [Chapter 3]), and I have continued to add new confirmed aetiological 
genes or likely candidates with each new iteration of the panel. This has been 
important not only to test all genes at once and increase our diagnostic yield, but 
also in identifying patients who have been referred with early-onset diabetes 
which it emerged was the first feature of monogenic autoimmunity.  
 
 The work detailed in chapter 1 (A Type 1 diabetes genetic risk score can 
discriminate monogenic autoimmunity with diabetes from early onset clustering 
of polygenic autoimmunity with diabetes) has also enabled me to develop a 
testing pipeline for monogenic autoimmunity and gene discovery (figure 1), as it 
showed that the genetic risk score could separate monogenic autoimmunity from 
polygenic clustering of diabetes and additional autoimmunity. This has so far 
proved fruitful, as we are able to triage samples into their most likely aetiology 
and easily select samples for gene discovery based on not having a causative 
variant in a known gene and having a low polygenic risk for type 1 diabetes. This 
has led to two new putative disease genes; replication studies and functional work 
are on-going (Johnson et al. unpublished).  
 
Figure 1: Testing flowchart for monogenic autoimmunity referrals as informed by 
work in this thesis. NGS – Next generation sequencing. WGS – Whole genome 
sequencing. T1D-GRS – type 1 diabetes genetic risk score. Dx – diagnosed. 
 Identifying monogenic causes of autoimmune diabetes has wider implications for 
patients with polygenic type 1 diabetes. There is increasing recognition that type 
1 diabetes is likely to be a common endpoint rather than a single aetiology and 
that significant heterogeneity exists between patients. Evidence for this includes 
the variation in the preclinical stage of disease (i.e. the time from seroconversion 
to clinical onset) and histological evidence from new onset T1D pancreata that 
distinct groups can be defined by the proportion of infiltrating CD20+ B cells 
(CD20hi or CD20lo) that correlate with age of onset. Furthermore, studies of 
individuals with type 1 diabetes have suggested that a defect in the regulatory T 
cell compartment be partly responsible for the breakdown in tolerance to the 
pancreatic β-cells. Many of the disorders described within this thesis result from 
reduced function or number of regulatory T-cells (e.g. IPEX syndrome caused by 
hemizygous FOXP3 mutations, CVID-8 caused by recessively inherited LRBA 
mutations and Immunodeficiency 41 caused by recessively inherited mutations 
in IL2RA).  
It may therefore be that there is overlap between the monogenic causes of 
autoimmune diabetes described and discussed in this thesis and some of the 
subgroups of type 1 diabetes. This could be assessed by immunophenotyping 
both those with confirmed monogenic aetiology and clinically defined type 1 
diabetes to look for similarities. If phenotypic overlap is found, patients with new 
onset type 1 diabetes could have trials of therapies that have shown efficacy in 
their counterpart monogenic subtype. For example, if some patients showed an 
immunophenotype similar to patients with LRBA deficiency (Chapter 3), 
abatacept may be an effective therapy to maintain beta cell mass.  
Monogenic autoimmunity represents a unique opportunity to study ‘human 
knockouts’. While animal models (e.g. mice, zebrafish and drosophila) have been 
 invaluable to study the functional consequences of mutations in a single gene, 
they are all evolutionarily separated from humans and therefore have key 
differences in their genetic make-up and physiology. This has meant that in many 
cases, the phenotype observed in humans is not replicated in the model 
organism, for example LRBA knockout mice do not show any overt immune 
disease. The ability to study the tissues and cells of patients with monogenic 
autoimmune disease will therefore offer truer insight into the role of these genes 
in the human immune system.  
These patients could also be used to generate a biobank resource accessible by 
researchers around the world who are studying the pathway or gene involved. 
Immune diseases are perhaps ideal for this; the primary tissue in monogenic 
autoimmunity is the lymphocytes within blood, which is easily obtainable and less 
invasive to biopsy than other tissues (for example the pancreas for the study of 
monogenic diabetes). Established technologies to isolate and study viable 
primary blood mononuclear cells (PBMCs) and intact RNA, and indeed store 
them long-term, mean the development of a monogenic autoimmunity biobank 
would be feasible. The uses for these samples are diverse, and could include 
benchmarking of assays, functional work on cell lines, or simply a discrete genetic 
phenotype to compare polygenic diseases against.  
Identifying further single gene defects in the immune system will also provide 
further knowledge of the adaptive immune system. There are over 1500 genes 
that have a role in the function of the immune system (www.immport.org), 
representing 10-15% of all human genes. For many of these genes, the true 
function of the gene is not known. Characterising human ‘knockouts’ or ‘knock-
ins’ offers the opportunity to study the consequence of a genes’ loss and therefore 
to deduce it’s normal function. Examples of this include the identification that 
 LRBA mutations cause CVID-8, which led to functional work to determine it has 
an essential role as a regulator of CTLA-4 (introduction part 1A and chapter 3). 
Known immune genes may also be shown to have pleiotropic effects that were 
previously unrecognised, for example CASP8 (introduction part 1B) was not 
known to be important for embryonic development prior to it’s implication in 
Mendelian disease. 
 
The case made for low IgE as a sensitive and specific biomarker of STAT3 GOF 
in chapter 4 of this thesis has now been refuted. As more patients are identified 
for new monogenic forms of autoimmunity, the phenotype invariably widens and 
original hallmarks become less prevalent. This is evidenced by the original report 
of STAT3 GOF mutations having a high prevalence of neonatal diabetes (4/5 
individuals), now it is known that only approximately 30% of patients with GOF 
mutations in STAT3 develop diabetes [11, 21, 22]. This progress to refute or 
confirm a finding with additional evidence is the very nature of science, and 
myself and the co-authors express gratitude to Tangye et al for publishing their 
findings. What this work does highlight however is the need to identify cheap 
biomarkers to prioritise genetic testing in individuals with suspected monogenic 
autoimmunity as the cost of genetic screening if prohibitive for many individuals. 
It is therefore important that the scientific community continues to investigate 
potential biomarkers for monogenic autoimmunity which will help to prioritise 
genetic testing.  
There are still approximately 60 patients within our cohort who have early-onset 
diabetes and additional autoimmunity without a known monogenic cause. Many 
of these are likely to harbour novel monogenic causes of autoimmunity, and this 
cohort is now primed for gene discovery. Identifying novel causes of monogenic 
 autoimmunity will give insight into the complex nature of the adaptive immune 
system and could give new insights into beta-cell autoimmunity which will have 
relevance for the millions around the world with type 1 diabetes. Furthermore, in 
the age of personalised medicine, finding new monogenic causes of disease 
could lead to new treatments tailored to the underlying molecular defect. 
For patients with confirmed monogenic autoimmunity, further study is warranted 
to determine the factors underlying the high level of variability in clinical 
presentation and disease course. Identifying the underlying reason why some 
patients develop diabetes while others, some with identical variants, do not, may 
hold the key to understanding heterogeneity in polygenic type 1 diabetes. This 
could enable new treatment avenues targeting the specific defect underlying the 
development of islet autoimmunity. 
The data presented within this thesis has been presented at international 
conferences to disseminate findings rapidly, and much of it has been published 
in peer-reviewed journals. This has contributed to the knowledge base in 
monogenic autoimmunity and autoimmune diabetes research, and fuelled 
additional research and collaboration in the field. 
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 APPENDIX 1 
Reference sequence transcripts and genes in targeted pancreatic panel 
v5.1 
GENE REFSEQ ID 
MODY 
ABCC8 NM_001287174 
CEL NM_001807 
CISD2 NM_001008388 
GATA4 NM_002052 
GATA6 NM_005257 
GCK NM_000162 
HNF1A NM_000545 
HNF1B NM_000458 
HNF4A NM_175914 
INS NM_001185098 
INSR NM_000208 
KCNJ11 NM_000525 
LMNA NM_170707 
mtDNA_3243 NC_012920 
NEUROD1 NM_002500 
PAX6 NM_001604 
PCBD1 NM_000281 
PDX1 NM_000209 
PLIN1 NM_002666 
POLD1 NM_002691 
PPARG NM_015869 
RFX6 NM_173560 
TRMT10A NM_001134665 
WFS1 NM_006005 
ZFP57 NM_001109809 
Neonatal Diabetes 
ABCC8 NM_001287174 
BSCL2 NM_032667 
CISD2 NM_001008388 
EIF2AK3 NM_004836 
FOXP3 NM_014009 
GATA4 NM_002052 
GATA6 NM_005257 
GCK NM_000162 
GLIS3 NM_001042413 
HNF1B NM_000458 
IER3IP1 NM_016097 
IL2RA NM_000417 
 INS NM_001185098 
INSR NM_000208 
LRBA NM_006726 
KCNJ11 NM_000525 
MNX1 NM_005515 
NEUROD1 NM_002500 
NEUROG3 NM_020999 
NKX2-2 NM_002509 
PDX1 NM_000209 
PTF1A NM_178161 
C10orf115 NR_103721 
RFX6 NM_173560 
SLC19A2 NM_006996 
SLC2A2 NM_000340 
STAT3 NM_139276 
WFS1 NM_006005 
ZFP57 NM_001109809 
Early-onset autoimmunity with diabetes 
AIRE NM000383.3 
CD274 NM_014143 
FOXP3 NM_014009 
IL2RA NM_000417 
ITCH NM_001257138 
LRBA NM_001199282 
STAT1 NM_007315 
STAT3 NM_139276 
STAT5B NM_012448 
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PLEASE RETURN THIS FORM WITH EDTA BLOOD OR DNA WHEN GENETIC TESTING IS REQUESTED 
Genetic testing for early-onset multiple autoimmune disease 
Genetic testing is provided free of charge for any patient diagnosed with diabetes and ≥1 other autoimmune disorders before 5 years. 
 
Samples must be labelled with name and date of birth, please send either 
(1) Our preferred option is 3-5 mls blood taken in tubes containing EDTA and transported fresh (not frozen) at room temperature to arrive in the 
UK within 5 days. Blood samples should be sent in leak-proof packaging and include absorbent material to absorb any leakage OR 
(2) Send 5-10 micrograms of DNA (to allow repeats) at room temperature. Again please make sure the tube is very securely sealed. 
 
Please include samples from both parents whenever possible – whether affected or unaffected. 
 
Please fill in this form electronically, e-mail to Matthew Johnson (mj318@exeter.ac.uk) and send a printed copy with samples to: Prof Sian Ellard, 
Department of Molecular Genetics, RILD Level 3, Royal Devon and Exeter NHS Foundation Trust, Barrack Road, Exeter, EX2 5DW, UK 
 
For clinical advice please contact Prof Andrew Hattersley by e-mail a.t.hattersley@exeter.ac.uk or telephone +44 1392 408260  
 
Patient details      
SURNAME: 
      
CLINICIAN NAME: 
      
FORENAME: 
      
CLINICIAN E-MAIL ADDRESS FOR REPORT: 
      
D.O.B. (DD/MM/YYYY): 
      
HOSPITAL: 
      
NHS/CHI NUMBER (for UK patients): 
      
GENDER: 
      
CITY 
      
ETHNIC ORIGIN: 
      
COUNTRY 
      
 Parent details 
MOTHER’S SURNAME: 
      
MOTHER’S FORENAME: 
      
MOTHER’S D.O.B.: 
      
FATHER’S SURNAME: 
      
FATHER’S FORENAME: 
      
FATHER’S D.O.B.: 
      
Clinical information 
PRESENTING FEATURE: 
      
DATE OF DIAGNOSIS (DD/MM/YYYY): 
      
BIRTH WEIGHT (g): 
      
CURRENT WEIGHT: 
      
GESTATION (WEEKS): 
      
CURRENT HEIGHT: 
      
DIABETIC? 
      
DATE OF DIAGNOSIS (DD/MM/YYYY): 
      
INITIAL TREATMENT: 
      
CURRENT TREATMENT: 
      
GAD ANTIBODIES TESTED? 
      
IA2 ANTIBODIES TESTED? 
      
DOSE: 
      
DOSE: 
      
GAD TITRE: 
      
IA2 TITRE: 
      
THYROID DYSFUNCTION? 
      
DATE OF DIAGNOSIS (DD/MM/YYYY): 
      
 TREATMENT: 
      
TPO ANTIBODY MEASURED? 
      
Tg ANTIBODY MEASURED? 
      
TR ANTIBODY MEASURED? 
      
DOSE: 
      
TPO Ab TITRE: 
      
Tg Ab TITRE: 
      
TR Ab TITRE: 
      
GASTROINTESTINAL SYMPTOMS (GIVE TYPE)? 
      
DATE OF DIAGNOSIS (DD/MM/YYYY): 
      
TREATMENT: 
      
ENTERIC PROTEIN LOSS? 
      
tTG ANTIBODY TESTED? 
      
AE ANTIBODY MEASURED? 
      
DOSE: 
      
RESPONSE TO TREATMENT? 
      
tTG Ab TITRE: 
      
AE Ab TITRE: 
      
HAEMATOLOGICAL SYMPTOMS (GIVE TYPE)? 
      
 
 
DATE OF DIAGNOSIS (DD/MM/YYYY): 
      
IMMUNOGLOBULINS MEASURED? 
      
LYMPHOCYTE PROFILE MEASURED? 
      
IgA LEVEL (NORMAL RANGE):  
      
IgE LEVEL (NORMAL RANGE): 
      
IF SO, PLEASE PROVIDE DETAILS: 
      
 
 
IgG LEVEL (NORMAL RANGE): 
      
IgM LEVEL (NORMAL RANGE): 
      
ADRENAL INSUFFICIENCY? 
      
DERMATOLOGICAL DISORDERS (GIVE TYPE)? 
      
ANY KNOWN ALLERGIES? 
      
ARTHRITIS? 
      
HISTORY OF RECURRENT INFECTIONS? 
      
CHRONIC MUCOCUTANEOUS CANDIDIASIS? 
      
DEVELOPMENTAL DELAY? 
      
DELAYED PUBERTY? 
      
FACIAL DYSMORPHISM? 
      
ANY OTHER FURTHER DETAILS/OTHER (A SEPARATE DOCUMENT WITH FULL DETAILS OF ANY ADDITIONAL MEDICAL PROBLEMS WOULD BE VERY HELPFUL): 
      
 
 
Family history  
ARE PARENTS RELATED? IF YES, HOW?: 
      
AFFECTED FATHER? (AGE DIAGNOSED, AUTOIMMUNE FEATURES, TREATMENT): 
      
 AFFECTED MOTHER? (AGE DIAGNOSED, AUTOIMMUNE FEATURES, TREATMENT): 
      
AFFECTED SIBLING(S)? (AGE DIAGNOSED, AUTOIMMUNE FEATURES, TREATMENT): 
      
OTHER FAMILY MEMBERS AFFECTED? (A PEDIGREE SHOWING AGE AT DIAGNOSIS, AUTOIMMUNE FEATURES AND CURRENT TREATMENT OF AFFECTED FAMILY MEMBERS WOULD BE 
VERY HELPFUL): 
      
IF SAMPLES FROM OTHER FAMILY MEMBERS HAVE BEEN SENT PREVIOUSLY PLEASE GIVE DETAILS: 
      
IF A MUTATION HAS ALREADY BEEN IDENTIFIED IN A FAMILY MEMBER PLEASE GIVE DETAILS:   
Gene              Mutation                            Name and date of birth of relative with mutation:                                                             Relationship to this person       
 
 
 
 
 
 
 
 
Consent  
1. I understand that my sample will be used only for diagnostic and research purposes relevant to myself and others in my family. Please Tick   
2. I also consent for my sample to be used for future research into all forms of genetic diabetes and other beta cell conditions, whether or not it is of direct 
clinical benefit to me.  Please Tick:   Yes             No          
3. I am also happy to be contacted about research into genetic diabetes and you may contact me directly at:    
Name                                Address                                                              Telephone                                      E-mail                             
 
Signed by patient/ guardian/advocate: …………………………………….   Date: ……………..……… 
For more information (and patient information sheets) please see www.diabetesgenes.org/content/genetic-beta-cell-research-bank  
 
 
